,PageNo,Text
0,page_1,"['NCT03033511', 'abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.0', 'Title Page', 'Clinical Study Protocol M16-298', 'A Randomized, Double-Blind, Placebo-Controlled', 'Phase 3 Study of Rovalpituzumab Tesirine as', 'Maintenance Therapy Following First-Line', 'Platinum-Based Chemotherapy in Subjects with', 'Extensive Stage Small Cell Lung Cancer (MERU)', 'Incorporating Amendments 1, 2, 3 and 4', 'AbbVie Investigational', 'Rovalpituzumab tesirine (Rova-T)', 'Product:', 'Date:', '05 March 2019', 'Development Phase:', '3', 'Study Design:', 'A Randomized, Double-Blind, Placebo-Controlled Phase 3', 'Study of Rovalpituzumab Tesirine as Maintenance Therapy', 'Following First-Line Platinum-Based Chemotherapy in', 'Subjects with Extensive Stage Small Cell Lung Cancer', '(MERU)', 'EudraCT Number:', '2016-003503-64', 'Investigators:', 'Investigator information is on file at AbbVie.', 'Sponsor:', 'Abb Vie Inc. *', 'Sponsor/Emergency', 'Phone:', 'Contact:', 'Senior Medical Director', 'Cell Phone:', 'AbbVie', 'Fax:', '1 North Waukegan Road', 'Email:', 'North Chicago, IL 60064', 'USA', '* The specific contact details of the AbbVie legal/regulatory entity (person) within the relevant country are', 'provided within the clinical trial agreement with the Investigator/Institution and in the Clinical Trial', 'Application with the Competent Authority.', 'This study will be conducted in compliance with the protocol, Good Clinical Practice and all other', 'applicable regulatory requirements, including the archiving of essential documents.', 'Confidential Information', 'No use or disclosure outside AbbVie is permitted without prior written authorization from AbbVie.', '1']"
1,page_2,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.1', 'Protocol Amendment: Summary of Changes', 'Previous Protocol Versions', 'Protocol', 'Date', 'Original', '13 October 2016', 'Amendment 1', '03 February 2017', 'Amendment 2', '20 April 2017', 'Amendment 3', '09 May 2017', 'The purpose of this amendment is to:', 'Modified Section 1.0 Sponsor/Emergency Contact', 'Rationale: Modification of the emergency contact for the study.', 'Update Section 1.2, Synopsis, Section 4.0, Study Objectives, Section 5.3.3.2,', 'Section 5.3.3.3, Section 5.3.3.4, Section 8.1.4 Primary Efficacy Endpoints,', 'Section 8.1.5 Secondary Efficacy Endpoints, Section 8.1.6 Exploratory', 'Efficacy Endpoints to clarify the DLL3high population, secondary endpoints', 'updated to include, OS, PFS and PRO endpoints to be tested in all randomized', 'patient population and prioritize these ahead of other efficacy endpoints such', 'as ORR, CBR and DOR. Exploratory endpoints were added.', 'Rationale: This clarifies the population for primary endpoints (unchanged', 'from prior protocol version) and allows evaluation of Rova-T efficacy on OS,', 'PFS, and PRO in all enrolled patient population in secondary endpoint. ORR,', 'CBR etc., are clinically less relevant than PFS, os and PRO and thus, will be', 'tested as exploratory endpoints.', 'Modified Section 1.2, Synopsis Study sites and Section 5.1 Overall Study', 'Design to Approximately 300 from 275.', 'Rationale: The number of study sites has increased since the last amendment.', 'Update Section 1.2 Synopsis, Section 5.2.1, Inclusion criteria 1 to add the', ""option of the subject's legally accepted representative as a person that can sign"", ""consent on the subject's behalf."", 'Rationale: To align with the approved informed consent language.', '2']"
2,page_3,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Updated Section 1.2 Synopsis, Section 5.2.1, Inclusion criteria 3 to say', ""'Histologically or cytologically confirmed ED SCLC (extensive stage disease"", 'at initial diagnosis) with ongoing clinical benefit (SD, PR, or CR per RECIST', 'v1.1) following completion of 4 cycles of first-line platinum-based therapy', '(cisplatin or carboplatin in combination with etoposide or irinotecan).', 'Rationale: Clarify that intended patient population is ED SCLC as per', 'staging performed at the initial diagnosis and not any other time point.', 'Updated Section 1.2 Synopsis, Section 5.2.1, Inclusion criteria 5 to say', ""'Subject is eligible to be randomized at least 3 but no more than 9 weeks from"", 'Day 1 of the fourth cycle of first-line platinum-based chemotherapy.', 'Rationale: Clarify intended window between front-line therapy and', 'randomization.', 'Updated Section 1.2 Synopsis, Section 5.2.1, Inclusion criteria 9f to add', ""'modified' to say 'Calculated creatinine clearance > 30 mL/min by the modified"", 'Cockroft-Gault formula (Refer to Appendix E).', 'Rationale: Clarify required method for assessment of calculated creatinine', 'clearance.', 'Updated Section 1.2 Synopsis, Section 5.2.2, Exclusion criteria 1 to remove', ""'the disease under study' and replace it with 'SCLC."", 'Rationale: Further clarify that subjects who received prior treatment for LD-', 'SCLC are excluded', 'Updated Section 1.2 Synopsis, Section 5.2.2, Exclusion criteria 2 to add', ""'palliative radiotherapy to a radiographically documented non-progressing"", 'lesion for symptom control.', 'Rationale: Clarify that palliative radiotherapy is allowed for non-progressing', 'lesions.', 'Updated Section 1.2 Synopsis, Section 5.2.2, Exclusion criteria 4 to change the', 'reference from Appendix E to Appendix F.', 'Rationale: Correcting a typo from the previous amendment.', 'Updated Section 1.2 Synopsis Statistical Methods section, Section 8.1', 'Statistical and Analytical Plans, Section 8.4, Section 8.5 and Section 8.6 to', '3']"
3,page_4,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'remove the efficacy interim analysis after observing 75% of the final OS', 'events and to add a futility analysis at 50% of the final OS events.', 'Rationale: Enable earlier stopping of the trial in the event of. futility and', 'improve statistical properties at final OS.', 'LD SCLC defined in List of Abbreviations as Limited-stage disease small cell', 'lung cancer', 'Rationale: Definition added to clarify the different disease states for SCLC.', 'Modified Section 3.3 Rovalpituzumab Tesirine to provide updated data.', 'Rationale: Latest data added from ongoing Rova-T studies.', 'Modified Section 3.5 Benefits and Risks to update safety language.', 'Rationale: To provide updated safety information', 'Modified Section 5.1 Overall Study Design, Footnote number 3 under Figure 1', ""to include the following updated language- 'Subject is eligible to be"", 'randomized at least 3 but no more than 9 weeks from Day 1 of the fourth cycle', ""of first-line platinum-based chemotherapy.'"", 'Rationale: To be consistent with the update to Inclusion Criteria 5.', 'Modified Section 5.2 Selection of Study Population to include the LD and ED', 'SCLC definition.', 'Rationale: Modified to include the definition per IASLC/VA for LD and ED', 'SCLC.', 'Modified Section 5.2.3.1 Prior therapy to be consistent with changes to', 'Inclusion Criteria 3 and 5.', 'Rationale: To be consistent with the update to Inclusion Criteria 3 and 5.', 'Modified Section 5.2.3.2 Concomitant Therapy to add additional safety', 'guidelines regarding sun exposure.', 'Rationale: To provide updated guidelines regarding sun exposure and to', 'maintain consistent with the Toxicity Management language in Section 6.1.8.2.', 'Modified Section 5.3.1.1 Study Procedures, Vital signs, to address weight', ""increases of 5% or greater and add 'actual' prior to 'weight.'"", 'Rationale: To ensure accurate determination of dose in the event of blinded', 'investigational product-related weight gain due to fluid retention', '4']"
4,page_5,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Section 5.3.1.1 Study Procedures, Echocardiogram, the following', ""language has been changed: 'Echocardiograms will be performed per"", 'Appendix C, Study Activities to rule out pericardial effusion (or assess, if', 'present), as well as assess cardiac function (left ventricular ejection fraction,', 'LVEF).', 'Rationale: Clarifying the purpose of on-study Echocardiograms.', 'Modified Section 5.3.1.1 Study Procedures, Disease/Response Assessment', '(Radiographic Imaging), language has been added to advise sites on the need', 'to discuss with TA MD regarding the gaps between tumor assessments and', 'doses in certain cases of dose delays.', 'Rationale: Modified to address the planning of CTs in cases of treatment', 'delays.', 'Modified Section 5.3.1.1 Study Procedures, MRI/CT of the Brain and Footnote', 't under Appendix C to clarify that the MRI/CT of the brain is required at', 'screening and when clinically indicated thereafter.', 'Rationale: Modified to clarify when MRI/CT of the brain is required on study.', 'Modified Section 5.3.1.1 Study Procedures, Fluid Retention Questionnaire', '(Including Subject Daily Weight), the following language has been added:', ""'The site will advise subjects to contact the site in cases where sudden weight"", ""gain (5% or greater) is observed for possible assessment in the clinic.'"", 'Rationale: Modified to clarify the definition of weight gain that requires', 'additional assessment by the site.', 'Modified Section 5.3.1.1 Study Procedures, End of Treatment (EOT) Visit, the', ""following language has been added: 'The EOT procedures should be done"", 'within 7 days of documented decision to discontinue treatment and prior to', ""subjects beginning any new anti-cancer therapy if possible.'"", 'Rationale: Modified to fix conflicted language in the protocol.', ""Modified Section 5.3.3.2 Primary Variables to add' determined by a Central"", 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall', ""survival (OS) in DLL3high population.'"", 'Rationale: To clarify the version of RECIST used for this study and to clarify', 'that the DLL3high subjects are analyzed.', '5']"
5,page_6,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', ""Modified Section 5.5.1 Treatment Administration to add 'placebo' after"", ""'dexamethasone' in the last sentence of the first paragraph"", 'Rationale: Modified to be consistent with the rest of the paragraph.', 'Modified Section 5.5.2.1 Packing and Labeling, Rovalpituzumab Tesirine and', 'Placebo to include updated Hazardous Drug packing and shipping standards.', 'Rationale: Added to clarify packaging and shipping requirements as per', 'applicable regulations.', 'Modified Section 5.5.2.2 Storage and Disposition of Blinded Investigational', 'Product(s) and Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'to note specific instructions for reconstituted and diluted IP will be found in an', 'outside document.', 'Rationale: Site awareness for a separate document that contains additional', 'information on IP storage and disposition.', 'Modified Section 5.5.4.1 Dosing to add fluid retention weight gain guidance.', 'Rationale: To instruct sites on cases of weight gain due to fluid retention.', 'Modified Table 5 to include:', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Addition of footnote b.', 'Rationale: Update dose modification guidelines to align with safety profile', 'for Rova-T as described in the IB v.7.', 'Modified Section 5.5.5.2 Blinding of Data for Independent Data Monitoring', 'Committee (IDMC) to update the change from an interim analysis to a futility', 'analysis.', 'Rationale: To align with the updated statistical plan.', 'Modified Section 5.5.7 Drug Accountability to update classification of Rova-T', 'as a dangerous good/hazardous material.', 'Rationale: Added to clarify classification as well as packaging and shipping', 'requirements as per applicable regulations.', '6']"
6,page_7,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Section 6.1.1.3 to update guidance on capturing disease progression', 'and fatal events for AEs and SAEs in the CRF.', 'Rationale: To clarify on AE/SAE reporting regarding events due to disease', 'progression.', 'Modified Section 6.1.4 Deaths to add language about capturing these events in', 'the CRF.', 'Rationale: To provide guidance on capturing deaths during AE/SAE', 'reporting period in EDC.', ""Modified Section 6.1.5 Adverse Event Collection Period, to say 'All adverse"", 'events reported from the time of blinded investigational product administration', 'until 70 days following the last dose of blinded investigational product will be', ""collected, whether solicited or spontaneously reported by the subject.'"", 'Rationale: To clarify AE collection period from last dose of blinded IP.', 'Modified Section 6.1.6 Adverse Event Reporting to update the emergency', 'contact for the study and add updated language regarding SUSARs and', 'guidelines for the Reference Safety Information (RSI).', 'Rationale: Modification of the emergency contact for the study and current', 'information regarding SUSAR reporting.', 'Modified Section 6.1.8 Toxicity Management to add additional safety', 'guidance on serosal effusions, skin reactions, edema, and pneumonitis.', 'Rationale: Provide additional guidance to investigators and subjects for', 'awareness and guidance to align with IBv7.', 'Updated Section 7.0 Protocol Deviations-Primary and Alternate contact', 'information.', 'Rationale: To provide sites with current AbbVie contact information.', 'Modified Section 8.1.3 Efficacy Endpoints and Analyses to delete the first', 'sentence.', 'Rationale: Align with updated analysis plan as outlined above.', 'Updated Section 8.1.7 to Patient Reported Outcomes (PRO) and add the', ""following language, 'Physical functioning scale score in EORTC QLQ-C30 is"", ""the key secondary endpoint.'"", 'Rationale: Align with updated analysis plan as outlined above.', '7']"
7,page_8,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Changed Section Planned Sensitivity and Subgroup Analysis to 8.1.8 and', 'delete the first, third and last sentence of the section.', 'Rationale: Align with updated analysis plan as outlined above.', 'Changed Section Pharmacokinetic and Exposure-Response Analyses to 8.1.9.', 'Modified Synopsis Section 1.2 Criteria for Evaluation, Pharmacokinetic,', 'Section 5.3.5 Pharmacokinetic Variables and Section 8.1.9 Pharmacokinetic', ""and Exposure-Response Analyses to change 'plasma' to 'serum.'"", 'Rationale: To update numbering in the section of the protocol and align with', 'the lab manual.', 'Modified Section 8.3 Type I Error Adjustment Procedure for Multiple Testing', 'to', 'include the DLL3 high set, update the null hypotheses and level of', 'significance. Figure 3 was also added. This is outlined above in the Synopsis', 'section.', 'Rationale: Align with updated analysis plan as outlined above.', 'Modified Section 10.1 Source Documents to clarify that the Investigator', 'Awareness date of a SAE should be noted in the source, not the EDC.', 'Rationale: This data point cannot be captured in the EDC.', ""Added the following addition to References, '19. AbbVie. Rovalpituzumab"", 'Tesirine Dear Rova-T Investigator Letter. 05 December 2018.', 'Rationale: Added reference due to new safety data.', 'Modified Appendix B: List of Protocol Signatories', 'Rationale: Updated new team members since last amendment.', 'Modified Appendix C: Echocardiogram. Now a required assessment listed', 'under Screening.', 'Rationale: To provide a bigger window for sites to complete the assessment.', ""Modified Footnote b under Appendix C to say, 'End of Treatment Visit"", 'procedures should be done within 7 days of documentation of the decision to', 'discontinue treatment and prior to subjects beginning any new anti-cancer', ""therapy if possible.'"", 'Rationale: Updated to be consistent with EOT treatment language.', '8']"
8,page_9,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Modified Footnote e under Appendix C to add the following language,', ""'Cycle 1 Day 1 procedures, with the exception of weight.'"", 'Rationale: Updated to clarify when weight should be done to be used for', 'dosing decisions.', 'Modified Footnote n under Appendix C to clarify when Echocardiograms are', 'required throughout the study and in relation to pericardial effusion', 'assessments.', 'Rationale: To allow for a larger window for the assessment to be completed.', 'Modified Footnote q under Appendix C to advise sites on the need to contact', 'TA MD for the gaps in tumor assessments.', 'Rationale: Updated to indicate when the TA MD should be consulted.', 'Make administrative changes of typographical errors, minor language and', 'word revision as needed throughout the document.', 'Rationale: Clarifies and ensures consistency throughout.', 'An itemized list of all changes made to this protocol under this amendment can be found', 'in Appendix K.', '9']"
9,page_10,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.2', 'Synopsis', 'AbbVie Inc.', 'Protocol Number: M16-298', 'Name of Study Drug: rovalpituzumab tesirine', 'Phase of Development: 3', '(Rova-T)', 'Name of Active Ingredient: rovalpituzumab', 'Date of Protocol Synopsis: 05 March 2019', 'tesirine', 'Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab', 'Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with', 'Extensive Stage Small Cell Lung Cancer (MERU)', 'Objectives:', 'Primary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival, assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1. and overall survival', 'in subjects with extensive-stage small cell lung cancer (ED SCLC) tumors with a high level of', 'DLL3 expression (DLL3high) who have ongoing clinical benefit (SD, PR, or CR) following', 'first-line platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or etoposide)', 'compared to placebo.', 'Secondary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by CRAC and overall', 'survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical functioning as measured by', 'the EORTC QLQ-C30 questionnaire in all randomized subjects compared to placebo.', 'Exploratory', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining objective response rate', '(ORR), clinical benefit rate (CBR), and duration of responses (DOR) by CRAC and Investigator', 'assessment in DLL3hig and in all randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by Investigator', 'assessment compared to placebo in DLL3high and in all randomized subjects.', 'To assess change from baseline in all patient reported outcomes (PRO) domains (except physical', 'functioning) measured by EORTC QLQ-C30/LC13 and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic antibodies (ATAs)', 'against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor for association', 'with sensitivity, efficacy and safety.', 'To explore DLL3 expression in circulating tumor cells (CTCs) for association with efficacy.', 'Investigators: Multicenter, International', 'Study Sites: Approximately 300', 'Study Population: Subjects with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of first-line', 'platinum-based chemotherapy (cisplatin or carboplatin in combination with etoposide or irinotecan).', '10']"
10,page_11,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Number of Subjects to be Enrolled: Up to approximately 740 SCLC subjects, to obtain approximately', '480 subjects with DLL3high expression in tumor (DLL3high DLL3 high is defined as > 75% tumor cells', 'staining positive according to the VENTANA DLL3 (SP347) IHC Assay.', 'Methodology:', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study.', 'ED SCLC subjects who meet all the inclusion criteria and none of the exclusion criteria, and demonstrate', 'ongoing clinical benefit (SD, PR, or CR) at the completion of 4 cycles of first-line platinum-based', 'chemotherapy (such benefit must be ongoing at the last re-staging assessment prior to randomization),', 'will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg rovalpituzumab tesirine or placebo, and will', 'receive their assigned therapy on Day 1 of each 6-week cycle, omitting every third cycle. Upon', 'completion of first-line chemotherapy, eligible subjects must be offered prophylactic cranial irradiation', '(PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. Subjects will also receive 8 mg', 'orally (PO) of dexamethasone or placebo twice daily on Day -1, Day 1, and Day 2 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response after completion', 'of first-line platinum-based chemotherapy at screening assessment (SD VS. PR/CR), DLL3 expression,', '(Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or above), history of central nervous system', '(CNS) metastases (Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to follow-up or', 'withdraws consent, or termination of the study by AbbVie, whichever occurs first.', 'Diagnosis and Main Criteria for Inclusion/Exclusion:', 'Main Inclusion:', '1.', ""Subject or the subject's legally acceptable representative must voluntarily sign and date an informed"", 'consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB),', 'prior to the initiation of any screening or study-specific procedures and should be willing and able to', 'comply with parameters as outlined in the protocol.', '2.', 'Subject must be > 18 years of age.', '3. Histologically or cytologically confirmed ED SCLC (extensive stage disease at initial diagnosis),', 'with ongoing clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of', 'first-line platinum-based therapy (cisplatin or carboplatin in combination with etoposide or', 'irinotecan).', '4. Subjects with a history of CNS metastases prior to the initiation of first-line platinum-based', 'chemotherapy must have received definitive local treatment and have documentation of stable or', 'improved CNS disease status based on brain imaging within 28 days prior to randomization, off or on', 'a stable dose of corticosteroids.', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the', 'fourth cycle of first-line platinum-based chemotherapy', '6.', 'Availability of archived or representative tumor material for assessment of DLL3 expression.', '7. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.', '8.', 'Recovery to VI Grade 1 of any clinically significant toxicity (excluding alopecia) prior to', 'randomization.', '11']"
11,page_12,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Inclusion (Continued):', '9. Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b.', 'Platelet count > 75,000/L', 'c.', 'Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin < 1.5 X upper limit of normal (ULN) or < 3 X ULN for subjects with', ""Gilbert's disease"", 'e.', 'Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 X ULN', '(< 5x ULN if evidence of hepatic involvement by malignant disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault formula (Refer to', 'Appendix E).', 'g.', 'Albumin > 3g/dL', '10. If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative medical cause.', 'Age < 55 years with no menses for 12 or more months without an alternative medical cause', 'AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).', 'OR a Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method', 'of birth control, starting at randomization through at least 6 months after the last dose of blinded', 'investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at least 6 months', 'after the last dose of blinded investigational product, to practice the protocol specified contraception.', '11. Females of childbearing potential must have a negative serum pregnancy test result at Screening, and', 'a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as', 'defined in the protocol) at Screening do not require pregnancy testing.', 'Main Exclusion:', '1. Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other', 'monoclonal antibodies, antibody-drug conjugates, adioimmunoconjugates, T-cell or other cell-based', 'or biologic therapies, or any other anti-cancer therapy than that described in Inclusion Criteria 3 - 5', 'for SCLC.', '2.', 'Any disease-directed radiotherapy (except, PCI, palliative radiotherapy to a radiographically', 'documented non-progressing lesion for symptom control, or pre-planned radiotherapy for CNS', 'metastases present prior to start of first-line therapy and non-progressing) after last dose of first-line', 'chemotherapy.', '3. Any significant medical condition including any suggested by screening laboratory findings that in', 'the opinion of the Investigator or Sponsor may place the subject at undue risk from the study.', '12']"
12,page_13,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Exclusion (Continued):', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac', 'symptoms consistent with New York Heart Association (NYHA) Class III - IV heart failure (refer to', 'Appendix F) within 6 months prior to randomization.', '5.', 'Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization or earlier history of', 'recurrent Grade 2 or higher effusions with ongoing requirement for pericardiocentesis or', 'thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or higher (per NCI', 'CTCAE version 4.0) viral, bacterial, or fungal infection.', '8.', 'Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study', 'or for approximately 6 months after the last dose of blinded investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the study or for', 'approximately 6 months after the last dose of blinded investigational product.', '10. Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent within 1 week prior to', 'randomization.', '11. Subject has a history of active malignancies other than SCLC within the past 2 years prior to study', 'entry, with the exception of in situ cancer which was curatively treated.', '12. Any prior exposure to a pyrrolobenzodiazepine (PBD-based)-or indolinobenzodiazepine-based drug,', 'prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other', 'contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.', '13. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.', 'Investigational Products:', 'Rovalpituzumab tesirine or Placebo', 'Dexamethasone or Placebo', 'Doses:', 'Rovalpituzumab tesirine/Placebo: 0.3 mg/kg, Day 1 of each 6-week', 'cycle, omitting every third cycle.', 'Dexamethasone/Placebo 8 mg orally (PO) twice daily on Day -1, Day 1', '(the day of dosing), and Day 2 of each 6 week cycle, omitting every', 'third cycle.', 'Mode of Administration:', 'Rovalpituzumab tesirine/Placebo: Intravenous', 'Dexamethasone/Placebo: Oral', 'Duration of Treatment: Subjects will receive rovalpituzumab tesirine/placebo in combination with', 'dexamethasone/placebo on Day 1 of a 6-week cycle, omitting every third cycle until disease progression.', 'Criteria for Evaluation:', 'Efficacy: Efficacy assessments will consist of evaluations for tumor progression using Response', 'Evaluation Criteria in Solid Tumors (RECIST) v1.1 and will be based on a Central Radiographic', 'Assessment Committee (CRAC) review of medical images, as outlined in the Schedule of Assessments.', 'Additionally, efficacy will be assessed by overall survival.', 'Pharmacokinetic: Serum concentrations of rovalpituzumab tesirine ADC and the presence of anti-', 'therapeutic antibodies (ATA) will be determined.', '13']"
13,page_14,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Criteria for Evaluation (Continued):', 'Biomarkers: Pharmacodynamic and predictive biomarker assessments will include analyses of tumor', 'material and circulating tumor cells for DLL3 expression, blood samples for inflammatory, tumor, and', 'soluble markers. Samples may also be used for other nucleic acid or protein based exploratory', 'biomarkers to understand the sensitivity or resistance to rovalpituzumab tesirine and biology of SCLC.', 'Safety: Safety assessments include physical exam, vital signs, body weight, ECOG score, clinical', 'adverse events, laboratory tests (hematology, serum chemistries, urinalysis, and coagulation), ECGs,', 'echocardiogram, fluid retention questionnaire, radiographic images review for fluid retention, and', 'monitoring of concomitant medications.', 'Patient Reported Outcome (PRO):', 'Changes in the patient reported outcomes (PROs) EORTC QLQ-C30, EORTC QLQ-LC13, and', 'EQ-5D-5L from baseline will be assessed.', 'Statistical Methods:', 'Efficacy:', 'Progression-free survival (PFS) per CRAC and overall survival (OS) in patients with DLL3 high ED SCLC', 'are the two primary efficacy endpoints. To meet global regulatory requirements, a multiple testing', 'strategy will be implemented to control the family-wise type I error (alpha) for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival (PFS) per', 'CRAC in DLL3 high patients, overall survival (OS) in DLL3high patients, PFS per CRAC in randomized', 'patients, OS in randomized patients, and physical functioning scale score (EORTC QLQ-C30) in the', 'randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in H01 are H01a and Holb.', 'H01a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in DLL3hig set.', 'Hoib: Rovalpituzumab tesirine arm is not superior to placebo arm in os in DLL3 high set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in os in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning scale score', '(EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {H01a, Holb, H02, H03, and H04} in order. To', 'maintain the family-wise type I error for the study, the null hypotheses in H01 (H01a and H01b) will be first', 'tested with an alpha-split approach. The one-sided alpha of 0.25% and 2.25% will be assigned for PFS', 'and OS hypothesis in H01, respectively. Out of one-sided alpha of 2.25% allocated to OS hypothesis', '(Ho1b), the one-sided alpha of 10-6 will be spent for the early look at the OS data for futility analysis. If', 'the hypothesis for PFS in H01 (H01a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in H01 (H01b). Hence, the hypothesis for OS in H01 (H01b) will be tested either at a one-sided', '2.4999% or one-sided 2.2499% level of significance depending on the PFS hypothesis in H01 a is rejected', 'or not.', 'If either PFS or os endpoint reaches statistical significance, the study is considered positive. No further', 'tests will be performed if the os endpoint in DLL3high population (H01b) does not reach statistical', 'significance.', '14']"
14,page_15,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'The hypothesis in H02 will be tested if the hypothesis in Hoib is rejected. If the hypothesis in H02 is', 'rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS endpoint in DLL3high subjects', '(H01a) is also rejected or (ii) only H04 will be tested if the PFS endpoint in DLL3hig subjects (Ho1a) is not', 'rejected.', 'Futility Analysis:', 'Unblinded interim data will be analyzed and reviewed by the IDMC. A futility analysis will be', 'conducted when approximately 160 deaths in subjects with DLL3¹ high ED SCLC (approximately 50% of', 'the planned deaths) are observed. The trial may be stopped for futility if the estimated Overall Survival', 'Cox HR of Rova-T to Placebo at this analysis exceeds 0.9. The one-sided alpha of 10-6 will be spent for', 'the early look at the efficacy data for futility analysis.', 'Sample Size:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS) based on the', 'CRAC and overall survival (OS) in subjects with DLL3 high ED SCLC. To maintain the overall 1-sided', 'type I error at a 2.5% for this study, the type I error will be split, assigning 0.25% to progression-free', 'survival and the remaining 2.25% to overall survival. However, the OS endpoint will be tested at a', 'one-sided 2.2499% significance level as a one-sided alpha of 10-6 will be spent for the early look at the', 'OS data for futility analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed, taking into', 'account the expected patient population for the study, that median overall survival in the placebo and', 'rovalpituzumab tesirine arm will be around 9 months and 13 months, respectively. The increase of', 'median OS in rovalpituzumab tesirine arm corresponds to a hazard ratio of 0.69, i.e., a reduction in the', 'hazard of death by 31%. With all these assumptions, a total of 319 deaths among subjects with DLL3 high', 'are needed to achieve a 90% power based on a log-rank test at a one-sided significance level of 0.022499.', 'Assuming a 19-month accrual period and the last enrolled subject followed for 12 months, at least', '480 subjects with DLL3hig are expected to be randomized (240 subjects in each arm). A total of', '740 subjects regardless of DLL3 expression level (including 480 subjects with DLL36 high will enroll in', 'the study, assuming an approximate prevalence of 65% for subjects with DLL3high For one-sided', 'significance level of 0.022499, it is projected that an observed hazard ratio of 0.799 or less,', 'corresponding to a 2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The', 'primary endpoints of OS and PFS in DLL3high patients will be analyzed at the same time after', 'observing at-least 319 OS event. It is expected at approximately 420 PFS events will be observed at the', 'time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that median progression-', 'free survival for the placebo and rovalpituzumab tesirine arm will be approximately 3 months and', '4.5 months, respectively. The increase of median progression-free survival in rovalpituzumab tesirine', 'arm corresponds to a hazard ratio of 0.667. With all these assumptions, a total of 420 PFS events', 'assessed by the CRAC for the subjects with DLL3high are needed to achieve a 91% power based on a log-', 'rank test at a one-sided significance level of 0.0025. It is projected that an observed hazard ratio of 0.760', 'or less, corresponding to approximately 1 month or greater improvement in median PFS, would result in', 'a statistically significant improvement in the PFS.', '15']"
15,page_16,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'Pharmacokinetic:', 'Individual concentrations of rovalpituzumab tesirine ADC will be tabulated and summarized for subjects', 'treated with the active regimen and summary statistics provided. The incidence of ATA will be', 'summarized.', 'Biomarkers:', 'Biomarkers will be measured at baseline and post-treatment and analyses performed to identify markers', 'associated with rovalpituzumab tesirine response, pharmacodynamics, PK, or safety.', 'Safety:', 'The safety of rovalpituzumab tesirine will be assessed by evaluating the study drug exposure, adverse', 'events, all deaths, as well as changes in laboratory determinations and vital sign parameters.', '16']"
16,page_17,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1.3', 'List of Abbreviations and Definition of Terms', 'Abbreviations', 'ADC', 'Antibody-drug conjugate', 'AE', 'Adverse event', 'ALT', 'Alanine aminotransferase', 'ANA', 'Anti-nuclear antibodies', 'ANC', 'Absolute neutrophil count', 'aPTT', 'Activated partial thromboplastin time', 'ASCL1', 'Achaete-scute homolog 1', 'ASRO', 'American Society for Radiation Oncology', 'AST', 'Aspartate aminotransferase', 'AT', 'Aminotransferase', 'ATA', 'Anti-therapeutic antibody', 'ATC', 'Anatomical therapeutic chemical (codes)', 'ß-hCG', 'Beta-human chorionic gonadotropin', 'BUN', 'Blood urea nitrogen', 'CBR', 'Clinical benefit rate', 'CDSM', 'Clinical Drug Supply Management', 'CFR', 'Code of Federal Regulations', 'CNS', 'Central nervous system', 'CR', 'Complete response', 'CRAC', 'Central Radiographic Assessment Committee', 'CRP', 'C-reactive protein', 'CSC', 'Cancer stem cell', 'CT', 'Computerized tomography', 'CTC', 'Circulating tumor cell', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'ctDNA', 'Circulating Tumor DNA', 'CYP3A4', 'Cytochrome P450 3A4', 'DILI', 'Drug-induced liver injury', 'DLL3', 'Delta-like protein 3', 'DLL3high', 'DLL3 high expression in tumor defined as > 75% tumor cells staining', 'positive according to the VENTANA DLL3 (SP347) IHC Assay', '17']"
17,page_18,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'DNA', 'Deoxyribonucleic acid', 'DOR', 'Duration of response', 'ECG', 'Electrocardiogram', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic Case Report Form', 'EDC', 'Electronic data capture', 'ED SCLC', 'Extensive-stage disease small cell lung cancer', 'EFNS', 'European Federation of Neurological Societies', 'EGF', 'Epidermal growth factor', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'EOT', 'End of Treatment', 'EQ-5D-5L', 'EuroQoL Five Dimensions Questionnaire', 'ESMO', 'European Society for Medical Oncology', 'ESR', 'Erythrocyte sedimentation rate', 'EU', 'European Union', 'FDA', 'US Food and Drug Administration', 'FSH', 'Follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'Gy', 'Gray', 'HDPE', 'High-density polyethylene', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HR', 'Hazard ratio', 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonisation', 'IDMC', 'Independent Data Monitoring Committee', 'IEC', 'Independent Ethics Committee', 'IHC', 'Immunohistochemistry', 'IL', 'Interleukin', 'IMP', 'Investigational Medicinal Product', 'INR', 'International normalized ratio', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive response technology', 'IUD', 'Intrauterine device', 'IV', 'Intravenous(ly)', '18']"
18,page_19,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'JSMO', 'Japanese Society of Medical Oncology', 'LCNEC', 'Large cell neuroendocrine cancer', 'LDH', 'Lactate dehydrogenase', 'LD SCLC', 'Limited-stage disease small cell lung cancer', 'LFT', 'Liver function test', 'LVEF', 'Left ventricular ejection fraction', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MRI', 'Magnetic resonance imaging', 'MTD', 'Maximum tolerated dose', 'nAb', 'Neutralizing antibodies', 'NASH', 'Non-alcoholic steatohepatitis', 'NCCN', 'National Comprehensive Cancer Network', 'NCI', 'National Cancer Institute', 'NEUROD1', 'Neurogenic differentiation 1', 'NSAID', 'Non-steroidal anti-inflammatory drug', 'NSE', 'Neuron-specific enolase', 'NYHA', 'New York Heart Association', 'ORR', 'Objective response rate', 'OS', 'Overall survival', 'PBD', 'Pyrrolobenzodiazepine', 'PCI', 'Prophylactic cranial irradiation', 'PD', 'Progressive disease', 'PDX', 'Patient-derived xenografts', 'PET', 'Positron emission tomography', 'PFS', 'Progression-free survival', 'PK', 'Pharmacokinetics', 'PO', 'Per os (by mouth)', 'PR', 'Partial response', 'PRO', 'Patient reported outcome', 'PT', 'Prothrombin time', 'PTFU', 'Post-treatment follow up', 'q6wk', 'Every 6 weeks', 'RECIST', 'Response Evaluation Criteria in Solid Tumors', 'RF', 'Rheumatoid factor', '19']"
19,page_20,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Rova-T', 'Rovalpituzumab tesirine', 'RPTD', 'Recommended Phase 2 dose', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SC-DR002', 'DNA cross-linking agent also known as D6.5', 'SC16', 'Humanized DLL3-specific IgG1 antibody', 'SCLC', 'Small cell lung cancer', 'SD', 'Stable disease', 'SIADH', 'Syndrome of Inappropriate Anti-Diuretic Hormone', 'SMPC', 'Summary of product characteristics', 'SPF', 'Sun protection factor', 'SUSAR', 'Suspected Unexpected Serious Adverse Reactions', 'TBL', 'Total bilirubin', 'TEAE', 'Treatment-emergent adverse event', 'TIC', 'Tumor-initiating cells', 'TNM', 'Tumor, node, metastases', 'TTP', 'Time to progression', 'ULN', 'Upper limit of normal', 'VA', 'Veterans Administration', 'VEGF', 'Vascular endothelial growth factor', 'WHODRUG', 'World Health Organization Drug (Dictionary)', 'WOCBP', 'Women of childbearing potential', '20']"
20,page_21,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '2.0', 'Table of Contents', '1.0', 'Title Page', '1', '1.1', 'Protocol Amendment: Summary of Changes', '2', '1.2', 'Synopsis', '10', '1.3', 'List of Abbreviations and Definition of Terms', '17', '2.0', 'Table of Contents', '21', '3.0', 'Introduction', '26', '3.1', 'Small Cell Lung Cancer', '26', '3.2', 'Delta-Like Protein 3', '26', '3.3', 'Rovalpituzumab Tesirine', '27', '3.4', 'Differences Statement', '29', '3.5', 'Benefits and Risks', '29', '4.0', 'Study Objectives', '30', '5.0', 'Investigational Plan', '32', '5.1', 'Overall Study Design and Plan: Description', '32', '5.2', 'Selection of Study Population', '33', '5.2.1', 'Inclusion Criteria', '34', '5.2.2', 'Exclusion Criteria', '36', '5.2.3', 'Prior and Concomitant Therapy', '38', '5.2.3.1', 'Prior Therapy', '38', '5.2.3.2', 'Concomitant Therapy', '39', '5.2.3.2.1', 'Allowed Concomitant Therapy', '39', '5.2.3.3', 'Prohibited Therapy', '41', '5.2.4', 'Contraception Recommendations', '41', '5.3', 'Efficacy, Pharmacokinetic, Biomarker, Pharmacogenetic and', 'Safety Assessments/Variables', '42', '5.3.1', 'Efficacy and Safety Measurements Assessed and Flow Chart', '42', '5.3.1.1', 'Study Procedures', '43', '5.3.1.2', 'Collection and Handling of Biomarker and Optional Exploratory', 'Research Samples', '55', '5.3.2', 'Drug Concentration Measurements', '58', '5.3.2.1', 'Collection of Samples for Analysis', '58', '21']"
21,page_22,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.2.2', 'Handling/Processing of Samples', '58', '5.3.2.3', 'Disposition of Samples', '58', '5.3.2.4', 'Measurement Methods', '59', '5.3.3', 'Efficacy Variables', '59', '5.3.3.1', 'Definition of Disease Progression', '59', '5.3.3.2', 'Primary Variables', '59', '5.3.3.3', 'Secondary Variables', '60', '5.3.3.4', 'Exploratory Variables', '60', '5.3.4', 'Safety Variables', '60', '5.3.5', 'Pharmacokinetic Variables', '61', '5.3.6', 'Biomarker and/or Optional Exploratory Research Variables', '61', '5.4', 'Removal of Subjects from Therapy or Assessment', '62', '5.4.1', 'Discontinuation of Individual Subjects', '63', '5.4.2', 'Discontinuation of Entire Study', '64', '5.5', 'Treatments', '64', '5.5.1', 'Treatments Administered', '64', '5.5.2', 'Identity of Investigational Product(s)', '65', '5.5.2.1', 'Packaging and Labeling', '65', '5.5.2.2', 'Storage and Disposition of Blinded Investigational Product(s)', '66', '5.5.2.3', 'Preparation/Reconstitution of Dosage Form(s)', '67', '5.5.3', 'Method of Assigning Subjects to Treatment Arms', '67', '5.5.4', 'Selection and Timing of Dose for Each Subject', '68', '5.5.4.1', 'Dosing', '68', '5.5.4.2', 'Dose Modifications', '68', '5.5.4.2.1', 'Dose Treatment Delays due to Toxicity or Progression', '68', '5.5.4.2.2', 'Dose Reduction Guidelines', '69', '5.5.5', 'Blinding', '72', '5.5.5.1', 'Blinding of Investigational Product', '72', '5.5.5.2', 'Blinding of Data for Independent Data Monitoring Committee', '(IDMC)', '72', '5.5.6', 'Treatment Compliance', '72', '5.5.7', 'Drug Accountability', '73', '5.6', 'Discussion and Justification of Study Design', '74', '22']"
22,page_23,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.6.1', 'Discussion of Study Design and Choice of Control Groups', '74', '5.6.2', 'Appropriateness of Measurements', '74', '5.6.3', 'Suitability of Subject Population', '75', '5.6.4', 'Selection of Doses in the Study', '75', '6.0', 'Complaints', '75', '6.1', 'Medical Complaints', '76', '6.1.1', 'Definitions', '76', '6.1.1.1', 'Adverse Event', '76', '6.1.1.2', 'Serious Adverse Events', '77', '6.1.1.3', 'Adverse Events Expected Due to SCLC or Progression of SCLC', '78', '6.1.2', 'Adverse Event Severity', '79', '6.1.3', 'Relationship to Study Drug', '79', '6.1.4', 'Deaths', '80', '6.1.5', 'Adverse Event Collection Period', '81', '6.1.6', 'Adverse Event Reporting', '82', '6.1.7', 'Pregnancy', '84', '6.1.8', 'Toxicity Management', '84', '6.1.8.1', 'Management of Serosal Effusions/Serositis', '85', '6.1.8.2', 'Management of Skin Reactions', '85', '6.1.8.3', 'Management of Potential Drug-Induced Liver Injury', '87', '6.1.8.4', 'Monitoring and Management of Edema', '89', '6.1.8.5', 'Pneumonitis', '91', '6.2', 'Product Complaint', '92', '6.2.1', 'Definition', '92', '6.2.2', 'Reporting', '92', '7.0', 'Protocol Deviations', '93', '8.0', 'Statistical Methods and Determination of Sample', 'Size', '94', '8.1', 'Statistical and Analytical Plans', '94', '8.1.1', 'Disposition of Study Subjects', '95', '8.1.2', 'Demographics and Baseline Characteristics', '95', '8.1.3', 'Efficacy Endpoints and Analyses', '95', '8.1.4', 'Primary Efficacy Endpoints', '96', '23']"
23,page_24,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.1.5', 'Secondary Efficacy Endpoints', '97', '8.1.6', 'Exploratory Efficacy Endpoints', '97', '8.1.7', 'Patient Reported Outcomes (PRO)', '98', '8.1.8', 'Planned Sensitivity and Subgroup Analyses', '99', '8.1.9', 'Pharmacokinetic and Exposure-Response Analyses', '99', '8.2', 'Safety Analyses', '100', '8.2.1', 'Treatment-Emergent Adverse Events (TEAEs)', '100', '8.2.2', 'Clinical Laboratory Evaluation', '101', '8.2.3', 'Vital Signs', '101', '8.2.4', 'ECOG Performance Status', '101', '8.2.5', 'Electrocardiogram', '101', '8.2.6', 'Concomitant Medications', '101', '8.3', 'Type I Error Adjustment Procedure for Multiple Testing', '101', '8.4', 'Determination of Sample Size', '105', '8.5', 'Futility Analysis', '106', '8.6', 'Accrual/Study Duration Considerations', '106', '8.7', 'Randomization Methods', '107', '9.0', 'Ethics', '107', '9.1', 'Independent Ethics Committee (IEC) or Institutional Review', 'Board (IRB)', '107', '9.2', 'Ethical Conduct of the Study', '108', '9.3', 'Subject Information and Consent', '108', '9.3.1', 'Informed Consent Form and Explanatory Material', '109', '9.3.2', 'Revision of the Consent Form and Explanatory Material', '109', '10.0', 'Source Documents and Case Report Form', 'Completion', '110', '10.1', 'Source Documents', '110', '10.2', 'Case Report Forms', '110', '11.0', 'Data Quality Assurance', '112', '12.0', 'Use of Information', '112', '13.0', 'Completion of the Study', '113', '14.0', ""Investigator's Agreement"", '114', '15.0', 'Reference List', '115', '24']"
24,page_25,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'List of Tables', 'Table 1.', 'Examples of Strong CYP3A4 Inhibitors', '41', 'Table 2.', 'Clinical Laboratory Tests', '49', 'Table 3.', 'Identity of Investigational Products', '65', 'Table 4.', 'Dose Reductions for Blinded Investigational Product (IP)', '70', 'Table 5.', 'Dose Reductions and Discontinuation for Unacceptable Toxicities', '71', 'Table 6.', 'Recommended Management of Photosensitivity', '87', 'List of Figures', 'Figure 1.', 'Study Schema', '33', 'Figure 2.', 'Adverse Event Collection', '81', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Endpoints', '104', 'List of Appendices', 'Appendix A.', 'Responsibilities of the Clinical Investigator', '117', 'Appendix B.', 'List of Protocol Signatories', '119', 'Appendix C.', 'Study Activities', '120', 'Appendix D.', 'Performance Status Scales Conversion', '127', 'Appendix E.', 'Calculated Creatinine Clearance Using Modified Cockcroft-Gault', 'Equation', '128', 'Appendix F.', 'New York Heart Association Classification', '129', 'Appendix G.', 'Response Evaluation Criteria for Solid Tumors (RECIST) V 1.1', 'for Tumor Response', '130', 'Appendix H.', 'CTCAE V 4.0 Grading of Relevant AEs', '137', 'Appendix I.', 'Fluid Retention Questionnaire', '142', 'Appendix J.', 'Adverse Events Expected Due to SCLC or Progression of SCLC', '144', 'Appendix K.', 'Protocol Amendment: List of Changes', '146', '25']"
25,page_26,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '3.0', 'Introduction', '3.1', 'Small Cell Lung Cancer', 'Small cell lung cancer (SCLC) is an important unmet medical need, representing 15 -', '20% of the 220,000 annual new cases of lung cancer. 1,2 SCLC arises from epithelial cells', 'with neuroendocrine differentiation. Historically, SCLC has been staged using the', 'Veterans Administration (VA) staging system as limited versus extensive stage disease,', 'the former being defined as disease limited to the chest that can be encompassed by a', 'radiation field while the latter includes all other cases. Approximately one-third of newly', 'diagnosed patients will have limited stage disease while the rest will be extensive.', 'Systemic chemotherapy remains the cornerstone of therapy for all stages of SCLC.', 'Standard initial chemotherapy for all patients with a suitable performance status consists', 'of a platinum salt (carboplatin or cisplatin) in combination with a second agent, usually', 'etoposide or irinotecan. For patients with limited stage disease, concurrent or sequential', 'involved-field thoracic radiotherapy is indicated. Response rates to initial therapy are', 'high, ranging from 70 - 90% for limited stage and 60 - 70% for extensive stage; however,', 'responses are typically not durable and recurrence rates are high in the limited stage', 'disease and nearly universal in the extensive stage disease, leading to median survivals of', '14 - 20 months and 9 - 11 months, respectively.³', 'Extensive stage disease subjects achieving SD or better during first-line platinum-based', 'therapy have median progression-free survival (PFS) of approximately 2.1 - 2.3 months', 'and median os of approximately 6.9 - 8.9 months from the completion of first-line', 'therapy. 4,5 Exploration of clinical benefit maintenance strategies in extensive disease', 'SCLC with the goal of prolonging PFS and OS after completion of first-line standard', 'therapies is therefore warranted.', '3.2', 'Delta-Like Protein 3', 'Delta-like protein 3 (DLL3) is an atypical, inhibitory ligand of the Notch receptor family,', 'discovered by AbbVie Stemcentrx scientists as a novel therapeutic target in SCLC and', '26']"
26,page_27,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'other high-grade neuroendocrine carcinomas. It was identified by whole transcriptome', 'sequencing of tumor initiating cells (TICs) isolated from SCLC and large cell', 'neuroendocrine cancer (LCNEC) patient-derived xenografts (PDXs), and found to be', 'expressed in the majority of SCLC and LCNEC tumors, but with no detectable protein', 'expression in normal tissues or non-neuroendocrine tumor types. 6 DLL3 has been', 'implicated in the regulation of cell fate decisions during development, and likely acts as', 'an oncogene in high-grade neuroendocrine tumors where it is a downstream', 'transcriptional target of the achaete-scute homolog 1 (ASCL1) transcription factor in', 'SCLC tumor cells, and acts to inhibit the Notch receptor pathway, thereby facilitating', 'neuroendocrine tumorigenesis. 6-8', '3.3', 'Rovalpituzumab Tesirine', 'Rovalpituzumab tesirine (SC16LD6.5) is a DLL3-targeted antibody-drug conjugate', '(ADC) consisting of the humanized DLL3-specific IgG1 monoclonal antibody SC16; the', 'DNA cross-linking agent SC-DR002 (D6.5); and a protease-cleavable linker that', 'covalently links SC DR002 to SC16. The primary mechanism of rovalpituzumab tesirine', 'is binding of the ADC to DLL3 on target-expressing cells, followed by internalization of', 'the ADC-DLL3 complex and release of SC-DR002 via proteolytic cleavage in late', 'endosomes. Interstrand crosslinks of cellular DNA induced by intercalated SC-DR002', 'leads to cellular cytotoxicity.', 'In the Phase 1 first in human study of rovalpituzumab tesirine (Study SCRX16-001) the', 'best overall response (confirmed) for all SCLC subjects (dose escalation, retreatment, and', 'maintenance cohorts) was retrospectively assessed by the Independent Review Committee', '(IRC) by RECIST v1.1 criteria. The ORR (confirmed) was 16% (95% CI: 7.35, 27.42),', 'with 12% achieving PR. The clinical benefit rate (CBR) was 59% (95% CI: 44.93,', '71.40). The median duration of response by the IRC was 1.7 months (95% CI: 0.03,', '3.06). The median progression-free survival by the IRC was 3.0 months (95% CI: 2.56,', '3.84), with a probability of progression-free survival at 12 weeks of 52% (95% CI: 39,', '63). The median overall survival was 4.3 months (95% CI: 3.22, 5.65). The probability', 'of overall survival at 12 weeks was 69% (95% CI: 52,81). In DLL3-positive (> 1%', '27']"
27,page_28,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay) subjects,', 'the ORR was 23% (95% CI: 10.42, 40.14), and the CBR was 77% (95% CI: 59.86,', '89.58). A slightly higher ORR (27%) and CBR (87%) were observed in DLL3-high', '( 50% tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay)', 'subjects.', 'In the Phase 2 Study SCRX001-002 (TRINITY) in patients with SCLC recurrent after at', 'least two systemic chemotherapy regimens, rovalpituzumab tesirine dosed at 0.3 mg/kg', 'every 6 weeks for two cycles (with an option for additional two cycles upon progression', 'occurring > 12 weeks after the second dose) resulted in the following:', 'In DLL3 high @ 75% tumor cells staining positive for DLL3 with VENTANA', 'Rabbit IHC (SP347) DLL3 assay) subjects, ORR of 14% per IRC assessment,', 'median OS of 5.7 months and median PFS of 3.8 months', 'In DLL3 high subjects, the clinical benefit rate was 74% with a median duration', 'of clinical benefit of 3.0 months per IRC assessment', 'Additionally, DLL3 positive (> 25% tumor cells staining positive for DLL3 with', 'VENTANA Rabbit IHC (SP347) DLL3 assay) and DLL3 high groups had comparable', 'response rates given highly overlapping populations where approximately 85% of DLL3', 'positive subjects were also DLL3 high', 'In December 2018, enrollment in Study M16-289 TAHOE (""A Randomized, Open-Label,', 'Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for', 'Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who', 'have First Disease Progression During or Following Front-Line Platinum-Based', 'Chemotherapy"") was discontinued at the recommendation of the Independent Data', 'Monitoring Committee (IDMC) after review of available efficacy data which', 'demonstrated shorter overall survival in the rovalpituzumab tesirine arm compared with', 'the topotecan control arm. At the time enrollment was halted, 444 DLL3 high (> 75%', 'tumor cells staining positive for DLL3 with VENTANA Rabbit IHC (SP347) DLL3', 'assay) subjects had enrolled on the trial. The IDMC recommended that investigators and', '28']"
28,page_29,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'subjects make individual decisions as to whether or not to continue treatment based on', 'patient level response. The results of the TAHOE study did not adversely impact the', 'safety profile for rovalpituzumab tesirine.', '19', '3.4', 'Differences Statement', 'This is the first randomized, double-blind, multicenter, Phase 3 study comparing', 'rovalpituzumab tesirine versus placebo as maintenance therapy following first-line', 'platinum-based therapy in subjects with extensive-stage SCLC.', '3.5', 'Benefits and Risks', 'Although response rates to first-line platinum-based chemotherapy in ED SCLC are high,', 'SCLC nearly invariably recurs, which may be attributed to the relative resistance of', 'cancer stem cells (CSCs)/TICs to conventional chemotherapy. Rovalpituzumab tesirine', 'has been found to reduce the frequency of TICs in low passage SCLC patient-derived', 'xenograft models significantly more than platinum-based SOC therapy. By targeting this', 'resistant, residual cell population, rovalpituzumab tesirine has a unique mechanistic', 'rationale for benefit in post-chemotherapy maintenance setting. Rovalpituzumab tesirine', 'had shown promising clinical activity in subjects with recurrent/relapsed SCLC', '(Section 3.3), and it is likely that the observed benefit will translate into maintenance', 'setting. This study will assess the efficacy, tolerability, and safety of rovalpituzumab in', 'subjects with extensive-stage SCLC who have ongoing clinical benefit (SD, PR, or CR)', 'following first-line platinum-based chemotherapy (cisplatin or carboplatin in combination', 'with etoposide or irinotecan).', 'As of 30 June 2018, 1246 subjects have received study medication in the rovalpituzumab', 'tesirine clinical program; an estimated 1039 subjects (with SCLC or other DLL3- -', 'expressing solid tumors) have received at least 1 dose of rovalpituzumab tesirine at doses', 'ranging from 0.05 mg/kg to 0.8 mg/kg on a q3w schedule and 0.3 mg/kg to 0.4 mg/kg on', 'a q6w schedule.', '29']"
29,page_30,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w, 96.8%', 'of subjects reported at least 1 adverse event. The most frequently reported adverse events', 'among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w were', 'decreased appetite (28.0%), photosensitivity reaction (27.7%), oedema peripheral', '(27.2%), dyspnoea (26.6%), and nausea (25.6%). Important identified risks following', 'treatment with rovalpituzumab tesirine include: pleural effusions (33.9%), pericardial', 'effusions (16.7%), generalized edema (2.7%) and photosensitivity reactions (27.7%).', 'Important potential risks following treatment with rovalpituzumab tesirine include', 'pneumonitis (1%). The following adverse events of special interest have also been', 'identified: cutaneous reactions (48.7%), thrombocytopenia and hemorrhage events', '(28%), edema (33.8%), hypoalbuminemia (16.2%), hepatotoxicity (19.3%),', 'nephrotoxicity (5.9%), anemia (19.7%), neutropenia (9.2%) and infusion related reaction', '(0.2%). In addition, preclinical toxicology studies conducted in the rat and the', 'cynomolgus monkey have identified bone marrow, lung, and kidney as potential sources', 'of clinical adverse events (AEs) (AbbVie Investigator Brochure v7). Accordingly, safety', 'assessments will include regular assessments at protocol-specified time points of routine', 'physical examination, laboratory and imaging tests including CT/MRI assessments and', 'echocardiograms, a fluid retention questionnaire, and daily weights (Section 5.3.1.1). The', 'timing and frequency of these assessments are designed so that potential rovalpituzumab', 'tesirine-related toxicities are identified prior to additional drug doses, limiting the risk of', 'toxicity exacerbation. The dose delay/reduction/discontinuation protocol guidelines', 'provide additional level of risk mitigation for subjects enrolled in this study.', 'It is thus considered that the study has acceptable benefit/risk profile for subjects with ED', 'SCLC and stable disease or better following completion of four cycles of platinum-based', 'standard front line treatment, taking into account short progression-free and overall', 'survival of these subjects.4', '4.0', 'Study Objectives', 'The primary objective of this study is to evaluate if rovalpituzumab tesirine improves', 'progression-free survival, assessed by CRAC, and overall survival in subjects with', '30']"
30,page_31,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'extensive-stage SCLC tumors with a high level of DLL3 expression (DLL3high) who have', 'ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles of', 'first-line, platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or', 'etoposide) compared to placebo.', 'The secondary objectives are:', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'CRAC and overall survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical', 'functioning as measured by the EORTO QLQ-C30questionnaire in all', 'randomized subjects compared to placebo.', 'The exploratory objectives are:', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining', 'objective response rate (ORR), clinical benefit rate (CBR), and duration of', 'responses (DOR) by CRAC and investigator assessment in DLL3high and in all', 'randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'investigator assessment compared to placebo in DLL3high and in all', 'randomized subjects.', 'To assess change from baseline in all patient reported outcomes (PRO)', 'domains (except physical functioning) measured by EORTC QLQ-C30/LC13', 'and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic', 'antibodies (ATAs) against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor', 'for association with sensitivity, efficacy and safety.', 'To explore the DLL3 expression in circulating tumor cells (CTCs) for', 'association with efficacy.', '31']"
31,page_32,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.0', 'Investigational Plan', '5.1', 'Overall Study Design and Plan: Description', 'The study is designed to enroll approximately 740 SCLC subjects to obtain approximately', '480 subjects with DLL3 high expression in tumor (DLL3high) and to meet scientific and', 'regulatory objectives without enrolling an undue number of subjects in alignment with', 'ethical considerations. DLL3high is defined as > 75% tumor cells staining positive', 'according to the VENTANA DLL3 (SP347) IHC Assay.', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and', 'multicenter study. Approximately 300 clinical sites will participate.', 'Eligible subjects will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg', 'rovalpituzumab tesirine or placebo, and will receive their assigned therapy on Day 1 of', 'each 6-week cycle, omitting every third cycle. Subjects will also receive 8 mg orally (PO)', 'of dexamethasone or placebo twice daily on Day -1, Day 1 (the day of dosing), and Day 2', 'of each 6-week cycle, omitting every third cycle. Subjects will be stratified by', 'RECIST v1.1 response after completion of first-line platinum-based chemotherapy at', 'screening assessment (SD VS. PR/CR), DLL3 expression (Unknown VS. 0% to < 25% VS.', '25% to < 75% VS. 75% or above), history of central nervous system (CNS) metastases', '(Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to', 'follow-up or withdraws consent, or termination of the study by AbbVie, whichever occurs', 'first.', 'A schematic of the study is provided in Figure 1, Study Schema.', '32']"
32,page_33,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Figure 1.', 'Study Schema', 'VV', '...', 'R', 'rovalpituzumab', 'Clinical Benefit', 'A', 'tesirine/dexamethasone', '(SD, PR, CR)', 'N', 'q6 wk (omit every 3rd cycle)', 'S', 'First-line', 'D', 'No', 'Screening', 'D', 'PTFU', 'os', 'C', 'o', 'End of', 'Progression', 'Chemotherapy', 'PCI¹', 'Procedures', 'A', 'L', '& Labs²', 'M', 'Treatment', '(4 Cycles)', 'Y', 'I', 'C', '1', 'os', 'Z', 'Progression', 'E', '...', '3', 'placebo q6 wk', '(omit every 3rd cycle)', 'Arrowheads = blinded investigational product administration; CR = complete response; os = overall survival;', 'PR = partial response; PTFU = post-treatment follow-up; SD = stable disease', '1. Upon completion of first-line platinum-based chemotherapy, eligible subjects must be offered prophylactic cranial', 'irradiation (PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study.', '2.', 'Collection of tumor material for DLL3 testing will be provided any time after the signing of the informed consent', 'and prior to randomization.', '3.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the fourth cycle of first-line', 'platinum-based chemotherapy.', 'On study disease assessments, for the purposes of efficacy assessments will be performed', 'by a Central Radiographic Assessment Committee (CRAC) blinded to study treatment', 'information and independent of Investigators and personnel who are involved in', 'conducting the study (Section 5.3.1.1).', '5.2', 'Selection of Study Population', 'Current standard of care after first-line platinum-based chemotherapy consists primarily', 'of observation until disease progression, at which time second line chemotherapy, such as', 'with topotecan, may be instituted. No therapy is approved for use or routinely used as', 'maintenance or consolidation after first-line platinum-based chemotherapy in extensive', 'stage SCLC. Rovalpituzumab tesirine may be beneficial in this setting, but no prior', 'studies have formally explored its potential. Therefore, this study will involve a', 'comparison of rovalpituzumab tesirine against placebo.', '33']"
33,page_34,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'For the purposes of study eligibility, limited stage disease SCLC (LD-SCLC) is defined as', 'a disease confined to the hemithorax of origin, with or without the involvement of', 'regional lymph nodes, including ipsilateral and contralateral hilar, ipsilateral and', 'contralateral mediastinal, and ipsilateral supraclavicular nodes. Extensive stage disease', 'SCLC (ED-SCLC) is defined as all other SCLC.', 'Subjects must meet all of the inclusion and none of the exclusion criteria to be eligible for', 'this study. Eligibility criteria may not be waived by the Investigator and are subject to', 'review in the event of a Good Clinical Practice (GCP) audit and/or regulatory authority', 'inspection.', '5.2.1', 'Inclusion Criteria', '1.', ""Subject or the subject's legally acceptable representative must voluntarily sign and"", 'date an informed consent, approved by an Independent Ethics Committee', '(IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or', 'study-specific procedures and should be willing and able to comply with', 'parameters as outlined in the protocol.', '2.', 'Subject must be > 18 years of age.', '3.', 'Histologically or cytologically confirmed ED SCLC (extensive stage disease at', 'initial diagnosis), with ongoing clinical benefit (SD, PR, or CR per RECIST v.1.1)', 'following completion of 4 cycles of first-line platinum-based therapy (cisplatin or', 'carboplatin in combination with etoposide or irinotecan).', '4.', 'Subjects with a history of CNS metastases prior to the initiation of first-line', 'platinum-based therapy must have received definitive local treatment and have', 'documentation of stable or improved CNS disease status based on brain imaging', 'within 28 days prior to randomization, off or on a stable dose of corticosteroids.', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from', 'Day 1 of the fourth cycle of first-line platinum-based chemotherapy.', '34']"
34,page_35,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.', 'Availability of archived or representative tumor material for assessment of DLL3', 'expression.', '7.', 'Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 (Refer', 'to Appendix D).', '8.', 'Recovery to < Grade 1 of any clinically significant toxicity (excluding alopecia)', 'prior to randomization.', '9.', 'Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b. Platelet count > 75,000/L', 'c. Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin V 1.5 X upper limit of normal (ULN) or < 3 X ULN for', ""subjects with Gilbert's disease"", 'e. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST)', '<3 X ULN (< 5 X ULN if evidence of hepatic involvement by malignant', 'disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault', 'formula (Refer to Appendix E)', 'g. Albumin > 3 g/dL', '10.', 'If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative', 'medical cause.', 'Age V 55 years with no menses for 12 or more months without an alternative', 'medical cause AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy', 'or hysterectomy).', '35']"
35,page_36,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'OR a Woman of Childbearing Potential (WOCBP) practicing at least one protocol', 'specified method of birth control (Section 5.2.4), starting at randomization through', 'at least 6 months after the last dose of blinded investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at', 'least 6 months after the last dose of blinded investigational product, to practice the', 'protocol specified contraception (Section 5.2.4).', '11.', 'Females of childbearing potential must have a negative serum pregnancy test result', 'at Screening, and a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently', 'surgically sterile as defined in Section 5.2.4) at Screening do not require pregnancy', 'testing.', 'Rationale for Inclusion Criteria', '1', 'In accordance with Harmonized Good Clinical Practice (GCP)', '2 7', 'To select and/or collect data on the subject population', '8 9', 'For the safety of the subjects', '10 - 11', 'The impact of rovalpituzumab tesirine on pregnancy in humans is', 'unknown', '5.2.2', 'Exclusion Criteria', 'A subject will not be eligible for study participation if he/she meets any of the following', 'criteria:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for SCLC.', '36']"
36,page_37,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '2.', 'Any disease-directed radiotherapy (except PCI, palliative radiotherapy to a', 'radiographically documented non-progressing lesion for symptom control, or pre-', 'planned radiotherapy for CNS metastases present prior to start of first-line therapy', 'and non-progressing) after last dose of first-line chemotherapy.', '3.', 'Any significant medical condition including any suggested by screening laboratory', 'findings that in the opinion of the Investigator or Sponsor may place the subject at', 'undue risk from the study.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '(NYHA) Class III - IV heart failure (refer to Appendix F) within 6 months prior to', 'randomization.', '5.', 'Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization', 'or earlier history of recurrent Grade 2 or higher effusions with ongoing requirement', 'for pericardiocentesis or thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or', 'higher (per NCI CTCAE version 4.0)11 viral, bacterial, or fungal infection.', '8.', 'Female subject who is pregnant, breastfeeding or is considering becoming pregnant', 'during the study or for approximately 6 months after the last dose of blinded', 'investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the', 'study or for approximately 6 months after the last dose of blinded investigational', 'product.', '10.', 'Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent', 'within 1 week prior to randomization.', '11.', 'Subject has a history of active malignancies other than SCLC within the past', '2 years prior to study entry, with the exception of in situ cancer which was', 'curatively treated.', '37']"
37,page_38,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD-based) or', 'indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine', 'clinical trial, or known hypersensitivity or other contraindications to', 'rovalpituzumab tesirine or excipient contained in the drug formulation.', '13.', 'Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary', 'cells.', 'Rationale for Exclusion Criteria', '1, 10 - 13', 'To select the appropriate subject population', '2-7', 'For the safety of the subjects', '8 9', 'The impact of rovalpituzumab tesirine on pregnancy in humans is', 'unknown', '5.2.3', 'Prior and Concomitant Therapy', 'Any concomitant medication or vaccine (including over-the-counter or prescription', 'medicines, vitamins and/or herbal supplements) that the subject is receiving at the time of', 'study drug administration or receives during the study through the safety reporting period', '(Section 6.1.5), must be recorded along with the reason for use, date(s) of administration', 'including start and end dates, and dosage information including dose, route and frequency.', 'Any concomitant therapy given for a protocol-related AE should be recorded from the', 'time of informed consent.', 'The AbbVie TA MD should be contacted if there are any questions regarding concomitant', 'or prior therapies.', '5.2.3.1', 'Prior Therapy', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', '38']"
38,page_39,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'irinotecan; administration of Day 1 of the last cycle of first-line chemotherapy must be at', 'least 3 weeks but no more than 9 weeks prior to randomization. Subjects previously', 'treated for LD-SCLC are not eligible.', 'Subjects with central nervous system (CNS) metastases present prior to the initiation of', 'first-line chemotherapy will have completed definitive local treatment (e.g., surgery or', 'radiotherapy). Upon completion of first-line chemotherapy, subjects without a history of', 'CNS metastases must have been offered prophylacti cranial irradiation (PCI), if offering', 'this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. PCI regimen must', 'be consistent with those endorsed by the National Comprehensive Cancer Network', '(NCCN) or European Society for Medical Oncology (ESMO).', '5.2.3.2', 'Concomitant Therapy', 'All subjects enrolled will receive premedication consisting of dexamethasone/placebo.', 'Refer to Section 5.5.1, Treatments Administered for details.', 'There are no other required concomitant therapies. However, due to the potential for', 'rovalpituzumab tesirine-related skin photosensitivity, patients should be advised to avoid', 'direct and indirect sun exposure as much as possible from Cycle 1 Day 1 until 30 days', 'after the final dose. When sun exposure is unavoidable, patients should wear protective', 'clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm (SPF 30 or', 'greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the patient may', 'resume outdoor activities with appropriate sun protection including broad brimmed hat,', 'protective clothing and sunscreen SPF 30 or higher.', '5.2.3.2.1', 'Allowed Concomitant Therapy', 'Standard supportive care for drug-related toxicity is permitted, including growth factors', 'and blood product transfusions per local institutional standards. Other standard', 'supportive care for symptom control or drug-related toxicity is allowed, such as', 'analgesics, anti-emetics, electrolyte replacement, and hydration. Bone modifying agents', '39']"
39,page_40,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '(e.g., bisphosphonates, denosumab) for bone metastases are also permitted per local', 'institutional standards. Other prescribed medications for non-neoplastic conditions are', 'allowed, as well as vitamins and nutritional supplements.', 'Concomitant prednisone (or equivalent) may be used at a dose of VI 10 mg/day. The use', 'of intermittent high-dose corticosteroid treatment to prevent or manage infusion reactions,', 'serosal effusions (see Section 6.1.8.1), or other non-cancer-related symptoms including', 'premedication for known hypersensitivity reactions to contrast for scans is allowed.', 'Routine prophylaxis with vaccines is permitted; however, vaccines used should not', 'contain live micro-organisms.', 'If the subject is taking chronic suppressive anti-infectives (antiviral, antifungal, or', 'antibacterial), appropriate investigation must be completed prior to randomization, and', 'documentation must exclude active infection. After exclusion of active infection,', 'otherwise eligible subjects should complete or continue suppressive anti-infectives as', 'prescribed.', 'If a subject requires palliative radiation during the study (e.g., symptomatic worsening of', 'a bone lesion) diagnostic imaging has to be performed to assess for radiographic', 'progression prior to radiation, and documentation of non-progressive status by', 'radiography will be captured in the eCRF. Any cancer-directed therapy a subject receives', 'due to disease improvement should be discussed with the TA MD in advance, if possible.', 'In the event of isolated CNS-only progression during study treatment, blinded', 'investigational product may be withheld while local treatment is administered', '(e.g., radiotherapy) in accordance with institutional practice. Blinded investigational', 'product may be restarted 1 week after the completion of local CNS disease-directed', 'therapy.', '40']"
40,page_41,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.2.3.3', 'Prohibited Therapy', 'Subjects may not receive other investigational drugs, immunosuppressive medications,', 'radiotherapy, or systemic anti-neoplastic therapy during the study, other than as allowed', 'in Section 5.2.3.2 and Section 5.2.3.2.1. Additionally, strong inhibitors of cytochrome', 'P450 3A4 (CYP3A4) should be avoided (refer to Table 1).', 'Table 1.', 'Examples of Strong CYP3A4 Inhibitors', 'Enzyme/Transporter', 'Strong Inhibitor Examples10', 'CYP3A4', 'boceprevir, clarithromycin, cobicistat, conivaptan,', 'danoprevir and ritonavir, diltiazem, elvitegravir', 'and ritonavir, idelalisib, indinavir and ritonavir,', 'itraconazole, ketoconazole, lopinavir and ritonavir,', 'nefazodone, nelfinavir paritaprevir and ritonavir', 'and (ombitasvir and/or dasabuvir), posaconazole,', 'ritonavir, saquinavir and ritonavir, telaprevir,', 'tipranavir and ritonavir, troleandomycin,', 'voriconazole', '(CYP) Cytochrome P450.', 'Note:', 'This is not an exhaustive list; so if in question, please refer to the appropriate product label.', '5.2.4', 'Contraception Recommendations', 'If female, subject must be either postmenopausal or permanently surgically sterile (refer', 'to inclusion criteria for definitions of both) OR a Woman of Childbearing Potential', '(WOCBP), practicing at least one of the following methods of birth control, on', 'randomization (or earlier) through at least 6 months after the last dose of blinded', 'investigational product.', 'Combined (estrogen and progestogen containing) hormonal contraception', '(oral, intravaginal, transdermal) associated with the inhibition of ovulation,', 'initiated at least 1 month prior to randomization.', 'Progestogen-only hormonal contraception (oral, injectable, implantable)', 'associated with inhibition of ovulation, initiated at least 1 month prior to', 'randomization.', '41']"
41,page_42,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Bilateral tubal occlusion/ligation.', 'Bilateral tubal occlusion via hysteroscopy (i.e., Essure), provided', 'a', 'hysterosalpingogram confirms success of the procedure.', 'Vasectomized partner(s), provided the vasectomized partner has received', 'medical assessment of the surgical success and is the sole sexual partner of the', 'WOCBP trial participant.', 'Intrauterine device (IUD).', 'Intrauterine hormone-releasing system (IUS).', 'True abstinence: Refraining from heterosexual intercourse when this is in line', 'with the preferred and usual lifestyle of the subject (periodic abstinence', '[e.g., calendar, ovulation, symptothermal, post-ovulation methods] and', 'withdrawal are not acceptable).', 'If required per local practices, male or female condom with or without spermicide OR', 'cap, diaphragm or sponge with spermicide should be used in addition to one of the birth', 'control methods listed above (excluding true abstinence).', 'Male subjects who are sexually active with a WOCBP, even if the male subject has', 'undergone successful vasectomy, must agree from randomization through at least', '6 months after the last dose of blinded investigational product to use condoms and his', 'female partner(s) must use at least one of the contraceptive measures (as defined in the', 'protocol for female study subjects of childbearing potential).', 'Male subject agrees not to donate sperm from randomization through at least 6 months', 'after the last dose of blinded investigational product.', '5.3', 'Efficacy, Pharmacokinetic, Biomarker, Pharmacogenetic', 'and Safety Assessments/Variables', '5.3.1', 'Efficacy and Safety Measurements Assessed and Flow', 'Chart', 'Study procedures described are listed in the following section of this protocol and are', 'summarized in tabular format in Appendix C, Study Activities.', '42']"
42,page_43,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.1.1', 'Study Procedures', 'Unless otherwise stated, the baseline measurement for any given variable will be defined', 'as the last value obtained for the variable prior to the first dose of blinded investigational', 'product.', 'Screening procedures must be performed within 21 days prior to randomization, with the', 'exception of radiographic assessments (CT scan or MRI including the head, chest, and', 'abdomen) which may be performed within 28 days prior to randomization. The collection', 'of tumor material for DLL3 testing will be provided any time after the signing of the', 'informed consent and prior to randomization. Randomization may occur within 3 days', 'prior to C1D1.', 'Subsequent study procedures should be performed within 3 days prior to the scheduled', 'treatment visits, within a 3 day window during the non-treatment visits, and within a', '1 week window during the post-treatment follow up, and survival follow up phase unless', 'otherwise indicated.', 'The results of all screening and evaluations at the time of randomization must be within', 'clinically acceptable limits, upon review by the investigator, before a subject can be', 'randomized. Subjects will not be randomized in the study if laboratory or other screening', 'results are unacceptable. Subjects are allowed to rescreen and have laboratory samples', 'redrawn to meet eligibility within the same 21 day screening window. Subjects who meet', 'the inclusion criteria and do not meet any of the exclusion criteria may be randomized.', 'Informed Consent', 'Signed informed consent will be obtained from the subject before any study-specific', 'procedures are undertaken or before any prohibited medications are withheld from the', 'subject in order to participate in this study. Informed consent may be obtained before the', '21-day screening window. For the optional tumor biopsy procedure at time of disease', 'progression an optional tumor material biopsy procedure informed consent should be', '43']"
43,page_44,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'completed. Details about how informed consent will be obtained and documented are', 'provided in Section 9.3.', 'Subjects will be considered screen failures if the informed consent has been signed and a', 'study-specific procedure has been performed (e.g., central laboratories drawn), but subject', 'does not randomize into the study. The reason for screen failure will be documented in', 'the source and will be captured in the eCRF.', 'Tumor Material at Screening', 'For all subjects, archived or fresh tumor material must be submitted to the AbbVie', 'designated central IHC laboratory for determination of DLL3 expression prior to', 'randomization, as per Appendix C, Study Activities.', 'Tumor material testing for DLL3 status may occur at any time after initial diagnosis for', 'subjects who provide consent. These subjects must be registered in IRT. Eligibility will', 'depend on the fulfillment of all other inclusion and exclusion criteria and the trial status', '(whether the study is still open for accrual).', 'For purposes of the study, ""unknown"" status is possible if all available samples were', 'tested and failed due to unforeseen technical or logistical reasons; subject with no tumor', ""sample will not be eligible for the trial or subject with sample not fulfilling sponsor's"", 'specifications (different method of tissue fixation, known necrotic, too few cells etc.) will', 'not be eligible.', 'Medical and Surgical History (Including Malignancy History); Adverse Event and', 'Prior/Concomitant Medication Assessment', 'The following will be collected during the Screening Visit:', 'Medical history, including demographics and documentation of any clinically', 'significant medical condition and/or surgical history', 'History of tobacco and alcohol use:', '44']"
44,page_45,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'current smoker [subject who has > 100 smoking events in their lifetime', 'and has smoked within the last 12 months]', 'past smoker [subject who has > 100 smoking events in their lifetime and', 'has not smoked in past 12 months]', 'never smoked [subject with VI 100 smoking events in lifetime]', 'Detailed oncology history including:', 'Histology', 'Date of initial cancer diagnosis', 'TNM Stage at diagnosis, if available', 'Veterans Administration (VA) Stage at diagnosis', 'Sites of metastases', 'Absence of active CNS metastases will be confirmed by MRI or CT of', 'the brain', 'Mutational status, if performed or applicable', 'Any surgical procedures', 'Treatments administered (including dates and type of modality)', 'Detailed prior and concomitant medication usage including dates of usage and', 'dosing information for all medications and supplements taken', 'Any changes observed from the Screening assessments (prior to dosing) will be recorded', ""in the subject's medical history. At each visit, including the End of Treatment Visit, the"", ""subject's medical history will be reviewed and any changes from baseline will be recorded"", 'on the adverse event eCRF.', 'All medication (prescription or over-the-counter, including vitamins and/or herbal', 'supplements) will be recorded from the first study drug administration through the', '70 days following the last dose of blinded investigational product.', '45']"
45,page_46,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Physical Examination', 'A physical examination will be performed per Appendix C, Study Activities. If the', 'Screening assessment is performed within 21 days of C1D1, it is not required to be', 'repeated on C1D1 unless clinically indicated. Clinically significant changes from', 'baseline will be documented in the source documentation and eCRFs as adverse events.', 'Height will be measured at the Screening visit only. For height assessments, the subject', 'should not wear shoes.', 'Investigators will assess subjects for pleural and pericardial effusion prior to dosing of', 'blinded investigational product on Day 1 of each cycle.', 'Physical exam will include cardiac, pulmonary (including cardiopulmonary exam for', 'serosal effusions), evaluation of extremities for peripheral edema, neurological (sensory,', 'motor, cranial nerves), head and neck, lymphatic, hepatobiliary, gastrointestinal,', 'genitourinary, and skin evaluation per local standard of care.', 'Vital Signs', 'Vital signs will be performed per Appendix C, Study Activities. Vital signs include actual', 'weight, sitting blood pressure, heart rate and body temperature. If possible, blood', 'pressure and heart rate measurements should not immediately follow scheduled blood', 'collections.', 'Actual weight will be collected in the clinic prior to dosing at each cycle and the recorded', 'weight will be utilized for dosing calculations. For weight assessments, the subject', 'should not wear shoes. In the event of a 5% or greater increase in weight within', '2 consecutive visits or compared to baseline which ever has the shorter interval, a prompt', 'workup for fluid retention (e.g., edema, effusions, etc.) should be conducted. If weight', 'gain is due to proven or suspected fluid retention related to study drug, and dosing is not', 'prohibited per Section 5.5.4, dose should be calculated based on actual weight before the', 'event of fluid retention.', '46']"
46,page_47,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Vital signs should be collected prior to the infusion.', '12-Lead Electrocardiogram (ECG)', 'A resting 12-lead ECG will be performed per Appendix C, Study Activities. ECGs', 'consist of a single 12-lead study performed within a 5-minute window after at least', '5 minutes of quiet rest in a supine position. Additional ECG monitoring may occur as', 'clinically indicated during the study.', 'A qualified physician will determine whether any findings outside of normal', 'physiological variation are clinically significant (in consultation with a cardiologist if', 'necessary). The physician will document whether findings are clinically significant (CS)', 'or not clinically significant (NCS) on the tracing and sign and date the tracing. The', ""original annotated ECG tracing containing the physician's assessment will be retained in"", ""the subject's records at the study site."", 'Echocardiogram', 'Echocardiograms will be performed per Appendix C, Study Activities to rule out', 'pericardial effusion (or assess, if present), as well as assess cardiac function (left', 'ventricular ejection fraction, LVEF).', 'ECOG Performance Status', 'The ECOG performance status will be documented according to Appendix C, Study', 'Activities. Refer to Appendix D, Performance Status Scales Conversion for details.', 'If the Screening assessment is performed within 21 days of C1D1, it is not required to be', 'repeated on C1D1 unless clinically indicated.', 'Documentation of Non-Childbearing Status and Pregnancy Testing', 'For each female subject, the Investigator will document non-childbearing status', '(surgically sterile or post-menopausal for at least 1 year) or potential childbearing status.', '47']"
47,page_48,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Should a female study subject become pregnant or suspect she is pregnant while', 'participating in this study, she should inform the treating Investigator immediately', '(Section 6.1.6).', 'For female subjects of childbearing potential, the laboratory will perform pregnancy', 'testing according to Appendix C, Study Activities. A serum pregnancy test will be', 'performed at Screening and the results must be available prior to the administration of the', 'first dose of blinded investigational product on C1D1. Subjects with borderline', 'pregnancy tests at Screening must have a serum pregnancy test > 3 days later to document', 'continued lack of a positive result. Urine pregnancy tests will be performed at Day 1 of', 'each cycle, the Non-Treatment cycle, End of Treatment Visit, and PTFU until 6 months', 'after the last dose of blinded investigational product.', 'Females of non-childbearing potential (either postmenopausal or permanently surgically', 'sterile as defined in Section 5.2.4) at Screening do not require pregnancy testing. Post-', 'menopausal female subjects VI 55 years of age must have an FSH level > 40 IU/L and will', 'have FSH performed at Screening and assessed by the Investigator.', 'Clinical Laboratory Tests', 'Samples for chemistry, hematology, coagulation, and urinalysis will be collected per', 'Appendix C, Study Activities. Specific laboratory assessments are outlined in Table 2,', 'Clinical Laboratory Tests.', 'If the Screening assessment is performed within 7 days of C1D1, it is not required to be', 'repeated on C1D1 unless clinically indicated. Starting at Cycle 2, lab assessments may be', 'performed 3 days prior to Day 1 visits. All laboratory samples will be assessed using a', 'certified central laboratory and these data will be used for all data analysis. The central', 'laboratory will provide instructions regarding the collection, processing, and shipping of', 'samples. All laboratory samples will be shipped to the central laboratory. A qualified', '(e.g., certification or accreditation) local laboratory may be used to perform laboratory', 'analyses for treatment decisions as per standard of care.', '48']"
48,page_49,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Qualified medical staff at the site will review, initial and date all local and central', 'laboratory results. Any laboratory value outside the reference range that is considered', 'clinically significant by the Investigator will be followed as appropriate. Clinically', 'significant laboratory values will be recorded as adverse events if they meet the criteria as', 'specified in Section 6.1.1.', 'Table 2.', 'Clinical Laboratory Tests', 'Hematology', 'Clinical Chemistry', 'Urinalysis (Dipstick)', 'Hematocrit', 'Blood urea nitrogen (BUN)', 'Specific gravity', 'Hemoglobin', 'Serum creatinine', 'Ketones', 'Red blood cell (RBC) count', 'Total bilirubin', 'pH', 'White blood cell (WBC) count', 'Serum glutamic-pyruvic', 'Protein', 'Neutrophils', 'transaminase (SGPT/ALT)', 'Blood', 'Bands (if indicated)', 'Serum glutamic-oxaloacetic', 'Glucose', 'Lymphocytes', 'transaminase (SGOT/AST)', 'Urobilinogen', 'Monocytes', 'Alkaline phosphatase', 'Bilirubin', 'Basophils (if indicated)', 'Sodium', 'Leukocyte esterase', 'Eosinophils (if indicated)', 'Potassium', 'Platelet count (estimate not', 'Calcium', 'acceptable)', 'Inorganic phosphorus', 'Mean corpuscular volume', 'Uric acid', 'Mean corpuscular hemoglobin', 'Total protein', 'concentration', 'Glucose', 'Serum Pregnancy Test', 'RBC distribution width', 'Albumin', 'Beta-Human Chorionic', 'Coagulation', 'Magnesium', 'Gonadotropin (B-hCG) (if', 'Chloride', 'applicable)', 'Activated Partial', 'Amylase', 'Follicle-stimulating hormone', 'Thromboplastin Time', 'Lipase', '(FSH) (if applicable)', '(aPTT)', 'Lactate dehydrogenase (LDH)', 'Prothrombin time (PT)', 'International Normalized Ratio', '(INR)', 'Disease/Response Assessment (Radiographic Imaging)', 'Treatment response will be assessed by radiographic tumor evaluation per RECIST v1.1', 'at protocol-specified time points as outlined in the Appendix C, Study Activities.', 'Diagnostic quality, spiral CT scan with contrast is recommended for all anatomic areas', 'except brain (MRI is recommended for brain imaging); other CT methods or MRI for', '49']"
49,page_50,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'respective anatomic areas may be used if performed consistently throughout the study for', 'each individual subject and only under the circumstances described in Appendix G. Scans', 'of the chest and abdomen must be obtained; scans of the neck and pelvis must also be', 'obtained if there is documented or suspected involvement in these regions. Screening', 'radiographic assessment must include brain MRI/CT. Diagnostic/baseline pre-first-line', 'scans through screening scans will be reviewed by the investigator to determine disease', 'response status per RECIST v1.1 for eligibility and stratification. On study disease', 'response will be determined by the Investigator at each assessment according to', 'RECIST v1.1 (Appendix G, Response Evaluation Criteria for Solid Tumors', '(RECIST) V 1.1)12 and independently reviewed by Central Radiographic Assessment', 'Committee (described below). Disease/Response Assessment may be performed within', '7 days prior to the Day 1 visit.', 'Effusion (pleural, pericardial, etc.) assessments will be performed by a radiologist at each', 'on-study radiographic assessment and any new findings communicated to the Investigator', 'prior to the next dose of blinded investigational product. Effusions should contribute to', 'disease status assessment per RECIST V 1.1 only if confirmed malignant by cytology or', 'otherwise clearly disease-related; if disease progression is suspected solely based on the', 'appearance of new or increase of existing effusions, confirmation of malignant nature of', 'such effusions is strongly recommended due to known adverse event profile of', 'rovalpituzumab tesirine. If collected, effusion fluid must be tested for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', 'Isolated CNS-only progression will not require removal of the subject from therapy.', 'Refer to Section 5.2.3.2.1, Allowed Concomitant Therapy for details associated with CNS', 'only progression.', 'The EOT assessment may be omitted if the previous assessment was performed within the', 'preceding 6 weeks.', 'Scheduled tumor assessments should not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', '50']"
50,page_51,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'progression warrants otherwise. In some cases, mandatory dose delays due to toxicity', 'will lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Subjects who discontinue treatment for reasons other than radiographic disease', 'progression will continue to be followed every 6 weeks from randomization to determine', 'the extent of tumor burden, until disease progression occurs.', 'MRI/CT of the Brain', 'MRI of the brain will be performed at protocol-specified time points as outlined in', 'Appendix C, Study Activities. Brain MRI may be substituted by CT with intravenous', 'contrast at the discretion of the Investigator. MRI/CT of the brain is required at screening', 'and when clinically indicated (e.g., if CNS progression is suspected) thereafter.', 'Central Radiographic Assessment Committee (CRAC)', 'In addition to being reviewed by the investigator and/or site staff, radiological scans will', 'be assessed by a Central Radiographic Assessment Committee (CRAC), as outlined in the', 'Appendix C, Study Activities. Sites will collect the appropriate scans and ship by courier', ""or submit electronically to the central facility at each subject's disease assessment. If, in"", 'addition to protocol-specified disease assessment modalities other modalities were used to', 'assess disease (e.g., FDG-PET, X-ray), imaging should also be transferred to the central', 'facility.', 'The EOT assessment may be omitted if the previous assessment was performed within the', 'preceding 6 weeks.', 'Subject treatment management will be based on review by the local investigator and/or', 'site staff. The investigator should treat according to clinical judgment and the CRAC will', 'make the definitive decision on tumor response or progression in regards to the PFS', 'endpoint.', '51']"
51,page_52,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Randomization and Subject Number Assignment', 'An Interactive Response Technology system (IRT) will be utilized to register subjects.', 'Subjects who complete all Screening procedures and meet the eligibility criteria will', 'proceed to randomization. Refer to Section 5.5.3 for details associated with subject', 'assignment to treatment arms.', 'Health Resource Utilization', 'Health Resource Utilization will be documented at each clinic visit per Appendix C,', 'Study Activities. Information regarding hospitalizations, emergency room visits, and', 'physician office visits will be collected since the last study visit.', 'Patient Reported Outcomes (PRO)', 'Health-related quality of life and symptom assessments will be performed per', 'Appendix C, Study Assessments using the EORTC QLQ-C30, the EORTC QLQ-LC13,', 'and the European Quality of Life-5 Dimensions (EQ-5D-5L). The European Organization', 'for Research and Treatment of Cancer Quality of Life Questionnaire', '(EORTC QLQ-C30) 13 is used as general cancer-specific instrument. The', 'EORTC QLQ-C30 has 30 items and 5 functional domain scales: Physical, Role,', 'Emotional, Social, and Cognitive; two items evaluate global quality of life. The EORTC', 'QLQ-C30 core questionnaire can be supplemented by the additional lung module EORTC', 'QLQ-LC13, resulting in a 43-item disease and cancer site-specific quality of life and', 'symptom questionnaire. The EORTC QLQ-LC13 module items evaluate symptoms such', 'as cough, haemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling', 'hands or feet, hair loss, and pain. The EuroQol 5 Dimensions 5 Level (EQ-5D-5L) is a', 'generic preference instrument that has been validated in numerous populations. The', 'EQ-5D-5L is composed of 5 questions and a visual analog scale (VAS) assessing overall', 'health that can be converted into a single health status or ""utility"" score for use in an', ""economic evaluation to adjust life-years gained by the subject's health-related quality of"", 'life.', '52']"
52,page_53,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Fluid Retention Questionnaire (Including Subject Daily Weight)', 'Throughout the treatment period as outlined in the Appendix C, Study Activities, subjects', 'will be asked about the development of any new or worsening peripheral edema or', 'dyspnea (Appendix I, Fluid Retention Questionnaire). The assessments on Days 8, 15,', '29, and 36 may take place by phone, with the site contacting the subject and reviewing the', 'questionnaire.', 'Starting on Day 1 through the EOT visit, subjects will maintain a diary of daily weights', '(captured on the Fluid Retention Questionnaire). Subjects should be instructed to use a', 'consistent device throughout the study. The site will advise subjects to contact the site in', 'cases where sudden weight gain (5% or greater) is observed for possible assessment in the', 'clinic.', 'Non-Treatment Cycle Visit', 'In order to establish 12 weeks of non-treatment after two dosing cycles, every third cycle', 'of treatment should be omitted and a clinic visit conducted, as outlined in Appendix C,', 'Study Activities. The visit should be performed after the Disease Response/Assessment', 'has been conducted and reviewed by the Investigator. The subject should continue to', 'complete the Fluid Retention Questionnaire, including conducting daily weight', 'assessments, and the site should contact the subject weekly during this 42 day non-', 'treatment cycle to review the questionnaire and assess for any adverse events or changes', 'in concomitant medications. The following cycle of treatment may be resumed', '42 days 3d if the subject has not met any reason for study treatment discontinuation as', 'outlined in Section 5.4.', 'End of Treatment (EOT) Visit', 'The visit at which an investigator identifies disease progression or a subject meets other', 'criteria for study treatment discontinuation will be considered the End of Treatment Visit.', 'The EOT procedures should be done within 7 days of documented decision to discontinue', 'treatment and prior to subjects beginning any new anti-cancer therapy if possible. The', '53']"
53,page_54,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'EOT visit is the last visit during the treatment phase before subjects begin the Post', 'Treatment Follow Up and/or Survival Follow Up phase. The reason(s) for the', 'discontinuation from study treatment will be recorded and assessments will be performed', 'per Appendix C, Study Activities.', 'Disease/Response Assessment, CT/MRI of the brain (if applicable), and submission of', 'scans to the CRAC, may be omitted if performed within the last 6 weeks.', 'Post-Treatment Follow Up', 'For all subjects who discontinue study treatment for reasons other than disease', 'progression, the first follow-up visit will occur at 6 weeks (= 1 week) after the last', 'Disease Response/Assessment, then every 6 weeks (= 1 week) until disease progression or', 'initiation of new anti-cancer therapy, whichever occurs first. Refer to Appendix C, Study', 'Activities for details of required assessments.', 'At disease progression, an optional collection of fresh tumor material may be conducted', '(Section 5.3.1.2, Collection and Handling of Biomarker and Optional Exploratory', 'Research has details regarding Tumor Material at Time of Disease Progression).', 'Survival Follow Up (OS)', 'After disease progression or if subjects stop treatment and decline further study', 'radiographic assessments prior to the endpoint of disease progression, subjects will be', 'followed for subsequent anti-cancer therapies (dates and responses), as well as survival', 'status, every 6 weeks* (= 1 week) until the endpoint of death, the subject becomes lost to', 'follow-up or withdraws consent, or termination of the study by AbbVie, whichever occurs', 'first (*or as requested by AbbVie to support data analysis). If the subject withdraws from', 'study follow-up, the study staff may use a public information source (such as county', 'records) to obtain information about survival status only, as appropriate per local', 'regulations. Refer to Appendix C, Study Activities for details of required assessments.', '54']"
54,page_55,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.1.2', 'Collection and Handling of Biomarker and Optional', 'Exploratory Research Samples', 'Biomarker Samples', 'Blood, tumor material, and serosal fluid will be collected as noted in Appendix C, Study', 'Activities and may be utilized to evaluate known and/or novel markers (nucleic acids,', 'peptides/proteins and/or metabolites) of disease status, related conditions or to evaluate', 'the association with pharmacokinetics, safety or efficacy. Samples will also be utilized', 'for the development of Companion Diagnostics in conjunction with rovalpituzumab', 'tesirine clinical development. The biomarker rationale is discussed in the Biomarker', 'Research Variables Section (Section 5.3.6).', 'All biomarker samples should be labeled and shipped as outlined in the study-specific', 'laboratory manual.', 'AbbVie (or people or companies working with AbbVie) will store the samples in a secure', 'storage space with adequate measures to protect confidentiality. The samples may be', 'retained while research on rovalpituzumab tesirine (or drugs of this class) or this disease', 'and related conditions continues, but for no longer than 20 years after study completion,', 'or per local requirement.', 'Tumor Material at Screening', 'For all subjects, tumor material representative of the qualifying malignancy must be', 'submitted to a central laboratory for determination of DLL3 expression. An archived', 'tumor specimen or fresh tumor material (obtained via on-study biopsy procedure if', 'archival tumor specimen is unavailable) may be used for DLL3 expression evaluation by', 'methods such as but not necessarily limited to immunohistochemistry (IHC). Additional', 'analyses, such as routine hematoxylin and eosin for morphology, IHC for confirmation of', 'diagnosis (e.g., for synaptophysin, chromogranin-A, or CD56), or scoring of immune', 'infiltrates (e.g., IHC for CD3+, CD4+, CD8+, and Foxp3+ cells) may be performed.', '55']"
55,page_56,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Material may also be utilized for exploratory biomarkers research of drug sensitivity,', 'resistance, or disease biology.', 'Blood (Plasma) for Inflammatory Markers and Circulating Tumor DNA (ctDNA)', 'At the indicated times noted in Appendix C, Study Activities, blood will be collected,', 'processed to plasma for testing of inflammatory markers including erythrocyte', 'sedimentation rate (ESR), C-reactive protein (CRP), antinuclear antibodies (ANA),', 'rheumatoid factor (RF), and ctDNA. On Day 1 (-3 day window is permitted) of each', 'cycle, the collection will be pre-infusion. A sample will also be collected at the EOT or at', 'the time of disease progression.', 'Blood (Serum) for Tumor and Soluble Markers', 'At the indicated times noted in Appendix C, Study Activities, blood will be collected,', 'processed as serum for possible testing of tumor-specific biomarkers that may reflect', 'disease burden such as but not necessarily limited to neuron-specific enolase (NSE) and', 'biomarkers that may be related to the pharmacodynamics effects of rovalpituzumab', 'tesirine such as but not necessarily limited to soluble DLL3, circulating chemokines, or', 'cytokines such as vascular endothelial growth factor (VEGF), epidermal growth factor', '(EGF), interleukin (IL)-6, or IL-8. Other biomarkers based on emerging science may also', 'be assessed. On Day 1 (-3 day window is permitted) of each cycle, the collection will be', 'pre-infusion. A sample will also be collected at the EOT or at the time of disease', 'progression.', 'Blood for Circulating Tumor Cells', 'At the indicated times noted in Appendix C, Study Activities, blood samples will be', 'collected for assessment and characterization of circulating tumor cells (CTCs) as a', 'possible reflection of disease burden and DLL3 expression to study association with', 'efficacy. Whole blood sample will be collected for CTC analysis at pre-dose on Cycle 1', 'Day 1 (-3 days window is permitted) and EOT only at specific sites based on feasibility.', '56']"
56,page_57,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Serosal Fluid', 'Any pericardial, pleural, and/or ascitic fluid collected as part of routine care (e.g., as part', 'of a therapeutic thoracentesis, pericardiocentesis, or paracentesis) will be procured for', 'possible PK, pharmacodynamic, and/or biomarker testing. See the laboratory manual for', 'additional details.', 'Pharmacogenetic Samples', 'A whole blood sample for DNA isolation will be collected on Cycle 1 Day 1 (pre-', 'infusion) and End of Treatment Visit from each subject. Pharmacogenetic collection', 'should occur unless precluded by local or national regulations or policies.', 'Samples will be shipped frozen to AbbVie or a designated laboratory for DNA extraction', 'and long-term storage. Instructions for the preparation and shipment of the', 'pharmacogenetic exploratory research samples will be provided in a laboratory manual.', 'Optional Exploratory Research Samples', 'Subjects will have the option to provide samples for exploratory research. Subjects may', 'still participate in the main study even if they decide not to participate in this optional', 'exploratory research.', 'AbbVie (or people or companies working with AbbVie) will store the exploratory', 'research samples in a secure storage space with adequate measures to protect', 'confidentiality. The samples will be retained while research on rovalpituzumab tesirine', '(or drugs of this class) or this disease and related conditions continues, but for no longer', 'than 20 years after study completion. The procedure for obtaining and documenting', 'informed consent for exploratory research samples is discussed in Section 9.3.', 'Tumor Material at the Time of Disease Progression', 'An optional tumor material collection by biopsy procedure may be obtained at the time of', 'disease progression, from subjects who consent to undergo biopsy procedure to better', '57']"
57,page_58,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'understand mechanisms of resistance and expression of DLL3. Other nucleic acid or', 'protein based biomarkers related to the response to rovalpituzumab tesirine and SCLC', 'biology may be assessed.', 'Samples will be shipped to AbbVie or a designated laboratory for long-term storage.', 'Instructions for the preparation and shipment of the biomarker exploratory research', 'samples will be provided in a laboratory manual.', '5.3.2', 'Drug Concentration Measurements', '5.3.2.1', 'Collection of Samples for Analysis', 'Approximately 6 mL of blood will be collected by venipuncture for pharmacokinetic', '(PK), Anti-therapeutic antibody (ATA), and neutralizing antibodies (nAb) testing as', 'indicated in Appendix C, Study Activities. Two samples will be collected at each', 'treatment cycle. The pre-infusion sample will be collected prior to dosing on Day 1', '(-3 days window is allowed) and the second sample will be collected within 60 minutes', 'post-infusion. Only one collection will be required at the Non-Treatment Cycle visit and', 'EOT visit. Blood will be processed to serum and three aliquots generated, each', 'containing approximately 0.8 mL of serum.', 'The date and time of each sample collected will be recorded to the nearest minute.', '5.3.2.2', 'Handling/Processing of Samples', 'Specific instructions for collection of blood/serum samples and subsequent preparation', 'and storage of the samples for the assays will be provided by the central laboratory,', 'AbbVie, or its designee.', '5.3.2.3', 'Disposition of Samples', 'The frozen serum samples for the rovalpituzumab tesirine ADC, rovalpituzumab tesirine', 'ADC ATA, and neutralizing antibodies (nAb) assays will be packed in dry ice sufficient', 'to last during transportation and shipped from the study site to the central laboratory.', '58']"
58,page_59,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'An inventory of the included samples will accompany the package and an electronic copy', 'of the manifests (including subject number, study day, the time of sample collection and', 'barcode) will be sent to the contact person at gprd_lupet@abbvie.com.', '5.3.2.4', 'Measurement Methods', 'Serum concentrations of rovalpituzumab tesirine ADC and relative titers of', 'rovalpituzumab tesirine ADC ATA will be determined using validated methods. Any', 'additional related analytes may be analyzed using non-validated methods. Serum samples', 'collected for the PK, ATA and nAb analysis may be used for future assay development or', 'validation activities. Rovalpituzumab tesirine ADC nAb samples upon request may be', 'used for the analysis of neutralizing anti-drug antibodies in a validated assay.', '5.3.3', 'Efficacy Variables', '5.3.3.1', 'Definition of Disease Progression', 'Disease progression will be defined as radiographic progression of disease by RECIST', 'version 1.1. Refer to Appendix G, Response Evaluation Criteria for Solid Tumors', '(RECIST) version 1.1 for Tumor Response. 12 Effusions (pleural, pericardial, etc.) will', 'contribute to disease response assessment only if confirmed malignant by cytology or', 'otherwise clearly disease-related; if disease progression is suspected solely based on the', 'appearance of new or increase of existing effusions, confirmation of malignant nature of', 'such effusions is strongly recommended prior to making the decision on treatment', 'discontinuation due to known adverse event profile of rovalpituzumab tesirine. If', 'collected, effusion fluid must be tested centrally and/or locally for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', '5.3.3.2', 'Primary Variables', 'The primary endpoints are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in DLL3high population.', '59']"
59,page_60,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.3.3', 'Secondary Variables', 'The secondary variables are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in randomized set population. Change in patient reported outcome (PRO) with', 'physical functioning as measured by European Organization for Research and Treatment', 'of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in randomized set', 'population is also a secondary endpoint in this study.', '5.3.3.4', 'Exploratory Variables', 'The exploratory variables are progression-free survival (PFS) based on investigator', 'assessment, objective response rate (ORR) per the CRAC and investigator assessment,', 'respectively, clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, and the duration of response (DOR) per the CRAC and investigator', 'assessment, respectively. Response assessment will be based on RECIST v1.1. Changes', 'in patient reported outcomes (PROs) as measured by EQ-5D-5L and all other PRO', 'domains (except for physical functioning) as measured by European Organization for', 'Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)', 'and Lung Cancer Module (QLQ-LC13) are also exploratory endpoints in this study.', '5.3.4', 'Safety Variables', 'AbbVie will assess adverse events, laboratory data, ECGs and vital signs throughout the', 'study. Adverse events intensity and laboratory evaluation changes will be assessed by', 'utilizing NCI CTCAE Version 4.0. 11', 'During the conduct of the study, the AbbVie medical and safety team will be monitoring', 'blinded, subject laboratory results and serious adverse event data as they are reported.', 'Safety endpoints will be summarized using data from the Safety set. Safety analyses will', 'involve examination of the incidence, severity, and type of treatment-emergent adverse', 'events (TEAEs) reported, changes in vital signs and laboratory test results from baseline', '(the assessment prior to first dose) to specified time points throughout the study.', '60']"
60,page_61,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.5', 'Pharmacokinetic Variables', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the timing and incidence', 'of ATAs will be tabulated and summarized.', '5.3.6', 'Biomarker and/or Optional Exploratory Research Variables', 'Biomarker Research Variables', 'Blood, serosal fluid, and tumor material samples will be collected to conduct analyses to', 'investigate biomarkers. The types of biomarkers to be analyzed may include, but are not', 'limited to, nucleic acids, proteins, lipids or metabolites.', 'Tumor specimen and CTCs will be tested for DLL3 expression and analyses will be', 'performed to correlate the expression levels to rovalpituzumab tesirine response.', 'Enumeration of CTCs, soluble DLL3 in plasma, or markers that are related to the disease', 'or to drug response will be measured at baseline and post-treatment. The information', 'learned from analyzing these samples may be used to investigate factors influencing', 'response to treatment, pharmacodynamics, PK, safety, scientific questions related to', 'SCLC, and/or in the development of new therapies and diagnostic tests. The results of', 'biomarker testing may not be included with the study summary.', 'Whole blood for pharmacogenetic analysis may include but not be limited to DLL3,', 'ASCL1, or NEUROD1.', 'Exploratory Research Variables', 'Optional samples may be collected to conduct exploratory investigations into known and', 'novel biomarkers. The types of biomarkers to be analyzed may include, but are not', 'limited to, nucleic acids, proteins, lipids or metabolites. The samples may be analyzed as', ""part of a multi-study assessment of factors influencing the subjects' response to the"", 'blinded investigational product (or drugs of the same or similar class) or the development', ""and progression of the subjects' disease or related conditions. The samples may also be"", '61']"
61,page_62,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'used to develop new diagnostic tests, therapies, research methods or technologies. The', 'results from these analyses are exploratory in nature and may not be included with the', 'study report.', 'In the event a subject withdraws consent to participate from the study, stored biomarker', 'samples will continue to be used for research and analysis. In the event that a subject', 'would like to withdraw consent for research of samples, the subject may request for', 'samples to be withdrawn. Once AbbVie receives the request, remaining samples will be', 'destroyed. If the subject changes his/her consent, and the samples have already been', 'tested, those results will still remain part of the overall research data.', '5.4', 'Removal of Subjects from Therapy or Assessment', 'Each subject has the right to withdraw from study treatment at any time. In addition, the', 'Investigator may discontinue a subject from the study treatment at any time for any reason', 'if the Investigator considers it necessary. Each subject will be withdrawn from the study', 'or study treatment (as applicable) per Section 5.4.1 if any of the following occur:', 'The subject has radiographic progression according to RECIST v1.1 (with the', 'exception of CNS-only progression).', 'The subject requires cancer-directed radiotherapy or surgery related to clinical', 'disease progression, or alternate anti-cancer agents during the study period.', '(Refer to Section 5.2.3.2.1, Allowed Concomitant Therapy for exceptions from', 'this criterion).', ""The subject experiences treatment toxicity which, in the Investigator's opinion,"", 'prohibits further therapy or the Investigator believes it is otherwise in the best', 'interest of the subject.', 'Subject is pregnant or begins breastfeeding during the treatment portion of the', 'study.', 'The subject decides to withdraw consent for any reason.', 'Any other medical reason that AbbVie or the study Investigator deems', 'appropriate.', 'Significant non-compliance to the protocol.', '62']"
62,page_63,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Discontinued subjects will not be replaced.', '5.4.1', 'Discontinuation of Individual Subjects', 'When subject discontinuation from study treatment (without reaching a protocol-define', 'endpoint) is planned, the Investigator is to notify the AbbVie Therapeutic Area Medical', 'Director (TA MD) or the clinical team representative (Section 7.0) via telephone as soon', 'as possible (provided, in each case, subject care and safety are not compromised). If not', 'notified prior to discontinuation, the AbbVie TA MD may contact the site to discuss the', 'reason for withdrawal from the study.', 'The visit at which an investigator identifies disease progression or a subject meets other', 'criteria for study treatment discontinuation will be considered the End of Treatment Visit.', 'The reason(s) for the discontinuation from study treatment will be recorded and', 'assessments will be performed per Appendix C, Study Activities. It is preferable that End', 'of Treatment Visit procedures be conducted prior to the initiation of another anti-cancer', 'therapy. However, these procedures should not interfere with the initiation of any new', 'treatments or therapeutic modalities that the Investigator feels are necessary to treat the', ""subject's condition."", 'If a subject is discontinued with an ongoing adverse event or an unresolved clinically', 'significant laboratory result, the site will attempt to provide follow-up until a satisfactory', 'clinical resolution of the laboratory results or adverse event is achieved.', 'Subjects no longer undergoing clinical assessments will have survival information', 'collected at every 6 weeks ( 1 week) until the endpoint of death, the subject becomes lost', 'to follow-up or withdraws consent, or termination of the study by AbbVie, whichever', 'occurs first.', 'In the event that a positive result is obtained on a pregnancy test for a subject during the', 'study, the administration of blinded investigational product to that subject must be', '63']"
63,page_64,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'discontinued immediately. The site must report the positive pregnancy test result by', 'completing the appropriate eCRF within 24 hours of becoming aware of the pregnancy.', '5.4.2', 'Discontinuation of Entire Study', 'AbbVie may terminate this study prematurely, either in its entirety or at any study site, for', 'reasonable cause provided that written notice is submitted in advance of the intended', 'termination. The investigator may also terminate the study at his/her site for reasonable', 'cause, after providing written notice to AbbVie in advance of the intended termination.', 'Advance notice is not required by either party if the study is stopped due to safety', 'concerns. If AbbVie terminates the study for safety reasons, Abb Vie will notify the', 'investigator and provide written instructions for study termination.', '5.5', 'Treatments', '5.5.1', 'Treatments Administered', 'Rovalpituzumab tesirine, the investigational agent under study in this protocol, is an', 'ADC. All subjects randomized will receive premedication consisting of', 'dexamethasone/placebo orally (PO) at 8 mg twice daily on Day - -1, Day 1 (the day of', 'dosing), and Day 2 of each cycle in which rovalpituzumab tesirine/placebo is', 'administered. Dexamethasone/placebo dosing should occur such that there are', 'approximately 12-hours (i.e., 10 - 14 hours) between AM and PM doses. The first dose', 'of the dexamethasone/placebo on the day of dosing should be at least 30 minutes but no', 'more than 4 hours prior to the rovalpituzumab tesirine/placebo infusion. If the dose of', 'dexamethasone/placebo is vomited within 15 minutes of taking the medication, the', 'subject should retake the medication.', 'In the event that a subject arrives for rovalpituzumab tesirine/placebo administration on', 'Day 1, but has not taken any or all required dexamethasone/placebo doses on Day - 1', 'and/or Day 1, rovalpituzumab tesirine/placebo administration may not proceed, and', 'rovalpituzumab tesirine/placebo will be held until the required dexamethasone/placebo', 'dosing has occurred.', '64']"
64,page_65,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.5.2', 'Identity of Investigational Product(s)', 'Table 3.', 'Identity of Investigational Products', 'Placebo for', 'Investigational', 'Rovalpituzumab', 'Rovalpituzumab', 'Placebo for', 'Product', 'Tesirine', 'Tesirine', 'Dexamethasone*', 'Dexamethasone', 'Dosage Form', 'Powder for', 'Powder for', 'Capsules', 'Placebo capsules', 'solution for', 'solution for', 'infusion in vials', 'infusion in vials', 'Strength', '10 mg/ml when', 'N/A', '8 mg', 'N/A', 'reconstituted with', '3.2 ml of sterile', 'water for injection', 'Route of', 'Intravenous', 'Intravenous', 'Oral', 'Oral', 'Administration', '*', 'Commercially-available Dexamethasone tablets are over-encapsulated to maintain study blinding.', 'AbbVie will supply rovalpituzumab tesirine/placebo and dexamethasone/placebo.', 'Each site will be responsible for maintaining drug accountability records, including', 'product description, manufacturer, and lot numbers for all investigational products', 'dispensed by the site.', '5.5.2.1', 'Packaging and Labeling', 'Rovalpituzumab Tesirine and Placebo', 'Vials of rovalpituzumab tesirine/placebo will be packaged in cartons. Each vial and', 'carton will be labeled per country requirements. Labels must remain affixed to the vial', 'and carton. Rova-T drug product is classified as a Dangerous Goods/Hazardous Material', 'and is packaged and shipped by AbbVie according to US Department of Transportation', '(DOT) and International Air Transport Association (IATA) certified regulations.', '65']"
65,page_66,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dexamethasone and Placebo', 'Dexamethasone/placebo will be packaged in high-density polyethylene (HDPE) bottles', 'according to the study needs. The bottles will be labeled per country requirements.', 'Labels must remain affixed to the containers.', '5.5.2.2', 'Storage and Disposition of Blinded Investigational', 'Product(s)', 'For all storage areas and refrigerators, temperature logs will be maintained to document', 'proper storage conditions. The temperature must be recorded on the temperature logs to', 'verify proper function on each business day. Temperature excursions must be reported to', 'AbbVie immediately.', 'Sites should use the AbbVie Temperature Excursion Management System (ATEMS)', 'module via IRT, if available, or fax copies of the temperature log indicating the extent of', 'the excursion (time, duration of the temperature excursion, min/max values and study', 'drugs affected) to AbbVie Clinical Drug Supply Management (CDSM) including the', 'Storage Temperature Excursion Reporting Form.', 'In case of a temperature excursion, study medication should be quarantined and not', 'dispensed until AbbVie CDSM or ATEMS deems the medication as acceptable.', 'The investigational products are for investigational use only and are to be used only', 'within the context of this study. The study drug supplied for this study must be', 'maintained under adequate security and stored under the conditions specified on the label', 'until dispensed for subject use or returned to the destruction facility.', 'Rovalpituzumab Tesirine/Placebo', 'Rovalpituzumab tesirine/placebo must be stored refrigerated at 2° to 8°C (36° to 46°F),', 'protected from light, and must not be frozen. Specific storage conditions for reconstituted', 'and diluted rovalpituzumab tesirine/placebo will be provided in a separate document', 'outside of this protocol.', '66']"
66,page_67,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dexamethasone/Placebo', 'Dexamethasone/placebo should be stored at 15° to 25°C (59° to 77°F) and protected from', 'light. For Australia, dexamethasone/placebo should be stored below 25°C and protected', 'from light.', '5.5.2.3', 'Preparation/Reconstitution of Dosage Form(s)', 'Both rovalpituzumab tesirine and matching placebo will be supplied as a lyophilized', 'powder in a vial. Each vial of rovalpituzumab tesirine or placebo will be reconstituted', 'with 3.2 mL of sterile water for injection. When reconstituted, vial of rovalpituzumab', 'tesirine will contain 10 mg/mL (30 mg total per vial). The rovalpituzumab tesirine drug', 'product is dosed based on actual body weight. The contents of two or more vials of', 'reconstituted drug product may be required to accomplish the desired dose. The total', 'volume administered treatment arm will be dependent upon the assigned dose. The', 'rovalpituzumab tesirine drug product and placebo solution(s) will be administered via', 'intravenous (IV) infusion. Rovalpituzumab tesirine drug product and placebo solution(s)', 'will be added to 50 mL or 100 mL of 0.9% normal saline with an infusion over', '30 minutes (20 - 45 minute infusion window). The rate should be adjusted based on', 'patient tolerability. Specific dose preparation and documentation details will be provided', 'to the site pharmacy in a separate document. A complete description of the chemistry and', ""formulation may be found in the Investigator's Brochure.14"", '5.5.3', 'Method of Assigning Subjects to Treatment Arms', 'All subjects in the study will be randomized using an IRT system. Before the study is', 'initiated, directions for the IRT will be provided to each site. The site will contact the IRT', 'to obtain a Screening (subject) number once the subject has signed the informed consent', 'and a study-specific procedure has been performed (i.e., central laboratory samples', 'drawn). Once the screening number is assigned, if the subject is not randomized into the', 'study, the reason for screen failure will be documented in the source document and in the', 'eCRF. For others, the site will access the system and a unique randomization number will', 'be provided.', '67']"
67,page_68,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The IRT will randomize subjects in a 1:1 ratio, with one-half of the subjects being', 'randomized to the rovalpituzumab tesirine treatment arm and the other one-half to the', 'placebo arm. The stratification factors used for the randomization should be the last', 'values on or prior to the date of randomization.', '5.5.4', 'Selection and Timing of Dose for Each Subject', '5.5.4.1', 'Dosing', 'Dosing is based on actual body weight of the subject to the nearest kilogram, assessed in', 'the clinic prior to dosing at each cycle, and administered according to the calculated dose.', 'In cases of weight gain due to fluid retention, dosing should be based on most recent pre-', 'fluid retention actual weight.', 'Subjects must meet all of the following criteria on each dosing day before receiving', 'blinded investigational product:', 'Absolute neutrophil count (ANC) > 1,000/L', 'Platelet count > 75,000/L', 'Resolution of blinded investigational product-related AEs, including findings', 'indicative of pleural or pericardial effusions, and clinically-significant', 'laboratory abnormalities to Grade 0 or 1 (excluding ANC and alopecia), or to', 'baseline grade.', '5.5.4.2', 'Dose Modifications', '5.5.4.2.1', 'Dose Treatment Delays due to Toxicity or Progression', 'Subjects who experience blinded investigational product-related toxicity during a cycle', 'must have recovered as specified above before the next cycle may proceed. Any dose', 'modifications except those indicated as mandatory below (including dose delay,', 'reduction, resumption, and discontinuation) are to be performed at the discretion of the', 'Investigator. Further guidelines suggesting dose modifications based on prior studies of', 'rovalpituzumab tesirine are provided in Section 5.5.4.2.2, Dose Reduction Guidelines.', '68']"
68,page_69,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'In cases of treatment delays of > 28 days, the TA MD should be contacted regarding the', ""subject's continuation of treatment."", 'In the event of isolated CNS-only progression during study treatment, blinded', 'investigational product will be withheld while local treatment is administered', '(e.g., radiotherapy) in accordance with institutional practice. Blinded investigational', 'product may be restarted 1 week after the completion of local CNS disease-directed', 'therapy. If more than 6 weeks have elapsed since the previous radiographic tumor', 'assessment, the subject must undergo a radiographic tumor assessment to evaluate extra-', 'cranial disease status prior to resuming blinded treatment. If additional sites of PD are', 'present, the subject will be required to discontinue blinded investigational product.', '5.5.4.2.2', 'Dose Reduction Guidelines', 'Blinded investigational product dose reductions and discontinuation of blinded', 'investigational product for specific toxicities should occur as outlined in Table 4, Dose', 'Reductions for Blinded Investigational Product (IP) and Table 5, Dose Reductions and', 'Discontinuation for Unacceptable Toxicities. Dose reductions for unacceptable toxicities', 'described in Table 5 are mandatory. Reduced dose levels are described in (Table 4).', 'Generally, if unacceptable toxicity recurs after two dose reductions, treatment will be', 'discontinued (for further details, refer to Table 5). If the blinded investigational product', 'dose is reduced, no re-escalation will be allowed. If different unacceptable toxicities', 'occur in sequential treatment cycles (e.g., Grade 3 LFT after the first dose and Grade 3', 'thrombocytopenia lasting more than 7 days after the second dose), dose reduction will', 'proceed to the next lower dose level. If different unacceptable toxicities occur within', 'one cycle, maximum specified dose reduction will be implemented. Dose reductions and', 'discontinuation are not planned for dexamethasone/placebo. If full dose of', 'dexamethasone/placebo cannot be administered due to an AE, the blinded infusion should', 'be delayed until dexamethasone/placebo can be administered.', 'Exceptions to the dose modification guidelines should be discussed with the TA MD prior', 'to implementation.', '69']"
69,page_70,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Details of toxicity management are further outlined in Section 6.1.8, Toxicity', 'Management.', 'Table 4.', 'Dose Reductions for Blinded Investigational Product (IP)', 'First Dose Reduction', 'Second Dose Reduction', 'Starting Dose', '(Reduce Dose)', '(Reduce Dose)', '0.3 mg/kg', '0.2 mg/kg', '0.1 mg/kg', '70']"
70,page_71,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Table 5.', 'Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Toxicity', 'First Occurrence', 'Second Occurrence', 'Grade 3 thrombocytopenia lasting more than', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', '7 days', 'Grade 4 thrombocytopenia/Grade 3', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'thrombocytopenia with bleeding/Need for', 'platelet transfusion', 'Grade 4 neutropenia lasting more than 7 days', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 3 febrile neutropenia', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 4 febrile neutropenia', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'Grade 3 Liver Function Tests (LFTs)', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'Grade 4 LFTs or Grade 3 LFTs with', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'concomitant Bilirubin Grade 2 or higherb', 'Potential DILI (Drug-induced liver injury)', 'See Section 6.1.8.3', 'See Section 6.1.8.3', 'Grade 3 or 4 hypoalbuminemia', 'Reduce dose to 0.1 mg/kg', 'Discontinue Blinded IP', 'Any other Grade 3 or 4 laboratory', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'abnormality considered clinically significant', 'and treatment-related', 'Grade 2 serosal effusions or edema', 'Reduce to 0.2 mg/kg', 'Reduce to 0.1 mg/kg', 'Grade 3 serosal effusions or edema or', 'Reduce dose to 0.1.mg/kg', 'Discontinue Blinded IP', 'Grade 2 capillary leak syndrome', 'Grade 4 serosal effusions or edema or', 'Discontinue Blinded IP', 'N/A', 'Grade > 3 capillary leak syndrome', 'Grade 3 photosensitivity reaction', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'See Section 6.1.8.2', 'See Section 6.1.8.2', 'Grade 4 photosensitivity reaction', 'Discontinue Blinded IP', 'N/A', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Any other Grade 3 or Grade 4 non-laboratory', 'Reduce dose to 0.2 mg/kg', 'Reduce dose to 0.1 mg/kg', 'treatment-related toxicity with the exception', 'of fatigue, asthenia, nausea, or other', 'manageable constitutional symptom', 'a.', 'Refer to Appendix H, CTCAE V 4.0 Grading of Relevant AEs for definitions of NCI-CTCAE severity grades and', 'for definition of serosal effusions and edema.', 'b.', 'If potential DILI is suspected please follow guidelines of Section 6.1.8.3.', '71']"
71,page_72,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.5.5', 'Blinding', '5.5.5.1', 'Blinding of Investigational Product', 'AbbVie, the Investigator, the study site personnel, and subject will remain blinded to each', ""subject's treatment with rovalpituzumab tesirine or placebo and dexamethasone or placebo"", 'and throughout the course of the study.', 'The IRT system will provide access to blinded subject treatment information during the', 'study. AbbVie must then be notified within 24 hours of the blind being broken. The date', 'and reason that the blind was broken must be recorded in the source documentation and', 'eCRF, as applicable.', '5.5.5.2', 'Blinding of Data for Independent Data Monitoring', 'Committee (IDMC)', 'An Independent Data Monitoring Committee (IDMC) will be formed and constituted', 'according to appropriate regulatory guidelines. The IDMC will review the unblinded data', 'from the study with respect to subject accrual, pretreatment characteristics of accrued', 'subjects, the frequency and severity of toxicities and morbidity, and provide', 'recommendations according to the charter. Detailed information regarding the', 'composition of the committee and procedures including frequency of meetings and scope', 'of reviews will be documented in a separate charter. For the futility analysis, OS, other', 'efficacy and safety data will be analyzed and reviewed by the IDMC for recommendation.', '5.5.6', 'Treatment Compliance', 'The investigator or his/her designated and qualified representatives will', 'administer/dispense blinded investigational product only to subjects randomized in the', 'study in accordance with the protocol. The blinded investigational product must not be', 'used for reasons other than that described in the protocol.', 'Blinded investigational product administration must be performed by study site staff and', 'documented in source documents and the eCRF.', '72']"
72,page_73,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.5.7', 'Drug Accountability', 'The site will record the dose of rovalpituzimab tesirine/placebo and', 'dexamethasone/placebo given to each subject in the source documents and on the eCRF.', 'Upon receipt of a shipment of rovalpituzimab tesirine/placebo and', 'dexamethasone/placebo, the representative at each site will (1) open and inspect the', 'shipment; (2) verify that the rovalpituzimab tesirine/placebo has been received intact, in', 'the correct amounts and at the correct address; (3) sign and date the Proof of Receipt', '(POR) or similar documentation accompanying the shipment; (4) register the shipment as', 'received via the IRT. All blinded investigational products must be retained in the', 'designated secure area under proper storage conditions. This will be documented by', 'signing and dating the Proof of Receipt (POR) or similar document or via direct recording', 'in the IRT.', 'An overall accountability of the blinded investigational product will be performed and', 'verified by the site monitor throughout the study and at the study site closeout visit. An', 'accurate running inventory of rovalpituzimab tesirine/placebo and dexamethasone/placebo', 'will be maintained utilizing the IRT drug accountability module and, if required,', 'according to your institutional policy and will include the lot number, POR number(s), the', 'bottle/kit numbers, and the date blinded investigational product was dispensed for each', 'subject.', 'Upon completion or termination of the study, all original bottles/cartons containing', 'unused rovalpituzimab tesirine/placebo and dexamethasone/placebo (empty containers', 'will be defaced and discarded on site) will be returned to the Destruction Facility', ""according to AbbVie's instructions, or if pre-arranged between the sponsor and site,"", 'destruction of used and unused bottles will be performed at the site. Rova-T is classified', 'as a Dangerous Good/Hazardous Material according to US Department of Transportation', '(DOT) and International Air Transport Association (IATA). Dangerous', 'Goods/Hazardous Materials must be packaged and shipped according to applicable', 'regulations.', '73']"
73,page_74,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The study Investigator or his/her designated representative agrees not to supply study', 'medication to any persons not enrolled in the study or not named as a sub-investigator', 'listed on the FDA 1572 or Investigator Information and Agreement (IIA) form.', '5.6', 'Discussion and Justification of Study Design', '5.6.1', 'Discussion of Study Design and Choice of Control Groups', 'Phase 1 data described in Section 3.0 and proposed mechanism of action suggest that', 'rovalpituzumab tesirine may improve outcome of SCLC patients by extending clinical', 'benefit following first-line platinum-based chemotherapy. This randomized, double-', 'blind, placebo controlled phase 3 study will evaluate the effect of rovalpituzumab tesirine', 'as maintenance therapy following first-line platinum-based chemotherapy of extensive', 'stage SCLC. Primary endpoints of PFS and OS are well established in solid tumor trials', 'and in SCLC specifically.', 'A randomized, double-blind, placebo controlled study such as described here is optimal', 'for assessing the treatment effect of rovalpituzumab tesirine versus current standard, best', 'supportive care to a current standard treatment (placebo is required to allow for blinding).', '5.6.2', 'Appropriateness of Measurements', 'The safety measures that will be used in this trial are considered standard procedures for', 'evaluating the potential adverse effects of study medications. Adverse events and, when', 'applicable, clinical laboratory data will be graded using NCI CTCAE, version 4.0.¹ 11', 'Response will be assessed according to RECIST v1.1, 12 which includes standard criteria', 'for evaluating response in solid tumors. The intervals of evaluation in this protocol are', 'appropriate for disease management.', 'Standard tests will be performed to detect the possible presence of specific antibodies to', 'blinded investigational product. Pharmacokinetic assessments for drug activity are also', 'common in clinical studies.', '74']"
74,page_75,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.6.3', 'Suitability of Subject Population', 'Although response rates to first-line chemotherapy remain high with platinum-based', 'regimens, time to disease recurrence is short in extensive-stage SCLC. Rovalpituzumab', 'tesirine has demonstrated anti-tumor activity in relapsed/refractory SCLC population.', 'Exploring rovalpituzumab tesirine in ED SCLC subjects with stable disease or objective', 'response following first-line chemotherapy is acceptable considering observed', 'activity/toxicity profile of rovalpituzumab tesirine, and that the standard approach in this', 'setting is no treatment until progression.', '5.6.4', 'Selection of Doses in the Study', 'In a recent Phase 1 study (SCRX16-001) with rovalpituzumab tesirine, the maximum', 'tolerated dose (MTD) was established at 0.4 mg/kg every 3 weeks based on the incidence', 'of Cycle 1 toxicities, while the recommended Phase 2 dose (RPTD) in SCLC was chosen', 'as 0.3 mg/kg every 6 weeks for a total of two doses with the allowance to retreat at the', 'same dose level and schedule upon progression. The RPTD is based on the toxicity and', 'efficacy profile during multiple cycles dosing (AbbVie Stemcentrx data on file). This', 'experience included multiple doses of rovalpituzumab tesirine at a) 0.2 mg/kg every', '6 weeks, b) 0.3 mg/kg every 6 weeks or c) 0.3 mg/kg every 6 weeks for a total of', 'two doses and then at 0.1 mg/kg every 6 weeks thereafter. Based on the totality of the', 'experience with rovalpituzumab tesirine and taking into consideration its pharmacokinetic', 'characteristics, dosing of 0.3 mg/kg q6wk for 2 cycles, omitting every third cycle will be', 'used in this study. This study will not exceed a maximum dose of 1.5 mg/kg at each dose.', '6.0', 'Complaints', 'A complaint is any written, electronic, or oral communication that alleges deficiencies', 'related to the physical characteristics, identity, quality, purity, potency, durability,', 'reliability, safety, effectiveness, or performance of a product/device after it is released for', 'distribution.', '75']"
75,page_76,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The investigational product in this study is defined as rovalpituzumab tesirine or placebo', 'and dexamethasone or placebo. Complaints associated with any component of this', 'investigational product must be reported to the Sponsor (Section 6.2.2). For AEs, please', 'refer to Sections 6.1.1 through 6.1.6. For product complaints, please refer to Section 6.2.', '6.1', 'Medical Complaints', 'The investigator will monitor each subject for clinical and laboratory evidence of adverse', 'events on a routine basis throughout the study. The investigator will assess and record', 'any adverse event in detail including the date of onset, event diagnosis (if known) or', 'sign/symptom, severity, time course (end date, ongoing, intermittent), relationship of the', 'adverse event to blinded investigational product, and any action(s) taken. For serious', 'adverse events considered as having ""no reasonable possibility"" of being associated with', 'blinded investigational product, the investigator will provide an Other cause of the event.', 'For adverse events to be considered intermittent, the events must be of similar nature and', 'severity. Adverse events, whether in response to a query, observed by site personnel, or', 'reported spontaneously by the subject will be recorded.', 'All adverse events will be followed to a satisfactory conclusion.', '6.1.1', 'Definitions', '6.1.1.1', 'Adverse Event', 'An adverse event (AE) is defined as any untoward medical occurrence in a patient or', 'clinical investigation subject administered a pharmaceutical product and which does not', 'necessarily have a causal relationship with this treatment. An adverse event can therefore', 'be any unfavorable and unintended sign (including an abnormal laboratory finding),', 'symptom, or disease temporally associated with the use of a medicinal (investigational)', 'product, whether or not the event is considered causally related to the use of the product.', 'Such an event can result from use of the drug as stipulated in the protocol or labeling, as', 'well as from accidental or intentional overdose, drug abuse, or drug withdrawal. Any', 'worsening of a pre-existing condition or illness is considered an adverse event.', '76']"
76,page_77,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Worsening in severity of a reported adverse event should be reported as a new adverse', 'event. Laboratory abnormalities and changes in vital signs are considered to be adverse', 'events only if they result in discontinuation from the study, necessitate therapeutic', 'medical intervention, meets protocol specific criteria (see Section 6.1.8 regarding toxicity', 'management) and/or if the investigator considers them to be adverse events.', 'An elective surgery/procedure scheduled to occur during a study will not be considered an', 'adverse event if the surgery/procedure is being performed for a pre-existing condition and', 'the surgery/procedure has been pre planned prior to study entry. However, if the', 'pre-existing condition deteriorates unexpectedly during the study (e.g., surgery performed', 'earlier than planned), then the deterioration of the condition for which the elective', 'surgery/procedure is being done will be considered an adverse event.', 'All protocol-related AEs must be collected from the signing of the study specific informed', 'consent until study drug administration.', 'In addition, adverse events with onset or worsening reported by a subject from the time', 'that the first dose of study drug is administered until 70 days have elapsed following', 'discontinuation of study drug administration will be considered as treatment-emergent', 'adverse events.', '6.1.1.2', 'Serious Adverse Events', 'If an adverse event meets any of the following criteria, it is to be reported to AbbVie as an', 'SAE within 24 hours of the site being made aware of the SAE:', 'Death of Subject', 'An event that results in the death of a subject.', 'Life-Threatening', 'An event that, in the opinion of the investigator, would have', 'resulted in immediate fatality if medical intervention had not', 'been taken. This does not include an event that would have', 'been fatal if it had occurred in a more severe form.', 'Hospitalization or', 'An event that results in an admission to the hospital for any', 'Prolongation of', ""length of time or prolongs the subject's hospital stay. This"", 'Hospitalization', 'does not include an emergency room visit or admission to an', '77']"
77,page_78,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'outpatient facility or hospitalization for respite care.', 'Congenital Anomaly', 'An anomaly detected at or after birth, or any anomaly that', 'results in fetal loss.', 'Persistent or', 'An event that results in a condition that substantially interferes', 'Significant', 'with the activities of daily living of a study subject. Disability', 'Disability/Incapacity', 'is not intended to include experiences of relatively minor', 'medical significance such as headache, nausea, vomiting,', 'diarrhea, influenza, and accidental trauma (e.g., sprained', 'ankle).', 'Important Medical', 'An important medical event that may not be immediately life-', 'Event Requiring', 'threatening or result in death or hospitalization, but based on', 'Medical or Surgical', 'medical judgment may jeopardize the subject and may require', 'Intervention to', 'medical or surgical intervention to prevent any of the', 'Prevent Serious', 'outcomes listed above (i.e., death of subject, life-threatening,', 'Outcome', 'hospitalization, prolongation of hospitalization, congenital', 'anomaly, or persistent or significant disability/incapacity).', 'Additionally, any elective or spontaneous abortion or stillbirth', 'is considered an important medical event. Examples of such', 'events include allergic bronchospasm requiring intensive', 'treatment in an emergency room or at home, blood dyscrasias', 'or convulsions that do not result in inpatient hospitalization, or', 'the development of drug dependency or drug abuse.', 'For serious adverse events with the outcome of death, the date and cause of death will be', 'recorded on the appropriate case report form.', '6.1.1.3', 'Adverse Events Expected Due to SCLC or Progression of', 'SCLC', 'Adverse events that may be expected from primary SCLC lesions, compression of', 'adjacent thoracic structures or distant metastases are presented in Appendix J, Adverse', 'Events Expected Due to SCLC or Progression of SCLC of the protocol.', 'These adverse events may occur alone or in various combinations and are considered', 'expected adverse events in SCLC subjects.', '78']"
78,page_79,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Although exempted from expedited reporting to Health Authorities and Institutional', 'Review Boards (IRBs) as individual cases, these SAEs must be reported to the Sponsor', 'within 24 hours of the site being made aware of the SAE.', 'AEs or SAEs should not be reported as ""Disease progression,"" even if fatal, as PD is an', 'efficacy endpoint for the study. Rather, report the specific disease (clinical) manifestation', ""of the progression (eg, 'malignant pleural effusion, 'spinal bone metastases,'"", '\'lymphadenopathy,\' \'brain metastases\') or if not possible, report ""malignant neoplasm', 'progression"" as the AE or SAE as appropriate.', '6.1.2', 'Adverse Event Severity', 'The investigator will rate the severity of each adverse event according to the National', 'Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE', 'Version 4.0). 11 If a reported adverse event increases in severity, the initial adverse event', 'should be given an outcome date and a new adverse event reported on a different date', 'from the end date of the previous adverse event to reflect the change in severity. For all', 'reported serious adverse events that increase in severity, the supplemental eCRFs also', 'need to be updated to reflect the change in severity.', 'When CTCAE criteria cannot be used, the event should be graded as defined below:', 'Grade 1', 'The adverse event is transient and easily tolerated by the subject (mild).', 'Grade 2', 'The adverse event causes the subject discomfort and interrupts the', ""subject's usual activities (moderate)."", 'Grade 3/4', ""The adverse event causes considerable interference with the subject's"", 'usual activities and may be incapacitating or life-threatening (severe).', 'Grade 5', 'The adverse event resulted in death of the subject (severe).', '6.1.3', 'Relationship to Study Drug', 'The investigator will use the following definitions to assess the relationship of the adverse', 'event to the use of blinded investigational products:', '79']"
79,page_80,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Reasonable', 'After consideration of factors including timing of the event,', 'Possibility', 'biologic plausibility, clinical judgment, and potential alternative', 'causes, there is sufficient evidence (information) to suggest a', 'causal relationship.', 'No Reasonable', 'After consideration of factors including timing of the event,', 'Possibility', 'biologic plausibility, clinical judgment, and potential alternative', 'causes, there is insufficient evidence (information) to suggest a', 'causal relationship.', 'For causality assessments, events assessed as having a reasonable possibility of being', 'related to the study drug will be considered ""associated."" Events assessed as having no', 'reasonable possibility of being related to study drug will be considered ""not associated.\'', 'In addition, when the investigator has not reported causality or deemed it not assessable,', 'AbbVie will consider the event associated.', ""If an investigator's opinion of no reasonable possibility of being related to study drug is"", 'given, an Other cause of event must be provided by the investigator for the serious', 'adverse event.', '6.1.4', 'Deaths', 'For SAEs with the outcome of death, the date and cause of death will be recorded on the', 'appropriate case report form.', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'SAE and will not be subject to expedited reporting. These events should be recorded on', 'the AE eCRF as described in Section 6.1.1.3. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', 'Death should be considered an outcome and not a distinct event. The event or condition', 'that caused or contributed to the fatal outcome should be recorded as the single medical', 'concept on the AE eCRF. Generally, only one such event should be reported. The term', '""sudden death"" should only be used for the occurrence of an abrupt and unexpected death', '80']"
80,page_81,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'due to presumed cardiac causes in a patient with or without pre-existing heart disease,', 'within 1 hour of the onset of acute symptoms or, in the case of an unwitnessed death,', 'within 24 hours after the patient was last seen alive and stable. If the cause of death is', 'unknown and cannot be ascertained at the time of reporting, ""unexplained death"" should', 'be recorded on the AE eCRF. If the cause of death later becomes available (e.g., after', 'autopsy), ""unexplained death"" should be replaced by the established cause of death.', '6.1.5', 'Adverse Event Collection Period', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following the last dose of blinded investigational product will', 'be collected, whether solicited or spontaneously reported by the subject. In addition,', 'protocol-related serious adverse events and non-serious adverse events will be collected', 'from the time the subject signed the study-specific informed consent, only if considered', 'by the Investigator to be causally related to study-required procedures.', 'Adverse event information will be collected as shown in Figure 2.', 'Figure 2.', 'Adverse Event Collection', 'Protocol-Related SAEs', 'SAEs and Elicited and/or Spontaneously Reported', 'and Non-Serious AEs*', 'Non-Serious AEs', 'Consent', '5 Half Lives', 'Study Drug', 'Last Dose of', 'Signed', 'Start', 'Study Drug', '(70 days)', 'After Study', 'Drug Stopped', '*', 'Only if considered by the Investigator to be causally related to study-required procedures.', '81']"
81,page_82,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.6', 'Adverse Event Reporting', 'In the event of a serious adverse event, whether associated with blinded investigational', 'product or not, the Investigator will notify Clinical Pharmacovigilance within 24 hours of', 'the site being made aware of the serious adverse event by entering the serious adverse', 'event data into the electronic data capture (EDC) system. Serious adverse events that', 'occur prior to the site having access to the RAVE R system, or if RAVE is not operable,', 'should be documented on the SAE Non-CRF forms and emailed (preferred route) or faxed', 'to Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious', 'adverse event.', 'Email:', 'FAX to:', 'For safety concerns, contact the Oncology Safety Management Team at:', 'Oncology Safety Team', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'Office:', 'Email:', '82']"
82,page_83,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'For any subject safety concerns, please contact the physician listed below:', 'Primary Therapeutic Area Medical Director:', 'Senior Medical Director', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'USA', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', 'In emergency situations involving study subjects when the primary Therapeutic Area', 'Medical Director (TA MD) is not available by phone, please contact the 24-hour AbbVie', 'Medical Escalation Hotline where your call will be re-directed to a designated backup', 'AbbVie TA MD:', 'Phone:', 'AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'global and local guidelines and Appendix A of the Investigator Brochure will serve as the', 'Reference Safety Information (RSI). The RSI in effect at the start of a DSUR reporting', 'period serves as the RSI during the reporting period. For follow-up reports, the RSI in', ""place at the time of occurrence of the 'suspected' Serious Adverse Reaction will be used to"", 'assess expectedness.', 'In Japan, the principal investigator will provide documentation of all serious adverse', 'events to the Director of the investigative site and the Sponsor.', '83']"
83,page_84,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.7', 'Pregnancy', 'Pregnancy in a study subject must be reported to AbbVie within 24 hours of the', 'investigative site becoming aware of the pregnancy. Subjects who become pregnant', 'during the study must be discontinued (Section 5.4).', 'All subjects should be informed that contraceptive measures (refer to Section 5.2.4,', 'Contraception Recommendations and Pregnancy Testing for the details on contraception)', 'should be taken throughout the study and for at least 6 months after the last dose of study', 'drug. Male subjects should be informed that contraceptive measures should be taken by', 'their female partner.', 'Information regarding a pregnancy occurrence in a study subject and the outcome of the', 'pregnancy will be collected. In the event of a pregnancy occurring in the partner of an', 'enrolled subject, written informed consent for release of medical information from the', 'partner must be obtained prior to the collection of any pregnancy-specific information,', 'and the pregnancy will be followed to outcome.', 'Pregnancy in a study subject is not considered an adverse event. The medical outcome for', 'either mother or infant, meeting any serious criteria including an elective or spontaneous', 'abortion is considered a serious adverse event and must be reported to Abb Vie within', '24 hours of the site becoming aware of the event.', '6.1.8', 'Toxicity Management', 'Subjects will be monitored continuously for toxicity while on study treatment. Toxicity', 'will be assessed using the National Cancer Institute Common Terminology Criteria for', 'Adverse Events (NCI CTCAE) Version 4.0.11 If a subject has an AE possibly related to', 'blinded investigational product administration, then dose interruptions/holds with possible', 'modifications as described below may be implemented. Adjustments to these guidelines', 'may occur based on the clinical judgment of the investigator with notification to the TA', 'MD. Dose modifications for toxicities as described in Section 5.5.4.2.2 are mandatory.', '84']"
84,page_85,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.8.1', 'Management of Serosal Effusions/Serositis', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., cardiac', 'tamponade). Therefore, development of any of these events or worsening from baseline', 'warrants prompt evaluation by the Investigator or designee. Alternative causes such as', 'infection, congestive heart failure, or disease progression, should be ruled out. When', 'appropriate, a unifying diagnosis should be reported, e.g., ""heart failure,"" not the signs and', 'symptoms ""pleural effusion"" and ""edema limbs."" Effusion events were reported during', 'treatment and may occur up to several months after last Rova-T dose. As a result,', 'subjects should be advised of signs and symptoms of fluid retention and contact treating', 'physician if they arise during this time.', 'When considered clinically significant (e.g., Grade 2 or higher and considered related to', 'blinded investigational product):', 'Systemic corticosteroids, when initiated promptly, have been reported to be', 'beneficial in some prior cases. The Investigator should consider a tapering', 'regimen, such as dexamethasone up to 8 mg orally twice a day for 5 days,', 'followed by 4 mg orally twice a day for 5 days, then 2 mg orally twice a day', 'for 5 days. Alternatively, nonsteroidal therapies for serositis may be', 'considered, such as non-steroidal anti-inflammatory drugs (NSAIDs,', 'e.g., ibuprofen 400 - 600 mg orally three to four times daily) or colchicine', '(e.g., 0.6 mg orally two to three times daily) given for 1 - 2 weeks.', 'Until clinical experience suggests otherwise, guidance for dose delay and/or', 'reduction, as well as criteria for ongoing dosing, should follow Section 5.5.4.2.', '6.1.8.2', 'Management of Skin Reactions', 'All cutaneous reactions which develop during treatment warrant prompt evaluation. Skin', 'toxicity with rovalpituzumab tesirine may consist of photosensitivity but possibly other', 'reactions such as palmar-plantar erythrodysesthesia or erythema multiforme. As such,', '85']"
85,page_86,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'development of a cutaneous reaction during treatment warrants prompt evaluation by the', 'Investigator or designee.', 'Photosensitivity reactions may occur hours to days after sun exposure. Patients should be', 'advised to avoid direct and indirect sun exposure as much as possible from Cycle 1 Day 1', 'until 30 days after the final dose. When sun exposure is unavoidable, patients should', 'wear protective clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm', '(SPF 30 or greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the', 'patient may resume outdoor activities with appropriate sun protection including broad', 'brimmed hat, protective clothing and sunscreen SPF 30 or higher. Subjects with a grade 3', 'photosensitivity reaction should dose reduce Rova-T/placebo to 0.2 mg/kg after the first', 'occurrence and following a second grade 3 photosensitivity reaction, reduce Rova-', 'T/placebo to 0.1 mg/kg. Subjects with a grade 4 photosensitivity reaction must', 'permanently discontinue Rova-T/placebo.', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described in', 'Table 6.', 'Photo-documentation of skin toxicity should be available upon request by the TA MD.', 'The investigative site will take measures to protect the identity of the patient. These', 'measures include taking the photograph very close to the affected skin region to exclude', 'facial features, or if facial features cannot be excluded due to the location of the skin', 'reaction, covering identifying features (such as the eyes) with a black rectangle.', 'Formal evaluation by a dermatologist, including possible skin biopsy to rule out', 'alternative etiologies such as erythema multiforme, which may warrant discontinuation of', 'blinded investigational product, and to facilitate the most appropriate terminology for AE', 'reporting.', 'All events of cutaneous toxicity should be monitored until resolution or return to baseline.', 'Recommendations for management of photosensitivity reactions are outlined in Table 6.', '86']"
86,page_87,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Table 6.', 'Recommended Management of Photosensitivity', 'CTCAE v4.0', 'Treatment Recommendations', 'Dose Modifications', 'Grade 1', 'Painless erythema and', 'Low-potency topical steroid (face)', '-', 'erythema covering < 10% BSA', 'High-potency topical steroid', '(body)', 'Grade 2', 'Tender erythema covering 10 - Low-potency topical steroid (face)', '-', '30% BSA', 'High-potency topical steroid', '(body)', 'Nonsteroidal anti-inflammatory', 'agents orally as needed', 'Grade 3', 'Erythema covering > 30%', 'Low-potency topical steroid (face)', 'Reduce dose', 'BSA and erythema with', 'High-potency topical steroid', 'blistering; photosensitivity;', '(body)', 'oral corticosteroid therapy', 'Prednisone 0.5 mg/kg X 7 days', 'indicated; pain control', 'indicated (e.g., narcotics or', 'NSAIDs)', 'Grade 4', 'Life-threatening consequences;', 'Low-potency topical steroid (face)', 'Discontinue', 'urgent intervention indicated', 'High-potency topical steroid', '(body)', 'Prednisone 0.5 mg/kg X 7 days', 'Hospitalization', 'In order to simplify the collection of detailed Safety Data associated with dermatological', 'issues, prior to the verification of a specific diagnosis the general term of ""Skin Toxicity""', 'should be recorded on the Adverse Event eCRF and the corresponding details should be', 'captured on the Skin Toxicity Supplemental eCRF (as outlined in the form). Once a final', 'dermatological diagnosis is verified, the AE eCRF should be updated to reflect the', 'specific diagnosis.', '6.1.8.3', 'Management of Potential Drug-Induced Liver Injury', 'Wherever possible, timely confirmation of initial liver-related laboratory abnormalities', 'should occur prior to the reporting of a potential drug-induced liver injury (DILI) event.', 'All occurrences of potential DILIs, meeting the defined criteria, must be reported as', 'SAEs.', '87']"
87,page_88,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'A potential DILI is defined as:', 'ALT or AST elevation > 3 times (3x) upper limit of normal (ULN) and', 'Total bilirubin > 2 X ULN, without initial findings of cholestasis (elevated', 'serum alkaline phosphatase) and', 'No other immediately apparent possible causes of aminotransferase (AT)', 'elevation and hyperbilirubinemia including but not limited to viral hepatitis,', 'pre-existing chronic or acute liver disease or tumor(s), or the administration of', 'other drug(s) known to be hepatotoxic', 'In general, an increase of AT to > 3 X ULN should be followed by repeat testing within 48', '- 72 hours of all four of the usual measures (ALT, AST, alkaline phosphatase, and total', 'bilirubin) to confirm the abnormalities and to determine if they are increasing or', 'decreasing. An inquiry regarding symptoms should also be made (e.g., fatigue, nausea,', 'vomiting, right upper quadrant pain or tenderness, fever, rash). Subjects may be retested', 'locally, but normal laboratory ranges should be recorded and results made available to the', 'Investigator immediately. All data must be recorded in the CRF. If symptoms persist or', 'repeat testing shows AT > 3 X ULN for subjects with normal baseline measures or 2-fold', 'increases above baseline values for subjects with elevated values before drug exposure,', 'close observation should be initiated. If close monitoring is not possible, blinded', 'investigational product should be discontinued.', 'Close observation includes:', 'Repeating liver enzyme and serum bilirubin tests two or three times weekly.', 'Frequency of retesting can decrease to once a week or less if abnormalities', 'stabilize or the trial drug has been discontinued and the subject is', 'asymptomatic.', 'Obtaining a more detailed history of symptoms and prior or concurrent', 'diseases', 'Obtaining a history of concomitant drug use (including nonprescription', 'medications and herbal and dietary supplement preparations), alcohol use,', 'recreational drug use, and special diets', '88']"
88,page_89,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Ruling out acute viral hepatitis types A, B, C, D, and E; autoimmune or', 'alcoholic hepatitis; non-alcoholic steatohepatitis (NASH); hypoxic/ischemic', 'hepatopathy; and biliary tract disease', 'Obtaining a history of exposure to environmental chemical agents', 'Obtaining additional tests to evaluate liver function, as appropriate', '(e.g., international normalized ratio [INR], direct bilirubin)', 'Considering gastroenterology or hepatology consultations', 'Blinded investigational product will be discontinued if potential DILI is suspected and:', 'ALT or AST > 8 X ULN', 'ALT or AST > 5 X ULN for more than 2 weeks', 'ALT or AST > 3 X ULN and (TBL > 2x ULN or INR > 1.5)', 'ALT or AST > 3 X ULN with the appearance of fatigue, nausea, vomiting,', 'right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia', 'All subjects showing possible DILI should be followed until all abnormalities return to', 'normal or to the baseline state.', 'Any hepatic related adverse event should be recorded and the Hepatic Adverse Event', 'eCRF triggered from the Adverse Event page.', '6.1.8.4', 'Monitoring and Management of Edema', 'The majority of the edema events with rovalpituzumab tesirine have been reported as low', 'grade 1 or 2 (mild or moderate); however, a small number of fatal events of generalized', 'edema have been reported with rovalpituzumab tesirine. Physical exams and monitoring', 'of weight gain and signs or symptoms of fluid retention should be conducted during', 'treatment. Edema events were reported during treatment and may occur up to several', 'months after last Rova-T dose. As a result subjects should be advised of signs and', 'symptoms of fluid retention as well as monitor their weight and contact treating physician', 'if they arise during this time.', '89']"
89,page_90,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Consistent with institutional guidelines or standard practice, the use of diuretics with or', 'without albumin may be considered in subjects with clinically significant edema and', 'hypoalbuminemia. The selection and use of diuretics in subjects should be based on', 'individual clinical characteristics and include monitoring of electrolyte status and signs or', 'symptoms of intravascular volume depletion such as hypotension and impaired renal', 'function.', 'Systemic corticosteroids, when initiated promptly, have been reported to be beneficial in', 'some prior cases.', 'Reported Term', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Generalized', 'Noted on exam;', 'Interfering with', 'Interferes with', 'Life-', 'edema', '1+ pitting edema', 'instrumental ADLs; oral', 'self care ADL;', 'threatening', '(Anasarca)', 'therapy initiated', 'intravenous', 'consequences', 'therapy indicated;', 'skin breakdown', 'Definition: A disorder characterized by fluid accumulation in the tissues of the body including the skin.', 'Edema trunk', 'Swelling or', 'Readily apparent', 'Gross deviation', 'obscuration of', 'obscuration of anatomic', 'from normal', 'anatomic', 'architecture; obliteration', 'anatomic contour;', 'architecture on', 'of skin folds; readily', 'limiting self care', 'close inspection', 'apparent deviation from', 'ADL', 'normal anatomic contour;', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.', 'Edema limbs', '5 - 10% inter-limb', '> 10 - 30% inter-limb', '> 30% inter-limb', 'discrepancy in', 'discrepancy in volume or', 'discrepancy in', 'volume or', 'circumference at point of', 'volume; gross', 'circumference at', 'greatest visible difference;', 'deviation from', 'point of greatest', 'readily apparent', 'normal anatomic', 'visible difference;', 'obscuration of anatomic', 'contour; limiting', 'swelling or', 'architecture; obliteration', 'self care ADL', 'obscuration of', 'of skin folds; readily', 'anatomic', 'apparent deviation from', 'architecture on', 'normal anatomic contour;', 'close inspection', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the upper or', 'lower extremities', '90']"
90,page_91,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.1.8.5', 'Pneumonitis', 'Pneumonitis has been infrequently reported with rovalpituzumab tesirine but has resulted', 'in fatal outcomes. Although the causal role of rovalpituzumab tesirine could not be ruled', 'out, the reports of pneumonitis had one or more confounders including underlying', 'pulmonary disease/cancer, prior thoracic radiation, prior cytotoxic chemotherapy or', 'clinical evidence suggestive of an alternative diagnosis including pneumonia.', 'Heavily pretreated SCLC patients and patients with a history of pneumonitis may be at', 'increased risk, and careful monitoring for signs and symptoms of pneumonitis is', 'important. The risk of pneumonitis is increased with prior radiation to lung.', 'In general, signs and symptoms coinciding with or preceding pneumonitis may include', 'new or worsening cough, chest pain and/or shortness of breath, fever, and radiographic', 'changes (reticular markings, ground glass opacities). Protocol defined disease', 'assessments provide the opportunity for on study pulmonary monitoring with ""gold', 'standard"" diagnostic method for detection of pneumonitis. The protocol allows for', 'additional imaging per physician discretion for signs and symptoms of pulmonary', 'toxicity.', 'The diagnosis of drug induced pneumonitis is one of exclusion. Other etiologies', 'including infection, which is a common cause of pulmonary infiltrates with clinical and', 'radiographic appearance similar to drug-induced pneumonitis, need to be carefully', 'considered and excluded before the diagnosis of drug induced pneumonitis can be', 'established.', 'If pneumonitis is suspected, close monitoring including additional laboratory and imaging', 'investigation per institutional guidelines may be necessary. Systemic corticosteroids may', 'be beneficial for rapidly progressive or more severe pneumonitis. For events of Grade', '1', 'pneumonitis close monitoring is recommended; while dose modifications for Grade 2 and', 'discontinuation of Rova-T for Grades 3 and 4 are required. Please see Table 5.', '91']"
91,page_92,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.2', 'Product Complaint', '6.2.1', 'Definition', 'A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the', 'biologic or drug component of the product.', 'For a product this may include, but is not limited to, damaged/broken product or', 'packaging, product appearance whose color/markings do not match the labeling, labeling', 'discrepancies/inadequacies in the labeling/instructions (example: printing illegible),', 'missing components/product, or packaging issues.', 'Any information available to help in the determination of causality to the events outlined', 'directly above should be captured.', '6.2.2', 'Reporting', 'Product Complaints concerning the investigational product must be reported to the', ""Sponsor within 24 hours of the study site's knowledge of the event via the Product"", 'Complaint eCRF. Product Complaints occurring during the study will be followed-up to a', 'satisfactory conclusion. All follow-up information is to be reported to the Sponsor (or an', 'authorized representative) and documented in source as required by the Sponsor. Product', 'Complaints associated with adverse events will be reported in the study summary. All', 'other complaints will be monitored on an ongoing basis.', 'Product Complaints may require return of the product with the alleged complaint', 'condition. In instances where a return is requested, every effort should be made by the', 'investigator to return the product within 30 days. If returns cannot be accommodated', 'within 30 days, the site will need to provide justification and an estimated date of return.', 'The description of the complaint is important for AbbVie in order to enable AbbVie to', 'investigate and determine if any corrective actions are required.', '92']"
92,page_93,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '7.0', 'Protocol Deviations', 'AbbVie does not allow intentional/prospective deviations from the protocol unless when', 'necessary to eliminate an immediate hazard to study subjects. The principal investigator', 'is responsible for complying with all protocol requirements, and applicable global and', 'local laws regarding protocol deviations. If a protocol deviation occurs (or is identified)', 'after a subject has been enrolled, the principal investigator is responsible for notifying', 'Independent Ethics Committee (IEC)/Independent Review Board (IRB) regulatory', 'authorities (as applicable), and the following AbbVie Clinical Monitor(s):', 'Primary Contact:', 'Alternate Contact:', 'Study Project Manager II', 'Study Project Manager I', 'AbbVie Corporation', 'AbbVie s.r.o.', '8401 Trans-Canada Highway', 'METRONOM BUSINESS CENTER', 'Saint-Laurent, Québec', 'Bucharova 2817/13, Stodulky,', 'H4S 1Z1', '158 00 Praha 5', 'Canada', 'Czech Republic', 'Phone:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Such contact must be made as soon as possible to permit a review by AbbVie to', 'determine the impact of the deviation on the subject and/or the study.', 'In Japan, the Investigator will record all protocol deviations in the appropriate medical', 'records at site.', '93']"
93,page_94,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.0', 'Statistical Methods and Determination of Sample', 'Size', '8.1', 'Statistical and Analytical Plans', 'This section describes the planned statistical analyses to be performed using data captured', 'according to this protocol. A complete statistical analysis plan (SAP) describing in more', 'detail all planned analyses will be finalized prior to database lock.', 'The primary endpoints of OS and progress free survival (PFS) assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1 in DLL3high', 'patients will be analyzed at the same time after observing at least 319 os events. It is', 'expected at approximately 420 PFS events will be observed at the time of the primary', 'analysis.', 'The following analysis sets are considered:', 'DLL3high Set: It includes all randomized subjects with DLL3 high ED SCLC.', 'Subjects will be classified according to the treatment arm to which they are', 'randomized regardless the actual treatment received, following intent-to-treat', 'principle. The DLL3high set will be the analysis set for the analysis of the', 'primary efficacy endpoints of os and PFS. All the exploratory efficacy', 'endpoints will be analyzed based on the DLL3 high set unless the OS and PFS', 'based on the randomized set are statistically significant.', 'Randomized Set: It includes all randomized subjects, with subjects grouped', 'according to the treatment arm to which they are randomized regardless the', 'actual treatment received, following intent-to-treat principle. The randomized', 'set will be the analysis set for key secondary efficacy endpoints of OS and', 'PFS, and key secondary endpoint of EORTC QLQ-C30 physical functioning', 'domain. All the exploratory efficacy endpoints will be analyzed based on the', 'randomization set if the OS and PFS based on the randomization set are', 'statistically significant.', 'Per Protocol Set: It includes all subjects in the randomized set without any', 'major protocol violations which may affect the evaluation of the primary', '94']"
94,page_95,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'efficacy endpoint. Major protocol violations will be defined in the SAP prior', 'to the database lock. Subjects will be classified according to treatment', 'assigned at the time of randomization. The per protocol set will be used for', 'supportive analysis of efficacy endpoints.', 'Safety Set: It includes all subjects who received at least one dose of study', 'drug and subjects will be classified according to treatment received. Thus a', 'subject who is randomized to the rovalpituzumab tesirine arm but does not', 'receive rovalpituzumab tesirine will be considered in the placebo arm for', 'safety analysis. Dexamethasone treatment will not be taken into consideration', ""for subjects' classification in the Safety set."", 'Pharmacokinetic-Evaluable Set: It consists of all subjects who receive at', 'least one dose of study drug, with subjects classified according to the actual', 'treatment received. A baseline measurement and at least one blood sample', 'following a dose of study treatment is required for inclusion in this analysis.', '8.1.1', 'Disposition of Study Subjects', 'The disposition of subjects will be summarized by treatment arm in the randomized set.', 'The subject disposition includes the number of subjects for whom study drug was', 'permanently discontinued (including the reasons for discontinuation), and the number of', 'subjects who discontinued early from the study.', '8.1.2', 'Demographics and Baseline Characteristics', 'Demographic and baseline characteristics will be summarized in the DLL3 high set and', 'randomized set.', '8.1.3', 'Efficacy Endpoints and Analyses', 'Assessment of response and progression will be determined by the CRAC according to', 'RECIST v1.1.', '95']"
95,page_96,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.1.4', 'Primary Efficacy Enpoints', 'Progression-free survival (PFS) and overall survival (OS) in subjects with DLL3 high ED', 'SCLC are the two primary efficacy endpoints.', 'PFS will be defined as the number of months from randomization to disease progression,', 'as assessed by the CRAC per RECIST v1.1, or death of any cause, whichever occurs first.', 'Disease progression and censoring rules will be based on published conventions. 15 If a', 'subject neither experienced disease progression nor died, then the data will be censored at', 'the last date of post-baseline radiographic assessment. If a subject with no post-baseline', 'assessment did not experience disease progression nor died, then the data will be censored', 'at the date of randomization.', 'Differences between the treatment arm and the placebo arm in PFS will be assessed by a', 'log-rank test stratified by the randomization stratification factors, testing the null', 'hypothesis (rovalpituzumab tesirine arm is not superior to placebo arm in PFS). The', ""hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors. Median PFS and 95% confidence intervals will be estimated using Kaplan-Meier', 'survival methodology, with the Kaplan-Meier survival curves presented to provide a', 'visual description. PFS rates at 3, 6, 9, and 12 months after randomization with 95%', 'confidence intervals will be reported. Estimates of the treatment effect will be expressed', 'as hazard ratio including 95% confidence intervals estimated through a Cox proportional-', 'hazards regression model adjusting for the main-effects of the stratification factors.', 'Overall survival will be defined as the number of months from randomization to death of', 'any cause. OS and censoring rules will be based on published conventions. 15 If a subject', 'has not died, the data will be censored at the last date documented to be alive.', 'Differences between the treatment arm and the placebo arm in OS will be assessed by a', 'log-rank test stratified by the randomization stratification factors, testing the null', 'hypothesis (rovalpituzumab tesirine arm is not superior to placebo arm in OS). The', '96']"
96,page_97,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', ""hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors. Median OS and 95% confidence intervals will be estimated using Kaplan-Meier', 'survival methodology, with the Kaplan-Meier survival curves presented to provide a', 'visual description. OS rate at 6, 12, 18, and 24 months and corresponding 95%', 'confidence intervals will be reported. Estimates of the treatment effect on will be', 'expressed as hazard ratio including 95% confidence intervals estimated through Cox', 'proportional-hazards regression models adjusting for the main-effects of the stratification', 'factors.', '8.1.5', 'Secondary Efficacy Endpoints', 'The secondary efficacy endpoints in the randomized set are:', 'os', 'PFS per the CRAC based on RECIST v1.1', 'EORTC QLQ-C30 physical functioning domain', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', '8.1.6', 'Exploratory Efficacy Endpoints', 'The exploratory efficacy endpoints in both DLL3 high and randomization set are:', 'Objective response rate (ORR) per the CRAC based on RECIST v1.1', 'PFS per investigator assessment based on RECIST v1.1', 'ORR per investigator assessment based on RECIST v1.1', 'Clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, based on RECIST v1.1', 'Duration of response (DOR) per CRAC and investigator assessment,', 'respectively', '97']"
97,page_98,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Change from baseline in all PRO domains (except physical functioning)', 'measured by EORTC QLQ-C30/LC13 and EQ-5D-5L', 'ORR is defined as the proportion of patients with a best overall response (BOR) of', 'confirmed complete response (CR) or partial response (PR) by CRAC review according to', 'RECIST v1.1.', 'CBR is defined as the proportion of patients with a BOR of CR or PR, or SD by CRAC', 'review according to RECIST v1.1.', 'ORR and CBR in treatment arms will be compared using Cochran-Mantel-Haenszel test', 'stratified by randomization stratification factors. Rates and 95% confidence intervals will', 'be reported for each treatment arm.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for confirmed complete response (CR) or partial', 'response (PR) by CRAC (whichever is recorded first) to the date of progressive disease or', 'death, whichever comes first. If a subject is still responding (i.e., has not progressed nor', ""died after CR or PR), then the subject's data will be censored at date of the last"", 'radiographic assessment by CRAC. For subjects who never experienced CR or PR, these', ""subjects' data will not be included in the duration of response analysis. Distribution of the"", 'duration of response will be estimated for each treatment arm using Kaplan-Meier', 'methodology. Median duration of overall response with corresponding 95% CI for each', 'treatment arm will be provided.', '8.1.7', 'Patient Reported Outcomes (PRO)', 'The EORTC QLQ-C30/LC13 13 scoring manual will be used to transform the raw scores', 'into the domain scores (global heath, functional scales, symptom scales/items). Physical', 'functioning scale score in EORTC QLQ-C30 is the key secondary endpoint. Change from', 'baseline of the items and domains of the QLQ-C30/LC13 will be summarized by', 'treatment arm. The EQ-5D-5L manual and the published weights will be used to convert', 'the individual items to the utility scores. Change from baseline of the EQ-5D-5L utility', '98']"
98,page_99,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'score and VAS will be summarized by treatment arm. The treatment group differences', 'will be evaluated by analyzing the change from baseline using a one-way analysis of', 'variance (ANOVA) model.', '8.1.8', 'Planned Sensitivity and Subgroup Analyses', 'Efficacy analyses for the primary endpoints (PFS per CRAC and OS) will be performed in', 'the per-protocol set.', 'In', 'the', 'DLL3 high and randomized sets, treatment effects for the primary endpoints (PFS per', 'CRAC and OS) will be assessed in the following subgroups:', 'RECIST v1.1 response after completion of first-line platinum-based therapy at', 'screening assessment (SD VS. PR/CR)', 'DLL3 expression (Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or', 'above) for the randomized set only', 'History of CNS metastases (Yes VS. No)', 'For subjects with no history of CNS metastases, PCI VS. No PCI', 'Lactate dehydrogenase (LDH), ULN VS. > ULN', 'Number of metastatic sites, 0 - 1 VS. > 1', 'Age group (age < 40 VS. 40 to < 60 VS. 60 or older)', 'Gender', 'Race', 'ECOG (0 VS. 1)', 'Differences between rovalpituzumab tesirine arm and the placebo arm for time-to-event', 'endpoints will be assessed by an unstratified log-rank test for each subgroup. Hazard', ""ratios of treatment arm over the placebo arm will be calculated by a Cox's model."", '8.1.9', 'Pharmacokinetic and Exposure-Response Analyses', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the incidence and timing', 'of ATA formation will be tabulated and summary statistics will be computed. Serum', '99']"
99,page_100,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'concentration and ATA data from this study may be combined with data from other', 'studies and analyzed using population pharmacokinetic methodologies.', 'The relationship between pharmacokinetics (e.g., exposure) and clinical trial findings', 'including, but not limited to demographics, efficacy, and/or safety measures may also be', 'explored. Additional analyses will be performed if useful. Results of the population', 'pharmacokinetic and exposure-response analyses will be provided in a separate report.', '8.2', 'Safety Analyses', 'Safety endpoints will be summarized using data from the Safety set. Safety analyses will', 'involve examination of the incidence, severity, and type of treatment-emergen adverse', 'events (TEAEs) reported, changes in vital signs and laboratory test results from baseline', '(the assessment prior to first dose) to specified time points throughout the study, and', 'concomitant medications used. NCI CTCAE version 4.0 will be used in the grading of', 'adverse events and laboratory abnormalities that are reported as adverse events.', '8.2.1', 'Treatment-Emergent Adverse Events (TEAEs)', 'TEAEs reported during the study will be coded using a MedDRA 16 dictionary. Incidence', 'of TEAEs will be summarized by treatment arm and the following:', 'System organ class and preferred term', 'System organ class, preferred term, and severity', 'These summaries will be presented for the following subsets:', 'Serious TEAEs', 'All TEAEs', 'Drug-related TEAEs', 'For tables reporting AEs by severity, if a subject has multiple occurrences of an AE with', 'the same organ class and preferred term, the most severe event will be presented.', '100']"
100,page_101,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.2.2', 'Clinical Laboratory Evaluation', 'Laboratory parameters will be summarized by treatment arm at each visit. Each summary', 'will include the values of the laboratory parameters and changes from baseline. Shift', 'tables from baseline will be presented for laboratory values in the chemistry and', 'hematology panels. Parameters will be classified according to the laboratory reference', 'normal ranges. A listing will be provided for out-of-normal range as well as clinically', 'significant abnormal lab values.', '8.2.3', 'Vital Signs', 'Vital signs including pulse, blood pressure, temperature, and body weight will be', 'summarized by treatment arm and time point. For each assessment of vital signs, change', 'from baseline will be summarized by treatment arm.', '8.2.4', 'ECOG Performance Status', 'ECOG performance status will be summarized for each visit by treatment arm. Shifts', 'from baseline to the best and worst post-baseline score may be tabulated.', '8.2.5', 'Electrocardiogram', 'ECG status will be summarized for each scheduled visit by treatment arm. Shifts from', 'baseline may be tabulated.', '8.2.6', 'Concomitant Medications', 'Concomitant medications will be classified according to the anatomical therapeutic', 'chemical (ATC) codes in the World Health Organization Drug (WHODRUG) dictionary.', 'The incidence rate of each coded concomitant medication will be tabulated by treatment', 'arm. The table will be sorted by the incidence use of the entire sample.', '8.3', 'Type I Error Adjustment Procedure for Multiple Testing', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) to one-sided 0.025 level for comparisons of', '101']"
101,page_102,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival', '(PFS) per CRAC in DLL3 high set, overall survival (OS) in DLL3 high set, PFS per CRAC in', 'randomized set, OS in randomized set, and physical functioning scale score (EORTO', 'QLQ-C30) in randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in Hoi are Hola and Holb.', 'Ho1a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'DLL3 high set.', 'Ho1b: Rovalpituzumab tesirine arm is not superior to placebo arm in os in DLL3 high set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {H01a, Holb, H02, H03, and H04} in', 'order. To maintain the family-wise type I error for the study, the null hypotheses in H01', '(Ho1a and H01b) will be first tested with an alpha-split approach. The one-sided alpha of', '0.25% and 2.25% will be assigned for PFS and os hypothesis in H01, respectively. Out of', 'one-sided alpha of 2.25% allocated to OS hypothesis (Hoib), the one-sided alpha of 10-6', 'will be spent for the early look at the OS data for futility analysis. If the hypothesis for', 'PFS in H01 (Ho1a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in Hoi (Hoib). Hence, the hypothesis for OS in H01 (Hoib) will be tested either', 'at a one-sided 2.4999% or one-sided 2.2499% level of significance depending on the PFS', 'hypothesis in Ho1a is rejected or not.', '102']"
102,page_103,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'If either PFS or OS endpoint reaches statistical significance, the study is considered', 'positive. No further tests will be performed if the OS endpoint in DLL3 high population', '(H01b) does not reach statistical significance.', 'The hypothesis in H02 will be tested if the hypothesis in Holb is rejected. If the hypothesis', 'in H02 is rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS', 'endpoint in DLL3 high subjects (Ho1a) is also rejected or (ii) only H04 will be tested if the', 'PFS endpoint in DLL3 high subjects (H01a) is not rejected.', 'Diagram of Hierarchical Testing of Primary and Secondary Endpoints is described in', 'Figure 3.', '103']"
103,page_104,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Enppoints', 'Test Hola (PFS in DLL: 3High set) at one-sided a = 0.25%', 'If Ho1a not rejected', 'If Holaisrejected', 'Test Holb (OS in DLL3', 'Test Holb (OS in DLL3High', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Holb isrejected', 'If Holb is rejected', 'Test Ho2 (OS in Randomized', 'Test Ho2 (OS in Randomized', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Ho2 is rejected', 'If Ho2 is rejected', 'Test Ho4 (PF scale in EORTC', 'Test Ho3 (PFS in Randomized', 'QLQ-C30 in Randomized set)', 'set) at one-sided a = 2.4999%', 'at one-sided a = 2.2499%', 'If H03 is rejected', 'Test Ho4 (PF scale in EORTC', 'QLQ-C30 in Randomized set)', 'at one-sided a = 2.2499%', '104']"
104,page_105,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.4', 'Determination of Sample Size', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS) in DLL3high ED SCLC patients. To', 'maintain the overall 1-sided type I error at a 2.5% for this study, the type I error will be', 'split, assigning 0.25% to progression-free survival and the remaining 2.25% to overall', 'survival. However, the OS endpoint will be tested at a one-sided 2.2499% significance', 'level as a one-sided alpha of 10-6 will be spent for the early look at the OS data for futility', 'analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo and rovalpituzumab tesirine arm will be around 9 months and 13', 'months, respectively. The increase of median os in rovalpituzumab tesirine arm', 'corresponds to a hazard ratio of 0.69, i.e., a reduction in the hazard of death by 31%.', 'With all these assumptions, a total of 319 deaths among subjects with DLL3 high are needed', 'to achieve a 90% power based on a log-rank test at a one-sided significance level of', '0.022499. Assuming a 19-month accrual period and the last enrolled subject followed for', '12 months, at least 480 subjects with DLL3 high are expected to be randomized', '(240 subjects in each arm). A total of 740 subjects regardless of DLL3 expression level', '(including 480 subjects with DLL3high) will enroll in the study, assuming an approximate', 'prevalence of 65% for subjects with DLL3high For one-sided significance level of', '0.022499, it is projected that an observed hazard ratio of 0.799 or less, corresponding to a', '2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The primary endpoints of OS and PFS in DLL3 high patients will be analyzed at the same', 'time after observing at-least 319 OS event. It is expected at approximately 420 PFS', 'events will be observed at the time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that', 'median progression-free survival for the placebo and rovalpituzumab tesirine arm will be', '105']"
105,page_106,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'approximately 3 months and 4.5 months, respectively. The increase of median', 'progression-free survival in rovalpituzumab tesirine arm corresponds to a hazard ratio of', '0.667. With all these assumptions, a total of approximately 420 PFS events assessed by', 'the CRAC for the subjects with DLL3high are needed to achieve a 91% power based on a', 'log-rank test at a one-sided significance level of 0.0025. It is projected that an observed', 'hazard ratio of 0.760 or less, corresponding to approximately 1 month or greater', 'improvement in median PFS, would result in a statistically significant improvement in the', 'PFS.', '8.5', 'Futility Analysis', 'A futility analysis will be conducted when approximately 160 deaths in subjects with', 'DLL3high ED SCLC (approximately 50% of the planned deaths) are observed. The trial', 'may be stopped for futility if the estimated Overall Survival Cox HR of Rova-T to', 'Placebo in the DLL3high set at futility analysis exceeds 0.9. The one-sided alpha of 10-6', 'will be spent for the early look at the efficacy data for futility analysis.', 'Unblinded interim data will be analyzed and reviewed by the IDMC. The trial may be', 'considered for early stopping for futility and the Sponsor will be unblinded to the', 'aggregated data by randomized treatment arms if the IDMC makes such a', 'recommendation after consideration of the OS results and other supportive evidence', 'including other relevant efficacy and safety data.', 'Details for the futility analysis will be provided in the IDMC charter.', '8.6', 'Accrual/Study Duration Considerations', 'On average, it is expected that accrual rates are 1, 7, 27, 36, and 42 with DLL3 high subjects', 'per month at study initiation, 3, 6, 9, and 12 month and thereafter, respectively. The total', 'study duration and accrual duration are projected to be 31 months and 19 months with a', '5% rate of loss to follow-up, respectively. A total of 740 subjects regardless of DLL3', 'expression level in tumor are expected to enroll during the accrual period. It is projected', 'that 480 subjects with DLL3 high ED SCLC will have enrolled for the primary analysis by', '106']"
106,page_107,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'the time approximately 420 PFS events per CRAC and at least 319 OS events should be', 'observed in DLL3 high subjects after approximately 8 - 10 months of follow-up.', '8.7', 'Randomization Methods', 'The randomization numbers of the study will assign subjects in a 1:1 ratio to either', 'receive 0.3 mg/kg rovalpituzumab tesirine or placebo, on Day 1 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response', 'after completion of first-line platinum-based therapy at screening assessment (SD VS.', 'PR/CR), DLL3 expression (Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or', 'above), history of CNS metastases (Yes VS. No), and for subjects with no history of CNS', 'metastases, PCI VS. no PCI.', '9.0', 'Ethics', '9.1', 'Independent Ethics Committee (IEC) or Institutional Review', 'Board (IRB)', 'Good Clinical Practice (GCP) requires that the clinical protocol, any protocol', ""amendments, the Investigator's Brochure, 14 the informed consent and all other forms of"", 'subject information related to the study (e.g., advertisements used to recruit subjects) and', 'any other necessary documents be reviewed by an IEC/IRB. The IEC/IRB will review the', 'ethical, scientific and medical appropriateness of the study before it is conducted.', 'IEC/IRB approval of the protocol, informed consent and subject information and/or', 'advertising, as relevant, will be obtained prior to the authorization of drug shipment to', 'a', 'study site.', 'Any amendments to the protocol will require IEC/IRB (Competent Authority, if', 'applicable) approval prior to implementation of any changes made to the study design.', 'The investigator will be required to submit, maintain and archive study essential', 'documents according to ICH GCP and all other applicable regulatory requirements.', 'Any serious adverse events that meet the reporting criteria, as dictated by local', 'regulations, will be reported to both responsible Ethics Committees and Regulatory', '107']"
107,page_108,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Agencies, as required by local regulations. During the conduct of the study, the', 'investigator should promptly provide written reports (e.g., ICH Expedited Reports, and', 'any additional reports required by local regulations) to the IEC/IRB of any changes that', 'affect the conduct of the study and/or increase the risk to subjects. Written documentation', 'of the submission to the IEC/IRB should also be provided to AbbVie.', '9.2', 'Ethical Conduct of the Study', 'The study will be conducted in accordance with the protocol, International Conference on', 'Harmonization (ICH) guidelines17,18 applicable regulations and guidelines governing', 'clinical study conduct and the ethical principles that have their origin in the Declaration of', 'Helsinki. Responsibilities of the clinical investigator are specified in Appendix A.', '9.3', 'Subject Information and Consent', 'The investigator or his/her representative will explain the nature of the study to the', 'subject, and answer all questions regarding this study. Prior to any study-related', 'screening procedures being performed on the subject, the informed consent statement will', 'be reviewed and signed and dated by the subject, the person who administered the', 'informed consent, and any other signatories according to local requirements. A copy of', 'the informed consent form will be given to the subject and the original will be placed in', ""the subject's medical record. An entry must also be made in the subject's dated source"", 'documents to confirm that informed consent was obtained prior to any study-related', 'procedures and that the subject received a signed copy.', 'Information regarding incentives for subjects and information regarding provisions for', 'treating and/or compensating subjects who are harmed as a consequence of participation', 'in the study can be found in the informed consent form.', 'Tumor material obtained by biopsy procedure at the time of disease progression (for', 'exploratory research) is optional and will only be performed if the subject has voluntarily', 'signed and dated an optional tumor material biopsy procedure informed consent, approved', 'by an IEC/IRB, after the nature of the testing has been explained and the subject has had', '108']"
108,page_109,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'an opportunity to ask questions. If the subject does not consent to the optional informed', ""consent, it will not impact the subject's participation in the study."", 'In the event a subject withdraws consent to participate from the study, stored biomarker', 'and tumor specimen for exploratory research will continue to be used for research and', 'analysis. In the event that a subject would like to withdraw consent for research using', 'these samples, the subject may request that their samples be withdrawn. Once Abb Vie', 'receives the request, remaining biomarker and tumor specimen for exploratory research', 'will be destroyed. If the subject changes his/her consent, and the samples have already', 'been tested, those results will still remain as part of the overall research data.', '9.3.1', 'Informed Consent Form and Explanatory Material', 'In Japan, the principal investigator will prepare the consent form and explanatory material', ""required to obtain subject's consent to participate in the study with the cooperation of the"", 'sponsor and will revise these documents as required. The prepared or revised consent', 'forms and explanatory material will be submitted to the sponsor. Approval of the IRB', 'will be obtained prior to use in the study.', '9.3.2', 'Revision of the Consent Form and Explanatory Material', ""In Japan, when important new information related to the subject's consent becomes"", 'available, the principal investigator will revise the consent form and explanatory material', 'based on the information without delay and will obtain the approval of the IRB prior to', 'use in the study. The investigator will provide the information, without delay, to each', 'subject already participating in the study, and will confirm the intention of each subject to', 'continue the study or not. The investigator shall also provide a further explanation using', 'the revised form and explanatory material and shall obtain written consent from each', 'subject of their own free will to continue participating in the study.', '109']"
109,page_110,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '10.0', 'Source Documents and Case Report Form', 'Completion', '10.1', 'Source Documents', 'Source documents are defined as original documents, data and records. This may include', ""hospital records, clinical and office charts, laboratory data/information, subjects' diaries or"", 'evaluation checklists, pharmacy dispensing and other records, recorded data from', 'automated instruments, microfiches, photographic negatives, microfilm or magnetic', 'media, and/or x-rays Data collected during this study must be recorded on the', 'appropriate source documents. The Investigator Awareness Date of SAE should be noted', 'in the source.', 'The investigator(s)/institution(s) will permit study-related monitoring, audits, IEC/IRB', 'review, and regulatory inspection(s), providing direct access to source data documents.', '10.2', 'Case Report Forms', 'Case report forms (CRF) must be completed for each subject screened/enrolled in this', 'study. These forms will be used to transmit information collected during the study to', 'AbbVie and regulatory authorities, as applicable. The CRF data for this study are being', 'collected with an electronic data capture (EDC) system called RaveR provided by the', 'technology vendor Medidata Solutions Incorporated, NY, USA. The EDC system and the', 'study-specific electronic case report forms (eCRFs) will comply with Title 21 CFR', 'Part 11. The documentation related to the validation of the EDC system is available', 'through the vendor, Medidata, while the validation of the study-specific eCRFs will be', 'conducted by AbbVie and will be maintained in the Trial Master File at AbbVie.', 'The investigator will document subject data in his/her own subject files. These subject', 'files will serve as source data for the study. All eCRF data required by this protocol will', 'be recorded by investigative site personnel in the EDC system. All data entered into the', 'eCRF will be supported by source documentation.', '110']"
110,page_111,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', ""The investigator or an authorized member of the investigator's staff will make any"", 'necessary corrections to the eCRF. All change information, including the date and person', 'performing the corrections, will be available via the audit trail, which is part of the EDC', 'system. For any correction, a reason for the alteration will be provided. The eCRFs will', 'be reviewed periodically for completeness, legibility, and acceptability by AbbVie', 'personnel (or their representatives). AbbVie (or their representatives) will also be allowed', 'access to all source documents pertinent to the study in order to verify eCRF entries. The', 'principal investigator will review the eCRFs for completeness and accuracy and provide', 'his or her electronic signature and date to eCRFs as evidence thereof.', 'Medidata will provide access to the EDC system for the duration of the trial through a', 'password-protected method of internet access. Such access will be removed from', ""investigator sites at the end of the site's participation in the study. Data from the EDC"", 'system will be archived on appropriate data media (CD-ROM, etc.) and provided to the', ""investigator at that time as a durable record of the site's eCRF data. It will be possible for"", 'the investigator to make paper printouts from that media.', 'Patient reported data must be completed for each subject screened/enrolled in this study.', 'Some of these data are being collected with an Electronic Patient Reported Outcome', '(ePRO) system called Trialmax, provided by the technology vendor CRF Health of', 'Plymouth Meeting, PA, USA. The ePRO system is in compliance with Title 21 CFR', 'Part 11. The documentation related to the system validation of the ePRO system is', 'available through the vendor, CRF Health, while the user acceptance testing of the', 'study-specific PRO design will be conducted and maintained at AbbVie.', 'The subject will be entering the data on an electronic device; these data will be uploaded', 'to a server. The data on the server will be considered source, and maintained and', 'managed by CRF Health.', 'Internet access to the ePRO data will be provided by CRF Health for the duration of the', 'study. This access will be available for the duration of the study to the site investigator, as', 'well as delegated personnel. Such access will be removed from investigator sites', '111']"
111,page_112,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'following the receipt of the study archive. Data from the ePRO system will be archived', 'on appropriate data media (CD-ROM, etc.) and provided to the investigator at that time as', ""a durable record of the site's ePRO data. It will be possible for the investigator to make"", 'paper print-outs from that media.', 'The (instrument/scale) will be collected electronically via a Tablet/Laptop device into', 'which the patient will directly enter the required pieces of information. The electronic', 'device will be programmed to allow data entry for only the visits specified in the protocol', 'and will not allow for patients to complete more than one of the same assessment at any', 'one visit. All data entered on the device will be immediately stored to the device itself', 'and (manually/automatically) uploaded to a central server administrated by (ePRO', 'Vendor). The Investigator and delegated staff will be able to access all uploaded patient', 'entered data via a password protected website, up until the generation, receipt and', 'confirmation of the study archive.', '11.0', 'Data Quality Assurance', 'Computer logic and manual checks will be created to identify items such as inconsistent', 'study dates. Any necessary corrections will be made to the eCRF.', '12.0', 'Use of Information', 'Any research that may be done using optional exploratory research samples from this', 'study will be experimental in nature and the results will not be suitable for clinical', 'decision making or patient management. Hence, the subject will not be informed of', 'individual results, should analyses be performed, nor will anyone not directly involved in', 'this research. Correspondingly, researchers will have no access to subject identifiers.', 'Individual results will not be reported to anyone not directly involved in this research', 'other than for regulatory purposes. Aggregate data from optional exploratory research', 'may be provided to investigators and used in scientific publications or presented at', 'medical conventions. Optional exploratory research information will be published or', 'presented only in a way that does not identify any individual subject.', '112']"
112,page_113,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '13.0', 'Completion of the Study', 'The investigator will conduct the study in compliance with the protocol and complete the', 'study within the timeframe specified in the contract between the investigator (Director of', 'the Site in Japan) and AbbVie. Continuation of this study beyond this date must be', 'mutually agreed upon in writing by both the investigator (Director of the Site in Japan)', 'and AbbVie. The investigator will provide a final report to the IEC/IRB following', 'conclusion of the study, and will forward a copy of this report to AbbVie or their', 'representative.', 'The investigator (Director of the Site in Japan) must submit, maintain, and archive any', 'records related to the study according to ICH GCP and all other applicable regulatory', 'requirements. If the investigator (Director of the Site in Japan) is not able to retain the', 'records, he/she must notify Abb¹ Vie to arrange alternative archiving options.', 'AbbVie will select the signatory investigator from the investigators who participate in the', 'study. Selection criteria for this investigator will include level of participation as well as', 'significant knowledge of the clinical research, investigational drug and study protocol.', 'The signatory investigator for the study will review and sign the final study report in', 'accordance with the European Agency for the Evaluation of Medicinal Products (EMEA)', ""Guidance on Investigator's Signature for Study Reports."", ""The end-of-study is defined as the date of the last subject's last visit, or the date of the last"", ""subject's last survival follow-up contact, whichever is later."", '113']"
113,page_114,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '14.0', ""Investigator's Agreement"", '1.', ""I have received and reviewed the Investigator's Brochure for rovalpituzumab"", 'tesirine and the product labeling for dexamethasone.', '2.', 'I have read this protocol and agree that the study is ethical.', '3.', 'I agree to conduct the study as outlined and in accordance with all applicable', 'regulations and guidelines.', '4.', 'I agree to maintain the confidentiality of all information received or developed in', 'connection with this protocol.', '5.', 'I agree that all electronic signatures will be considered the equivalent of a', 'handwritten signature and will be legally binding.', 'Protocol Title:', 'A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of', 'Rovalpituzumab Tesirine as Maintenance Therapy Following', 'First-Line Platinum-Based Chemotherapy in Subjects with Extensive', 'Stage Small Cell Lung Cancer (MERU)', 'Protocol Date:', '05 March 2019', 'Signature of Principal Investigator', 'Date', 'Name of Principal Investigator (printed or typed)', '114']"
114,page_115,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '15.0', 'Reference List', '1.', 'Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell', 'lung cancer in the United States over the last 30 years: analysis of the surveillance,', 'epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-44.', '2.', 'Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal', 'for clinicians. 2012;62(1):10-29.', '3.', 'Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer.', 'Crit Rev Oncol Hematol. 2004;49(2): 119-33.', '4.', 'Ready N, Pang H, Gu L, A, et al. Chemotherapy with or without maintenance', 'sunitinib for untreated extensive-stage small-cell lung cancer: a randomized,', 'double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J Clin', 'Oncol. 2015;33(15):1660-5.', '5.', 'Schiller JH, Adak S, Cella D, et al. Topotecan versus observation after cisplatin', 'plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of', 'the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114-22.', '6.', 'Saunders L, Bankovich A, Anderson W, et al. A DLL3-targeted antibody-drug', 'conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells', 'in vivo. Science Transl Med. 2015;7(302):302ra136', '7. Chapman G, Sparrow D, Kremmer E, et al. Notch inhibition by the ligand delta-', 'like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal', 'dysostosis. Hum Mol Genet. 2011;20(5):905-16.', '8.', 'Dunwoodie S, Henrique D, Harrison S, et al. Mouse D113: a novel divergent Delta', 'gene which may complement the function of other Delta homologues during early', 'pattern formation in the mouse embryo. Development. 1997;124(16):3065-76.', '9.', 'Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-', 'targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-', 'human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18(1):42-51.', '115']"
115,page_116,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '10.', 'Drug Development and Drug Interactions: Table of Substrates, Inhibitors and', 'Inducers (FDA, 2016).', '11.', 'Common Terminology Criteria for Adverse Events, Version 4.0, DCTD, NCI,', 'NIH, DHHS. 28 May 2009 [cited 29 Sept 2016]. Available from:', 'ittps://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-', '14_QuickReference_5x7.pdf.', '12.', 'Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in', 'solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer.', '2009;45(2):228-47.', '13.', 'Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for', 'Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in', 'international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.', '14.', ""AbbVie Stemcentrx LLC. Investigator's Brochure for Rovalpituzumab Tesirine"", '(SC 16LD6.5) Edition 5.0. 13 September 2016.', '15.', 'Food and Drug Administration. Guidance for industry clinical trial endpoints for', 'the approval of cancer drugs and biologics. 2007.', '16.', 'AbbVie. Coding Guidelines for MedDRA Term Selection, AbbVie Global', 'Pharmaceutical Research and Development (GPRD), Global Pharmacovigilance', 'and Clinical Project Team. Current version on file at AbbVie.', '17.', 'International Conference on Harmonisation. Guidance for Industry, E6 Good', 'Clinical Practice: Consolidated Guidance. April 1996.', '18.', 'International Conference on Harmonisation. Guideline for Industry, Clinical safety', 'data management: definitions and standards for expedited reporting, E2A.', 'March 1995.', '19.', 'AbbVie. Rovalpituzumab Tesirine Dear Rova-T Investigator Letter. 05 December', '2018.', '116']"
116,page_117,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix A.', 'Responsibilities of the Clinical Investigator', 'Clinical research studies sponsored by AbbVie are subject to the Good Clinical Practices', '(GCP) and local regulations and guidelines governing the study at the site location. In', 'signing the Investigator Agreement in Section 14.0 of this protocol, the investigator is', 'agreeing to the following:', '1.', 'Conducting the study in accordance with the relevant, current protocol, making', 'changes in a protocol only after notifying AbbVie, except when necessary to', 'protect the safety, rights or welfare of subjects.', '2.', 'Personally conducting or supervising the described investigation(s).', '3.', 'Informing all subjects, or persons used as controls, that the drugs are being used for', 'investigational purposes and complying with the requirements relating to informed', 'consent and ethics committees (e.g., independent ethics committee [IEC] or', 'institutional review board [IRB]) review and approval of the protocol and', 'amendments.', '4.', 'Reporting adverse experiences that occur in the course of the investigation(s) to', 'AbbVie and the site director.', '5.', ""Reading the information in the Investigator's Brochure/safety material provided,"", 'including the instructions for use and the potential risks and side effects of the', 'investigational product(s).', '6.', 'Informing all associates, colleagues, and employees assisting in the conduct of the', 'study about their obligations in meeting the above commitments.', '7.', 'Maintaining adequate and accurate records of the conduct of the study, making', 'those records available for inspection by representatives of AbbVie and/or the', 'appropriate regulatory agency, and retaining all study-related documents until', 'notification from AbbVie.', '8.', 'Maintaining records demonstrating that an ethics committee reviewed and', 'approved the initial clinical investigation and all amendments.', '117']"
117,page_118,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '9.', 'Reporting promptly, all changes in the research activity and all unanticipated', 'problems involving risks to human subjects or others, to the appropriate individuals', '(e.g., coordinating investigator, institution director) and/or directly to the ethics', 'committees and AbbVie.', '10.', 'Following the protocol and not making any changes in the research without ethics', 'committee approval, except where necessary to eliminate apparent immediate', 'hazards to human subjects.', '118']"
118,page_119,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix B.', 'List of Protocol Signatories', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', '119']"
119,page_120,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C.', 'Study Activities', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatmentb', 'PTFU', '(OS)', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day 1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Location', 'Clinic Visit', 'X', 'X', 'X', 'X', 'X', 'X', 'Phone Contact', 'X', 'X', 'X', 'Safety', 'Informed Consent', 'X', 'Assessments', 'Inclusion/Exclusion', 'X', 'Criteria', 'Medical and', 'X', 'Surgical History', 'including', 'Malignancy', 'History8', 'Physical', 'X', 'X', 'X', 'X', 'X', 'examination', 'Vital Signs¹', 'X', 'X', 'X', 'X', 'X', 'Hematology and', 'X', 'Xk', 'X', 'X', 'X', 'Serum Chemistry', 'Coagulation Tests¹', 'X', 'Xk', 'X', 'X', '120']"
120,page_121,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(1wk)', 'Safety', 'Urinalysis', 'X', 'xk', 'X', 'X', 'X', 'Assessments', 'Pregnancy Test¹', 'X', 'X', 'X', 'X', 'X', '(cont.)', 'Electrocardiogram', 'X', 'X', '(ECG)1', 'Echocardiogram""', 'X', 'X', 'X', 'Performance Status', 'X', 'X', 'X', 'X', '(ECOG)', 'Fluid Retention', 'X', 'X', 'X', 'X', 'X', 'Questionnaire°', 'SAE/Adverse', 'SAE/', 'X', 'X', 'X', 'X', 'X', 'XP', 'XP', 'Events', 'Procedure', '-related', 'only', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'XP', 'XP', 'Medications', '121']"
121,page_122,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Treatment', 'rovalpituzumab', 'X', 'tesirine or placebo', 'dexamethasone or', 'X', 'X', 'placebo', 'Response', 'Disease/Response', 'X', 'X', 'X', 'XT', 'X', 'Assessment', 'Assessment', '(Radiographic', 'Imaging)', 'Central', 'X', 'X', 'X', 'XT', 'X', 'Radiographic', 'Assessment', 'Committee (CRAC)', 'Review', 'MRI/CT of the', 'Xt', 'Brain', 'Health Resource', 'X', 'X', 'X', 'X', 'X', 'Utilization', 'Patient Reported', 'X', 'X', 'X', 'X', 'X', 'Outcome (PRO""', 'Survival Status', 'X', '122']"
122,page_123,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29, 36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Pharmacoki', 'Pharmacokinetics', 'X', 'X', 'X', 'netic (PK),', '(PK), Anti-', 'Biomarkers,', 'therapeutic', 'and', 'Antibody (ATA),', 'Pharmacoge', 'and neutralizing', 'netic (PG)', 'antibodies (nAb)', 'Tumor Material at', 'X', 'Screening""', 'Tumor Material at', 'X', 'X', 'Time of Disease', 'Progression f', 'Blood (plasma) for', 'X', 'X', 'X', 'XX', 'Inflammatory', 'Markers & ctDNAX', 'Blood (serum) for', 'X', 'X', 'X', 'XX', 'Tumor & Soluble', 'Markers*', 'Circulating Tumor', 'X', 'X', 'Cellsy', 'Pharmacogenetics²', 'X', 'X', 'Serosal Fluida', 'Cycle 1 Day 1 through 70 days after last blinded study treatment', '123']"
123,page_124,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'a.', 'Every third cycle of treatment should be omitted and a clinic visit conducted. The visit should be performed after the Disease Response/Assessment has', 'been', 'conducted', 'and', 'reviewed by the Investigator. The subject should continue to complete the Fluid Retention Questionnaire, including conducting daily weight assessments, and the site should', 'contact the subject weekly during this 42 day non-treatment cycle to review the questionnaire. The following cycle of treatment may be resumed 42 days 3d if the subject', 'has not met any reason for study treatment discontinuation as outlined in Section 5.4.', 'b.', 'End of Treatment Visit procedures should be done within 7 days of documentation of the decision to discontinue treatment and prior to subjects beginning any new anti-', 'cancer therapy if possible.', 'c.', 'For subjects who discontinue blinded investigational product for reasons other than disease progression, the first follow-up visit will occur at 6 weeks ( 1 week) after the last', 'Disease Response Assessment, then every 6 weeks ( 1 week) until disease progression or initiation of new anti-cancer therapy, whichever occurs', 'first.', 'd.', 'Subjects will be followed for subsequent anti-cancer therapies (dates and responses), as well as survival status, every 6 weeks* (= 1 week) until the endpoint of death, the', 'subject becomes lost to follow-up or withdraws consent, or termination of the study by AbbVie whichever occurs first (*or as requested by AbbVie to support data analysis).', 'e.', 'Cycle 1 Day 1 procedures, with the exception of weight, do not need to be repeated if performed within 21 days of randomization unless clinically indicated. Randomization', 'may occur within 3 days prior to C1D1. Starting at C2D1, study assessments may be performed within 3 days prior to the visit. Disease/Response Assessment and CRAC', 'Review may be performed within 7 days prior to the Day 1 visit.', 'f. Signed informed consent will be obtained from the subject before any study-specific procedures are undertaken or before any prohibited medications are withheld from the', 'subject in order to participate in this study. Informed consent may be obtained before the 21-day screening window. Informed consent is also required for the optional tumor', 'biopsy at time of disease progression. The sample can be collected at the EOT or at the time of disease progression.', 'g.', 'Medical and Surgical History includes demographics and documentation of clinically significant medical condition, surgical history, and malignancy history.', 'h.', 'Height will be collected at the Screening visit only. For height assessments, the subject should not wear shoes.', 'i.', 'Vital signs include weight, sitting blood pressure, heart rate and body temperature. Weight will be collected in the clinic prior to dosing at each cycle and the recorded weight', 'will be utilized for dosing calculations. If possible, blood pressure and heart rate measurements should not immediately follow scheduled blood collections. Vital signs', 'should be collected prior to the infusion.', 'j.', 'All laboratory samples will be assessed using a certified central laboratory. A qualified (e.g., certification or accreditation) local laboratory may be used to perform laboratory', 'analyses for treatment decisions as per standard of care. Refer to Table 2, Clinical Laboratory Tests for details.', 'k.', 'The screening clinical laboratory tests do not need to be repeated on C1D1 if performed within 7 days of randomization and meet eligibility criteria, unless clinically', 'indicated. Starting at Cycle 2, lab assessment may be performed 3 days prior to Day 1 visits.', '124']"
124,page_125,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'l.', 'For female subjects of childbearing potential, a serum pregnancy test will be performed at Screening and the results must be available prior to the administration of the', 'first dose of blinded investigational product on C1D1. Urine pregnancy tests will be performed at Day 1 of each cycle, End of Treatment Visit, and PTFU until 6 months after', 'the last dose of blinded investigational product. Females of non-childbearing potential (either postmenopausal or permanently surgically', 'sterile', 'as', 'defined', 'in', 'Section', '5.2.4)', 'at', 'Screening', 'do', 'not require pregnancy testing. Post-menopausal female subjects VI 55 years of age must have an FSH level > 40 IU/L and will have FSH performed at Screening', 'and assessed by the Investigator.', 'm.', 'A resting 12-lead ECG will consist of a single 12-lead study performed within a 5-minute window after at least 5 minutes of quiet rest in a supine position. Additional ECG', 'monitoring may occur as clinically indicated during the study.', 'n.', 'Echocardiograms are required at Screening, Day 1 of each cycle starting C2D1, and EOT. Screening echocardiogram will be performed within 7 business days of', 'randomization to assess for the presence of any pericardial effusion as well as cardiac function (left ventricular ejection fraction, LVEF). Subsequent echocardiograms should', 'be performed within -3 business days of dosing visit to assess for the presence of any pericardial effusion. Additional echocardiogram monitoring may occur as clinically', 'indicated during the study.', 'o.', 'Subjects will be asked about the development of any new or worsening peripheral edema or dyspnea (Appendix I, Fluid Retention Questionnaire). The assessments on', 'Days 8, 15, 29, and 36 may take place by phone, with the site contacting the subject and reviewing the questionnaire. Starting on Day 1 and through the EOT visit, subjects', 'will maintain a diary of daily weights (captured on the Fluid Retention Questionnaire).', 'p.', 'Collection of SAE/AE and Concomitant Medications may be required at this visit in order to meet the collection window requirement of Day 1 of study treatment through', '70 days after last treatment. Any ongoing SAE/AE that require appropriate standard of care should also be conducted.', 'q.', 'Diagnostic quality, spiral CT scan with contrast is recommended for all anatomic areas except brain (MRI is recommended for brain imaging); other CT methods or MRI for', 'respective anatomic areas may be used if performed consistently throughout the study for each individual subject and only under circumstances described in Appendix G.', 'Scans of the chest and abdomen must be obtained; scans of the neck and pelvis must also be obtained if there is documented or suspected involvement in these regions.', 'Screening scans may be performed within 28 days prior to randomization. Disease response will be determined by the Investigator at each assessment according to', 'RECIST v1.1. Effusion (pleural, pericardial, and etc.) assessments will be performed by a radiologist at each radiographic assessment and any new findings communicated to', 'the Investigator prior to the next dose of blinded investigational product. Effusions should contribute to disease status assessment per RECIST v1.1 only if confirmed', 'malignant by cytology or otherwise clearly disease-related. Whenever possible, scheduled tumor assessments should not be affected by delays in therapy and/or drug', 'holidays. In some cases, mandatory dose delays due to toxicity will lead to a gap between tumor assessment and dosing. In cases where this gap exceeds 1 week, the TAMD', 'should be contacted for guidance. Subjects will continue to be monitored by the same diagnostic method throughout the study every 6 weeks after randomization.', 'r.', 'May be omitted if previous assessment was performed within the preceding 6 weeks.', ""S. Site will collect the appropriate scans and ship by courier or submit electronically to the central facility at each subject's disease assessment."", 't.', 'MRI/CT of the brain is required at screening and when clinically indicated (e.g., if CNS progression is suspected) thereafter.', 'u.', 'PRO assessments are required at Screening, only C2D1, the first Non-Treatment Cycle, EOT, and PTFU (if applicable).', '125']"
125,page_126,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'V.', 'Approximately 6 mL of blood will be collected by venipuncture for pharmacokinetic (PK), Anti-therapeutic antibody (ATA), and neutralizing antibodies (nAb) testing. The', 'pre-infusion sample will be collected prior to dosing on Day 1 (-3 days window is permitted) and the second sample will be collected within 60 minutes post-infusion. Only', 'one collection will be required at the Non-Treatment Cycle visit and EOT visit. The date and time of each sample collected will be recorded to the nearest minute.', 'W.', 'Archived or fresh tumor material must be submitted to the AbbVie designated central IHC laboratory for determination of DLL3 expression prior to randomization.', 'X.', 'On Day 1 (-3 days window is permitted) of each cycle, the collection will be pre-infusion. A sample will also be collected at the EOT or at the time of disease progression.', 'y. Whole blood sample will be collected for CTC analysis at pre-dose on Cycle 1 Day 1 (-3 days window is permitted) and EOT only at specific sites based on feasibility.', 'z. Pharmacogenetic collection should occur unless precluded by local or national regulations or policies. Pharmacogentic sample collected pre-infusion on Day 1 of Cycle 1.', 'aa.', 'Any pericardial, pleural, and/or ascitic fluid collected as part of routine care (e.g., as part of a therapeutic thoracentesis, pericardiocentesis, or paracentesis) will be procured', 'for', 'testing', 'for any AE starting from C1D1 through 70 days after the last blinded study treatment. Collected fluid must also be tested locally for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', '126']"
126,page_127,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix D.', 'Performance Status Scales Conversion', 'ECOG', 'Karnofsky', 'Score', 'Description', 'Percent', 'Description', '0', 'Normal activity. Fully active, able to', '100', 'Normal, no complaints, no evidence', 'carry on all pre-disease performance', 'of disease.', 'without restriction.', '90', 'Able to carry on normal activity;', 'minor signs or symptoms of disease.', '1', 'Symptoms, but ambulatory. Restricted', '80', 'Normal activity with effort; some', 'in physically strenuous activity, but', 'signs or symptoms of disease.', 'ambulatory and able to carry out work of', '70', 'Cares for self, unable to carry on', 'a light or sedentary nature (e.g., light', 'normal activity or to do active work.', 'housework, office work).', '2', 'In bed < 50% of the time. Ambulatory', '60', 'Requires occasional assistance, but is', 'and capable of all self-care, but unable to', 'able to care for most of his/her needs.', 'carry out any work activities. Up and', '50', 'Requires considerable assistance and', 'about more than 50% of waking hours.', 'frequent medical care.', '3', 'In bed > 50% of the time. Capable of', '40', 'Disabled, requires special care and', 'only limited self-care, confined to bed or', 'assistance.', 'chair more than 50% of waking hours.', '30', 'Severely disabled, hospitalization', 'indicated. Death not imminent.', '4', '100% bedridden. Completely disabled.', '20', 'Very sick, hospitalization indicated.', 'Cannot carry on any self-care. Totally', 'Death not imminent.', 'confined to bed or chair.', '10', 'Moribund, fatal processes', 'progressing rapidly.', '5', 'Dead.', '0', 'Dead.', '127']"
127,page_128,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix E.', 'Calculated Creatinine Clearance Using Modified Cockcroft-Gault', 'Equation', 'MODIFIED COCKCROFT AND GAULT FORMULA', 'For the calculation of estimated creatinine clearance rate (eCCR) using Ideal Body', 'Mass [IBM] instead of Mass.', '(140 - Age) IBM (kg) [0.85 if Female]', 'eCCr', '=', '72', 'Serum Creatinine (mg/dL)', 'Or, if serum creatinine is in mol/L:', '(140 - Age)', 'IBM (kg)', '[1.23 if Male, 1.04 if Female]', 'eCCr', '=', 'Serum Creatinine (umol/L)', 'Ideal Body Mass should be used:', 'IBM (kg) = [(height cm - 154) . 0.9] + (50 if Male, 45.5 if Female)', '128']"
128,page_129,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix F.', 'New York Heart Association Classification', 'Class I', 'Patients with no limitation of activities; they suffer no symptoms from ordinary activities.', 'Class II', 'Patients with slight, mild limitation of activity; they are comfortable with rest or with', 'mild exertion.', 'Class III', 'Patients with marked limitation of activity; they are comfortable only at rest.', 'Class IV', 'Patients who should be at complete rest, confined to bed or chair; any physical activity', 'brings on discomfort and symptoms occur at rest.', '129']"
129,page_130,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix G.', 'Response Evaluation Criteria for Solid Tumors (RECIST) V 1.1 for', 'Tumor Response', 'Response criteria will be assessed using RECIST (version 1.1). 12', 'Changes in the', 'measurable lesions over the course of therapy must be evaluated using the criteria listed', 'below.', 'Measurability', 'Measurable Lesions Lesions accurately measured in at least one dimension with a', 'minimum size of:', 'Longest diameter > 10 mm (CT scan slice thickness no', 'greater than 5 mm)', '10 mm caliper measurement by clinical exam', 'Non-Measurable', 'All other lesions, including small lesions (longest diameter', 'Lesions', '< 10 mm) as well as truly non-measurable lesions. Lesions', 'considered truly non-measurable include: leptomeningeal', 'disease, ascites, pleural/pericardial effusion, inflammatory', 'breast disease, lymphangitic involvement of skin or lung and', 'also abdominal masses that are not confirmed and followed by', 'imaging techniques.', 'Measurable', 'To be considered pathologically enlarged and measurable, a', 'Malignant Lymph', 'lymph node must be > 15 mm in short axis when assessed by', 'Nodes', 'CT scan (CT scan slice thickness recommended to be no', 'greater than 5 mm). At baseline and in follow-up, only the', 'short axis will be measured and followed.', 'Non-Measurable', 'Pathological lymph nodes with > 10 to < 15 mm short axis.', 'Malignant Lymph', 'Nodes', 'Special', 'Bone lesions', 'Considerations', 'Lytic bone lesions or mixed lytic-blastic lesions, with', 'Regarding Lesion', 'identifiable soft tissue components, that can be evaluated by', 'Measurability', 'cross sectional imaging techniques such as MRI/CT can be', 'considered as measurable lesions if the soft tissue component', 'meets the definition of measurability described above.', '130']"
130,page_131,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Blastic bone lesions are non-measurable.', 'Cystic lesions', 'Lesions that meet the criteria for radiographically defined', 'simple cysts should not be considered as malignant lesions', '(neither measurable nor non measurable) since they are, by', 'definition, simple cysts.', ""'Cystic lesions' thought to represent cystic metastases can be"", 'considered as measurable lesions, if they meet the definition of', 'measurability described above.', 'However, if non-cystic lesions are present in the same patient,', 'these are preferred for selection as target lesions.', 'Lesions with prior local treatment', 'Tumor lesions situated in a previously irradiated area, or in an', 'area subjected to other loco-regional therapy, are usually not', 'considered measurable unless there has been demonstrated', 'progression in the lesion.', 'All measurements should be taken and recorded in metric notation, using calipers if', 'clinically assessed. All baseline evaluations should be performed as closely as possible to', 'the beginning of treatment and not more than 28 days before the beginning of the', 'treatment.', 'The same method of assessment and the same technique should be used to characterize', 'each identified and reported lesion at baseline and during follow-up.', 'Clinical lesions will only be considered measurable when they are superficial (e.g., skin', 'nodules and palpable lymph nodes) and > 10 mm diameter as assessed using calipers. For', 'the case of skin lesions, documentation by color photography including a ruler to estimate', 'the size of the lesion is recommended.', '131']"
131,page_132,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Methods of Measurement', 'Spiral CT should be performed with cuts of 5 mm or less in slice thickness contiguously.', 'This applies to tumors of the chest and abdomen. A scale should be incorporated into all', 'radiographic measurements. MRI can be performed if required by local law or if CT is', ""contraindicated, and should be documented in the subject's source."", 'If prior to enrollment, it is known a subject is not able to undergo CT scans with IV', 'contrast due to allergy or renal insufficiency, the decision as to whether a non-contrast CT', 'or MRI should be used to evaluate the subject at baseline and follow-up should be guided', 'by the tumor type under investigation and the anatomic location of the disease. For', 'subjects who develop contraindications to contrast after baseline contrast CT is done, the', 'decision as to whether non-contrast CT or MRI should be made based upon discussion', 'with the AbbVie TA MD.', 'For accurate objective response evaluation, ultrasound (US) should not be used to', 'measure tumor lesions.', 'The utilization of endoscopy and laparoscopy for objective tumor evaluation is not', 'advised. However, such techniques can be useful in confirming complete pathological', 'response when biopsies are obtained.', 'Cytology and histology can be used to differentiate between partial response (PR) and', 'complete response (CR) in rare cases.', 'Baseline Documentation of ""Target"" and ""Non-Target"" Lesions', 'All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total,', 'representative of all involved organs should be identified as target lesions and recorded', 'and measured at baseline. Target lesions should be selected on the basis of their size', '(lesions with the longest diameter), be representative of all involved organs, but in', 'addition should be those that lend themselves to reproducible repeated measurements.', 'Tumor lesions situated in a previously irradiated area, or in an area subjected to other', '132']"
132,page_133,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'loco-regional therapy, are usually not considered measurable unless there has been', 'demonstrated progression in the lesion.', 'Lymph nodes merit special mention since they are normal anatomical structures which', 'may be visible by imaging even if not involved by tumor. Pathological nodes which are', 'defined as measurable and may be identified as target lesions must meet the criterion of a', 'short axis of > 15 mm by CT scan. Only the short axis of these nodes will contribute to', 'the baseline sum. The short axis of the node is the diameter normally used by radiologists', 'to judge if a node is involved by solid tumor. Nodal size is normally reported as two', 'dimensions in the plane in which the image is obtained (for CT scan this is almost always', 'the axial plane). The smaller of these measures is the short axis. For example, an', 'abdominal node which is reported as being 20 mm X 30 mm has a short axis of 20 mm', 'and qualifies as a malignant, measurable node. In this example, 20 mm should be', 'recorded as the node measurement. All other pathological nodes (those with short axis', '> 10 mm but < 15 mm) should be considered non-target lesions. Nodes that have a short', 'axis < 10 mm are considered non-pathological and should not be recorded or followed.', 'A sum of the longest diameter (LD) for all target lesions will be calculated and reported as', 'the baseline sum LD. If lymph nodes are to be included in the sum, then as noted above,', 'only the short axis is added into the sum. The baseline sum LD will be used as reference', 'by which to characterize the objective tumor response.', 'All other lesions (or sites of disease) including pathological lymph nodes should be', 'identified as non-target lesions and should also be recorded at baseline. Measurements of', 'these lesions are not required, but the presence (stable, increasing or decreasing) or', 'absence of each should be noted throughout follow-up.', 'Evaluation of Target Lesions', 'Complete Response (CR):', 'The disappearance of all target lesions. Any pathological lymph nodes (whether target or', 'non-target) must have reduction in short axis to < 10 mm.', '133']"
133,page_134,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Partial Response (PR):', 'At least a 30% decrease in the sum of diameters of target lesions, taking as reference the', 'baseline sum diameters.', 'Progressive Disease (PD):', 'At least a 20% increase in the sum of the LD of target lesions, taking as reference the', 'smallest sum LD recorded since the treatment started (baseline or after) or the appearance', 'of one or more new lesions. In addition to the relative increase of 20%, the sum must also', 'demonstrate an absolute increase of at least 5 mm.', 'Stable Disease (SD):', 'Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,', 'taking as reference the smallest sum LD since the treatment started (baseline or after).', 'Assessment of Target Lesions:', 'Lymph nodes identified as target lesions should always have the actual short axis', 'measurement recorded (measured in the same anatomical plane as the baseline', 'examination), even if the nodes regress to below 10 mm on study. This means that when', ""lymph nodes are included as target lesions, the 'sum' of lesions may not be zero even if"", 'complete response criteria are met, since a normal lymph node is defined as having a short', 'axis of < 10 mm. For PR, SD and PD, the actual short axis measurement of the nodes is', 'to be included in the sum of target lesions.', 'All lesions (nodal and non-nodal) recorded at baseline should have their actual', 'measurements recorded at each subsequent evaluation, even when very small (<< mm).', 'However, sometimes target lesions or lymph nodes become too small to measure. If it is', 'in the opinion of the radiologist that the lesion has likely disappeared, the measurement', 'should be recorded as 0 mm. If the lesion is believed to be present, but too small to', 'measure, a default value of 5 mm should be assigned (as derived from the 5 mm CT slice', '134']"
134,page_135,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'thickness). The measurement of these lesions is potentially non-reproducible; therefore', 'providing this default value will prevent false responses or progression based upon', 'measurement error.', 'Evaluation of Non-Target Lesions', 'Complete Response (CR):', 'The disappearance of all non-target lesions and normalization of tumor marker level. All', 'lymph nodes must be non-pathological in size (<10 mm short axis).', 'Non-CR/Non-PD:', 'Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level', 'above the normal limits.', 'Progressive Disease (PD):', 'Unequivocal progression of existing non-target lesions.', ""In this setting, to achieve 'unequivocal progression' on the basis of non-target disease,"", 'there must be an overall level of substantial worsening in non-target disease such that,', 'even in the presence of SD or PR in target disease, the overall tumor burden has increased', ""sufficiently to merit discontinuation of therapy. A modest 'increase' in the size of one or"", 'more non-target lesions is usually not sufficient to qualify for unequivocal progression', 'status. The designation of overall progression solely on the basis of change in non-target', 'disease in the face of SD or PR of target disease will therefore be extremely rare.', 'New Lesions', 'The appearance of new malignant lesions denotes disease. While there are no specific', 'criteria for the identification of new radiographic lesions, the findings of a new lesion', 'should be unequivocal; i.e., not attributable to differences in scanning technique, timing of', 'scanning, phase of contrast administration, change in imaging modality or finding thought', '135']"
135,page_136,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', ""to represent something other than tumor (e.g., some 'new' bone lesions may be simply"", 'healing or flare of pre-existing lesions). A lesion identified on a follow-up study in an', 'anatomical location that was not scanned at baseline is considered a new lesion and will', 'indicate disease progression.', 'If a new lesion is equivocal (e.g., too small to measure), continued therapy and follow-up', 'evaluation will clarify if it represents truly new disease. If repeat scans confirm there is a', 'new lesion, then progression should be declared using the date of the initial scan.', '136']"
136,page_137,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix H.', 'CTCAE V 4.0 Grading of Relevant AEs', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Serosal', 'Ascites', 'Asymptomatic; clinical', 'Symptomatic; medical', 'Severe symptoms;', 'Life-threatening', 'Effusions', 'or diagnostic', 'intervention indicated', 'invasive intervention', 'consequences; urgent', 'observations only;', 'indicated', 'operative intervention', 'intervention not indicated', 'indicated', 'Definition: A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.', 'Pericardial effusion', '-', 'Asymptomatic effusion size', 'Effusion with', 'Life-threatening', 'small to moderate', 'physiologic', 'consequences; urgent', 'consequences', 'intervention indicated', 'Definition: A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.', 'Pericardial tamponade', '-', 'Life-threatening', 'consequences; urgent', 'intervention indicated', 'Definition: A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.', 'Pleural effusion', 'Asymptomatic; clinical', 'Symptomatic; intervention', 'Symptomatic with', 'Life-threatening', 'or diagnostic', 'indicated (e.g., diuretics or', 'respiratory distress and', 'respiratory or', 'observations only;', 'limited therapeutic', 'hypoxia; surgical', 'hemodynamic', 'intervention not indicated', 'thoracentesis)', 'intervention including', 'compromise; intubation or', 'chest tube or pleurodesis', 'urgent intervention', 'indicated', 'indicated', 'Definition: A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough', 'and marked chest discomfort.', 'Capillary leak syndrome', '-', 'Symptomatic; medical', 'Severe symptoms;', 'Life-threatening', 'intervention indicated', 'intervention indicated', 'consequences; urgent', 'intervention indicated', '137']"
137,page_138,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Serosal', 'Definition: A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who', 'Effusions', 'demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias,', '(cont.)', 'medications, or poisoning. It can lead to generalized edema and multiple organ failure.', 'Edema', 'Edema face', 'Localized facial edema', 'Moderate localized facial', 'Severe swelling; limiting', '-', 'edema; limiting instrumental', 'self-care ADL', 'ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in facial tissues.', 'Edema limbs', '5 - 10% inter-limb', '> 10 - 30% inter-limb', '> 30% inter-limb', '-', 'discrepancy in volume or', 'discrepancy in volume or', 'discrepancy in volume;', 'circumference at point of', 'circumference at point of', 'gross deviation from', 'greatest visible', 'greatest visible difference;', 'normal anatomic', 'difference; swelling or', 'readily apparent obscuration', 'contour; limiting self-', 'obscuration of anatomic', 'of anatomic architecture;', 'care ADL', 'architecture on close', 'obliteration of skin folds;', 'inspection', 'readily apparent deviation', 'from normal anatomic', 'contour; limiting', 'instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.', 'Edema trunk', 'Swelling or obscuration', 'Readily apparent', 'Gross deviation from', 'of anatomic architecture', 'obscuration of anatomic', 'normal anatomic', 'on close inspection', 'architecture; obliteration of', 'contour; limiting self-', 'skin folds; readily apparent', 'care ADL', 'deviation from normal', 'anatomic contour; limiting', 'instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.', '138']"
138,page_139,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Edema', 'Localized edema', 'Localized to dependent', 'Moderate localized edema', 'Severe localized edema', '-', '(cont.)', 'areas, no disability or', 'and intervention indicated;', 'and intervention', 'functional impairment', 'limiting instrumental ADL', 'indicated; limiting self-', 'care ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.', 'Periorbital edema', 'Soft or non-pitting', 'Indurated or pitting edema;', 'Edema associated with', 'topical intervention', 'visual disturbance;', 'indicated', 'increased intraocular', 'pressure, glaucoma or', 'retinal hemorrhage; optic', 'neuritis; diuretics', 'indicated; operative', 'intervention indicated', 'Definition: A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.', 'Labs', 'Hypo-albuminemia', '< LLN - 3 g/dL;', '<3-2g/dL; <30-20 g/L', '<2 g/dL; < 20 g/L', 'Life-threatening', '< LLN - 30 g/L', 'consequences; urgent', 'intervention indicated', 'Definition: A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.', 'Neutrophil count decreased < LLN - 1500/mm³;', '< 1500 - 1000/mm³;', '< 1000 - 500/mm³:', '< 500/mm³; <0.5 x 109/L', '< LLN - 1.5 X 109/L', '< 1.5 - 1.0 X 109/L', '< 1.0 - 0.5 X 109/L', 'Definition: A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.', 'Platelet count decreased', '< LLN - 75,000/mm³;', '< 75,000 - 50,000/mm³;', '< 50,000 - 25,000/mm³;', '< 25,000/mm³;', '< LLN - 75.0 X 109/L', '< 75.0-50.0 x 109/L -', '< 50.0 - 25.0 x 10%/L -', '< 25.0 X 109/L', 'Definition: A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.', '139']"
139,page_140,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Skin', 'Erythema multiforme', 'Target lesions covering', 'Target lesions covering 10 -', 'Target lesions covering', 'Target lesions covering', '< 10% BSA and not', '30% BSA and associated', '> 30% BSA and', '> 30% BSA; associated', 'associated with skin', 'with skin tenderness', 'associated with oral or', 'with fluid or electrolyte', 'tenderness', 'genital erosions', 'abnormalities; ICU care', 'or burn unit indicated', 'Definition: A disorder characterized by target lesions (a pink-red ring around a pale center).', 'Palmar-plantar', 'Minimal skin changes or', 'Skin changes (e.g., peeling,', 'Severe skin changes', '-', 'erythrodysesthesia', 'dermatitis', 'blisters, bleeding, edema, or', '(e.g., peeling, blisters,', 'syndrome', '(e.g., erythema, edema, or', 'hyperkeratosis) with pain;', 'bleeding, edema, or', 'hyperkeratosis) without', 'limiting instrumental ADL', 'hyperkeratosis) with', 'pain', 'pain; limiting self-care', 'ADL', 'Definition: A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet.', 'Photosensitivity', 'Painless erythema and', 'Tender erythema covering', 'Erythema covering', 'Life-threatening', 'erythema covering < 10%', '10 - 30% BSA', '> 30% BSA and', 'consequences; urgent', 'BSA', 'erythema with blistering;', 'intervention indicated', 'photosensitivity; oral', 'corticosteroid therapy', 'indicated; pain control', 'indicated (e.g., narcotics', 'or NSAIDs)', 'Definition: A disorder characterized by an increase in sensitivity of the skin to light.', '140']"
140,page_141,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Group', 'Adverse Event', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Skin', 'Rash maculo-papular', 'Macules/papules', 'Macules/papules covering', 'Macules/papules', '-', '(cont.)', 'covering < 10% BSA', '10 - 30% BSA with or', 'covering > 30% BSA', 'with or without', 'without symptoms', 'with or without', 'symptoms (e.g., pruritus,', '(e.g., pruritus, burning,', 'associated symptoms;', 'burning, tightness)', 'tightness); limiting', 'limiting self-care ADL', 'instrumental ADL', 'Definition: A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the', 'most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritus.', 'Cross reference: NCI CTCAE version 4.011', '141']"
141,page_142,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix I.', 'Fluid Retention Questionnaire', 'Fluid Retention Questionnaire for Study M16-298', 'Subject ID:', 'Over the past 7 days, or since the last time this questionnaire was completed:', '1.', 'What has your daily weight been?', 'Please weigh yourself at the same time each day and record the date and your', 'weight for that day below. Weight should be taken without outer garments', 'such as hats, coats or shoes. Measurements while in light indoor clothing only,', 'or undergarments only, are acceptable; however, please try to use the same or', 'similar clothing (including any accessories or jewelry) from day to day when', 'measuring weight.', 'Please complete one questionnaire for every 7 day/1 week period.', 'Date (DD/MMM/YYYY)', 'Weight (Circle One: lb or kg)', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', 'lb or kg', '2.', 'Have you noticed any new or worsening edema - e.g., swelling of the ankles or', 'legs during the days above?', 'Yes or', 'No', '3.', 'Have you noticed any new or worsening shortness of breath during the days above?', 'Yes or', 'No', '142']"
142,page_143,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '4.', 'Please sign below to confirm that you have completed this questionnaire.', 'Date:', '143']"
143,page_144,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix J.', 'Adverse Events Expected Due to SCLC or Progression of SCLC', 'Preferred Term (MedDRA Version 19.1)', 'Pleural effusion', 'Malignant pleural effusion', 'Metastases to pleura', 'Dyspnoea', 'Cough', 'Non-cardiac chest pain', 'Haemoptysis*', 'Oesophageal obstruction', 'Pneumonia*', 'Vocal cord paralysis', 'Dysphonia', 'Dysphagia', 'Superior vena cava syndrome', ""Horner's syndrome"", 'Myasthenic syndrome', 'Metastases to bone', 'Metastases to lymph nodes', 'Metastases to liver', 'Metastases to spine', 'Metastases to the mediastinum', 'Metastases to pleura', 'Metastases to adrenals', 'Metastases to meninges', 'Metastases to central nervous system', 'Cancer pain', 'Inappropriate Anti-Diuretic Hormone (SIADH) secretion', 'Tumour pain', 'Fatigue', 'Asthenia', 'Pulmonary embolism*', 'Shock*', 'Septic shock*', '144']"
144,page_145,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Preferred Term (MedDRA Version 19.1)', 'Deep vein thrombosis*', 'Lower respiratory tract infection*', 'Respiratory tract infection*', 'Upper respiratory tract infection*', 'Opportunistic infection*', 'Viral infection*', 'Fungal infection*', 'Bacterial infection*', 'Pulmonary haemorrhage*', 'Lung abscess*', 'Empyema*', 'Sepsis*', 'Lymphadenopathy', 'Decreased appetite', 'Malaise', 'Weight decreased', 'Headache', 'Pain excluding chest pain', 'Pyrexia', '*', 'Includes life threatening or fatal events.', '145']"
145,page_146,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix K.', 'Protocol Amendment: List of Changes', 'The summary of changes is listed in Section 1.1.', 'Specific Protocol Changes:', 'Section 1.0 Title Page', '""Sponsor/Emergency Contact:"" previously read:', 'Phone:', 'Therapeutic Area Medical Director', 'Fax:', 'Abb Vie', '200 Sidney Street', 'Cambridge, MA 02139', 'Has been changed to read:', 'Phone:', 'Senior Medical Director', 'Cell Phone', 'AbbVie', 'Fax:', '1 North Waukegan Road', 'Email:', 'North Chicago, IL 60064', 'USA', 'Section 1.2 Synopsis', 'Previously read:', 'AbbVie Inc.', 'Protocol Number: M16-298', 'Name of Study Drug: rovalpituzumab tesirine', 'Phase of Development: 3', '(Rova-T)', 'Name of Active Ingredient: rovalpituzumab', 'Date of Protocol Synopsis: 09 May 2017', 'tesirine', 'Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab', 'Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with', 'Extensive Stage Small Cell Lung Cancer (MERU)', '146']"
146,page_147,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Objectives:', 'Primary', 'To evaluate if rovalpituzumab tesirine improves progression-free and overall survival in subjects', 'with extensive-stage small cell lung cancer (ED SCLC) who have ongoing clinical benefit (SD,', 'PR, or CR) following first-line platinum-based chemotherapy (cisplatin or carboplatin plus', 'irinotecan or etoposide) compared to placebo.', 'Secondary', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining objective response rate', '(ORR), clinical benefit rate (CBR), and duration of responses (DOR)', 'To assess change in patient reported outcomes (PRO) with EORTC QLQ-C30/LC13', 'questionnaires.', 'Exploratory', 'To characterize the pharmacokinetics and incidence of anti-therapeutic antibodies (ATAs)', 'against rovalpituzumab tesirine', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor for association', 'with sensitivity, efficacy and safety', 'To explore DLL3 expression in circulating tumor cells (CTCs) for association with efficacy', 'To assess EQ-5D-5L during treatment with rovalpituzumab tesirine.', 'Investigators: Multicenter, International', 'Study Sites: Approximately 275', 'Study Population: Subjects with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of first-line', 'platinum-based chemotherapy (cisplatin or carboplatin in combination with etoposide or irinotecan).', 'Number of Subjects to be Enrolled: Up to approximately 740 SCLC subjects, to obtain approximately', '480 subjects with DLL3 high expression in tumor (DLL3high DLL3high is defined as > 75% tumor cells', 'staining positive according to the VENTANA DLL3 (SP347) IHC Assay.', '147']"
147,page_148,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Methodology:', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study.', 'ED SCLC subjects who meet all the inclusion criteria and none of the exclusion criteria, and demonstrate', 'ongoing clinical benefit (SD, PR, or CR) at the completion of 4 cycles of first-line platinum-based', 'chemotherapy (such benefit must be ongoing at the last re-staging assessment prior to randomization),', 'will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg rovalpituzumab tesirine or placebo, and will', 'receive their assigned therapy on Day 1 of each 6-week cycle, omitting every third cycle. Upon', 'completion of first-line chemotherapy, eligible subjects must be offered prophylactic cranial irradiation', '(PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. Subjects will also receive 8 mg', 'orally (PO) of dexamethasone or placebo twice daily on Day -1, Day 1, and Day 2 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response after completion', 'of first-line platinum-based chemotherapy at screening assessment (SD VS. PR/CR), DLL3 expression,', '(Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or above), history of central nervous system', '(CNS) metastases (Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to follow-up or', 'withdraws consent, or termination of the study by AbbVie, whichever occurs first.', 'Diagnosis and Main Criteria for Inclusion/Exclusion:', 'Main Inclusion:', '1. Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics', 'Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-', 'specific procedures and should be willing and able to comply with parameters as outlined in the', 'protocol.', '2. Subject must be > 18 years of age.', '3. Histologically or cytologically confirmed extensive-stage SCLC with ongoing clinical benefit (SD,', 'PR, or CR per RECIST v1.1) following completion of 4 cycles of first-line platinum-based therapy', '(cisplatin or carboplatin in combination with etoposide or irinotecan).', '4.', 'Subjects with a history of CNS metastases prior to the initiation of first-line platinum-based', 'chemotherapy must have received definitive local treatment and have documentation of stable or', 'improved CNS disease status based on brain imaging within 28 days prior to randomization, off or on', 'a stable dose of corticosteroids.', '5. At least 3 but no more than 9 weeks between the administration of the last cycle of platinum-based', 'chemotherapy and randomization.', '6.', 'Availability of archived or representative tumor material for assessment of DLL3 expression.', '7. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.', '8. Recovery to V Grade 1 of any clinically significant toxicity (excluding alopecia) prior to', 'randomization.', '148']"
148,page_149,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Inclusion (Continued):', '9. Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b.', 'Platelet count > 75,000/L', 'c.', 'Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin < 1.5 X upper limit of normal (ULN) or < 3 X ULN for subjects with', ""Gilbert's disease"", 'e.', 'Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 X ULN', '(< 5x ULN if evidence of hepatic involvement by malignant disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the Cockroft-Gault formula', 'g. Albumin > 3g/dL', '10. If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative medical cause.', 'Age VI 55 years with no menses for 12 or more months without an alternative medical cause', 'AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).', 'OR a Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method', 'of birth control, starting at randomization through at least 6 months after the last dose of blinded', 'investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at least 6 months', 'after the last dose of blinded investigational product, to practice the protocol specified contraception.', '11. Females of childbearing potential must have a negative serum pregnancy test result at Screening, and', 'a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as', 'defined in the protocol) at Screening do not require pregnancy testing.', 'Main Exclusion:', '1. Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other', 'monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, T-cell or other cell-based', 'or biologic therapies, or any other anti-cancer therapy than that described in Inclusion Criteria 3 - 5', 'for the disease under study.', '2. Any disease-directed radiotherapy (except PCI or pre-planned radiotherapy for CNS metastases', 'present prior to start of first-line therapy and non-progressing) after last dose of first-line', 'chemotherapy.', '3. Any significant medical condition including any suggested by screening laboratory findings that in', 'the opinion of the Investigator or Sponsor may place the subject at undue risk from the study.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac', 'symptoms consistent with New York Heart Association (NYHA) Class III - IV heart failure within', '6 months prior to randomization.', '149']"
149,page_150,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Exclusion (Continued):', '5. Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization or earlier history of', 'recurrent Grade 2 or higher effusions with ongoing requirement for pericardiocentesis or', 'thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or higher (per NCI', 'CTCAE version 4.0) viral, bacterial, or fungal infection.', '8. Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study', 'or for approximately 6 months after the last dose of blinded investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the study or for', 'approximately 6 months after the last dose of blinded investigational product.', '10. Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent within 1 week prior to', 'randomization.', '11. Subject has a history of active malignancies other than SCLC within the past 2 years prior to study', 'entry, with the exception of in situ cancer which was curatively treated.', '12. Any prior exposure to a pyrrolobenzodiazepine (PBD)- or indolinobenzodiazepine-based drug, prior', 'participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other', 'contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.', '13. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.', 'Investigational Products:', 'Rovalpituzumab tesirine or Placebo', 'Dexamethasone or Placebo', 'Doses:', 'Rovalpituzumab tesirine/Placebo: 0.3 mg/kg, Day 1 of each 6-week', 'cycle, omitting every third cycle.', 'Dexamethasone/Placebo 8 mg orally (PO) twice daily on Day -1, - Day 1', '(the day of dosing), and Day 2 of each 6 week cycle, omitting every', 'third cycle.', 'Mode of Administration:', 'Rovalpituzumab tesirine/Placebo: Intravenous', 'Dexamethasone/Placebo: Oral', 'Duration of Treatment: Subjects will receive rovalpituzumab tesirine/placebo in combination with', 'dexamethasone/placebo on Day 1 of a 6-week cycle, omitting every third cycle until disease progression.', 'Criteria for Evaluation:', 'Efficacy: Efficacy assessments will consist of evaluations for tumor progression using Response', 'Evaluation Criteria in Solid Tumors (RECIST) v1.1 and will be based on a Central Radiographic', 'Assessment Committee (CRAC) review of medical images, as outlined in the Schedule of Assessments.', 'Additionally, efficacy will be assessed by overall survival.', 'Pharmacokinetic: Plasma concentrations of rovalpituzumab tesirine ADC and the presence of anti-', 'therapeutic antibodies (ATA) will be determined.', '150']"
150,page_151,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Criteria for Evaluation (Continued):', 'Biomarkers: Pharmacodynamic and predictive biomarker assessments will include analyses of tumor', 'material and circulating tumor cells for DLL3 expression, blood samples for inflammatory, tumor, and', 'soluble markers. Samples may also be used for other nucleic acid or protein based exploratory', 'biomarkers to understand the sensitivity or resistance to rovalpituzumab tesirine and biology of SCLC.', 'Safety: Safety assessments include physical exam, vital signs, body weight, ECOG score, clinical', 'adverse events, laboratory tests (hematology, serum chemistries, urinalysis, and coagulation), ECGs,', 'echocardiogram, fluid retention questionnaire, radiographic images review for fluid retention, and', 'monitoring of concomitant medications.', 'Patient Reported Outcome (PRO):', 'Changes in the patient reported outcomes (PROs) EORTC QLQ-C30, EORTC QLQ-LC13, and', 'EQ-5D-5L from baseline will be assessed.', 'Statistical Methods:', 'Efficacy:', 'Progression-free survival (PFS) and overall survival (OS) are the two primary efficacy endpoints. No', 'order of testing of these two endpoints is specified. To meet global regulatory requirements, a multiple', 'testing strategy will be implemented to control the family-wise type I error (alpha) for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival (PFS) per', 'CRAC, and overall survival (OS), ORR per CRAC, and physical functioning scale score (EORTC', 'QLQ-C30).', 'The following null hypotheses are considered for subjects with DLL3 high.', 'H1: Rovalpituzumab tesirine arm is not superior to placebo arm in both PFS and OS.', 'H2: Rovalpituzumab tesirine arm is not superior to placebo arm in ORR per CRAC.', 'H3: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning scale score', '(EORTC QLQ-C30).', 'The null hypotheses will be tested in a fixed sequence of {H1, H2, H3) in order. To maintain the family-', 'wise type I error for the study, the null hypothesis H1 will be first tested with an alpha-split approach.', 'The hypothesis for PFS will be tested at a one-sided 0.25% level of significance and the hypothesis for', 'OS at a one-sided 2.25% level of significance. If either PFS or OS endpoint reaches statistical', 'significance, the study is considered positive. No further tests will be performed if H1 is not rejected.', 'Each hypothesis of H2 and H3 will be tested in order specified above if H1 is rejected and the preceding', 'hypothesis shows statistically significant results at the 1-sided 2.5% level of significance. Otherwise', 'testing in the hierarchical sequence will stop.', 'Interim Analysis:', 'An interim efficacy analysis is planned for overall survival after at least 239 deaths in subjects with', ""DLL3high (i.e., 75% of planned deaths are observed) using a one-sided log-rank test. The O'Brien-"", 'Fleming method will be implemented to protect the type I error rate of 0.0225 for OS. A one-sided alpha', 'spending of 0.0084 for the interim will be allocated for declaring statistical superiority in OS at the time', 'of the interim analysis. The final analysis of os will be performed at a one-sided nominal alpha level of', '0.01998, adjusting for the interim look at os data.', '151']"
151,page_152,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'Interim Analysis (Continued):', 'Unblinded interim data will be analyzed and reviewed by the IDMC. The trial may be considered for', 'early stopping for superiority and the Sponsor will be unblinded to the aggregated data by randomized', 'treatment arms if the IDMC makes such a recommendation after consideration of the PFS and OS results,', 'and all supportive evidence including other efficacy endpoints and safety.', 'Sample Size:', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed, taking into', 'account the expected patient population for the study, that median overall survival in the placebo arm will', 'be around 9 months. Based on a log-rank test, at a one sided significance level of 0.0225 and a power of', '90%, a total of 319 deaths among subjects with DLL3 high are needed to detect an increase of median OS', 'to 13 months in rovalpituzumab tesirine arm, corresponding to a hazard ratio of 0.69 (i.e., a reduction in', 'the hazard death of 31%). Assuming a 19-month accrual period and the last enrolled subject followed for', '12', 'months, at least 480 subjects with DLL3high are expected to be randomized (240 subjects in each arm).', 'A total of 740 subjects regardless of DLL3 expression level (including 480 subjects with DLL3 high will', 'enroll in the study, assuming an approximate prevalence of 65% for subjects with DLL3 high It is', 'projected that an observed hazard ratio of 0.795 or less, corresponding to a 2.3 months or greater', 'improvement in median OS, would result in a statistically significant improvement in the final analysis of', 'OS.', 'It is assumed, taking into account the expected patient population for the study, that median progression-', 'free survival for the placebo arm will be approximately 3 months. Treatment with rovalpituzumab', 'tesirine is hypothesized to increase median progression-free survival to 4.5 months (i.e., a hazard ratio of', '0.667). With approximately 407 PFS events assessed by the CRAC for subjects with DLL3hig the study', 'provides a 90% power to detect a hazard ratio of 0.667 in PFS at a one-sided significance level of 0.0025.', 'It is projected that an observed hazard ratio of 0.757 or less, corresponding to approximately 1 month or', 'greater improvement in median PFS, would result in a statistically significant improvement in the PFS.', 'Pharmacokinetic:', 'Individual concentrations of rovalpituzumab tesirine ADC will be tabulated and summarized for subjects', 'treated with the active regimen and summary statistics provided. The incidence of ATA will be', 'summarized.', 'Biomarkers:', 'Biomarkers will be measured at baseline and post-treatment and analyses performed to identify markers', 'associated with rovalpituzumab tesirine response, pharmacodynamics, PK, or safety.', 'Safety:', 'The safety of rovalpituzumab tesirine will be assessed by evaluating the study drug exposure, adverse', 'events, all deaths, as well as changes in laboratory determinations and vital sign parameters.', 'Has been changed to read:', 'AbbVie Inc.', 'Protocol Number: M16-298', 'Name of Study Drug: rovalpituzumab tesirine', 'Phase of Development: 3', '(Rova-T)', '152']"
152,page_153,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Name of Active Ingredient: rovalpituzumab', 'Date of Protocol Synopsis: 05 March 2019', 'tesirine', 'Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab', 'Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with', 'Extensive Stage Small Cell Lung Cancer (MERU)', 'Objectives:', 'Primary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival, assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1 and overall survival', 'in subjects with extensive-stage small cell lung cancer (ED SCLC) tumors with a high level of', 'DLL3 expression (DLL3high) who have ongoing clinical benefit (SD, PR, or CR) following', 'first-line platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or etoposide)', 'compared to placebo.', 'Secondary', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by CRAC and overall', 'survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical functioning as measured by', 'the EORTC QLQ-C30 questionnaire in all randomized subjects compared to placebo.', 'Exploratory', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining objective response rate', '(ORR), clinical benefit rate (CBR), and duration of responses (DOR) by CRAC and Investigator', 'assessment in DLL3high and in all randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by Investigator', 'assessment compared to placebo in DLL3high and in all randomized subjects.', 'To assess change from baseline in all patient reported outcomes (PRO) domains (except physical', 'functioning) measured by EORTC QLQ-C30/LC13 and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic antibodies (ATAs)', 'against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor for association', 'with sensitivity, efficacy and safety.', 'To explore DLL3 expression in circulating tumor cells (CTCs) for association with efficacy.', 'Investigators: Multicenter, International', 'Study Sites: Approximately 300', 'Study Population: Subjects with extensive-stage Small Cell Lung Cancer (ED SCLC) with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of first-line', 'platinum-based chemotherapy (cisplatin or carboplatin in combination with etoposide or irinotecan).', 'Number of Subjects to be Enrolled: Up to approximately 740 SCLC subjects, to obtain approximately', '480 subjects with DLL3 high expression in tumor (DLL3 high DLL3 high is defined as > 75% tumor cells', 'staining positive according to the VENTANA DLL3 (SP347) IHC Assay.', '153']"
153,page_154,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Methodology:', 'This is a Phase 3, randomized, double-blinded, placebo-controlled, multinational, and multicenter study.', 'ED SCLC subjects who meet all the inclusion criteria and none of the exclusion criteria, and demonstrate', 'ongoing clinical benefit (SD, PR, or CR) at the completion of 4 cycles of first-line platinum-based', 'chemotherapy (such benefit must be ongoing at the last re-staging assessment prior to randomization),', 'will be randomly assigned in a 1:1 ratio to receive 0.3 mg/kg rovalpituzumab tesirine or placebo, and will', 'receive their assigned therapy on Day 1 of each 6-week cycle, omitting every third cycle. Upon', 'completion of first-line chemotherapy, eligible subjects must be offered prophylactic cranial irradiation', '(PCI), if offering this procedure is not contradictory to country or institutional guidelines. Subjects', 'receiving PCI must complete it prior to randomization into the study. Subjects will also receive 8 mg', 'orally (PO) of dexamethasone or placebo twice daily on Day -1, Day 1, and Day 2 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response after completion', 'of first-line platinum-based chemotherapy at screening assessment (SD VS. PR/CR), DLL3 expression,', '(Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or above), history of central nervous system', '(CNS) metastases (Yes VS. No), and for subjects with no history of CNS metastases, PCI VS. no PCI.', 'Survival Follow-up will continue until the endpoint of death, the subject becomes lost to follow-up or', 'withdraws consent, or termination of the study by AbbVie, whichever occurs first.', 'Diagnosis and Main Criteria for Inclusion/Exclusion:', 'Main Inclusion:', '1.', ""Subject or the subject's legally acceptable representative must voluntarily sign and date an informed"", 'consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB),', 'prior to the initiation of any screening or study-specific procedures and should be willing and able to', 'comply with parameters as outlined in the protocol.', '2.', 'Subject must be > 18 years of age.', '3. Histologically or cytologically confirmed ED SCLC (extensive stage disease at initial diagnosis),', 'with ongoing clinical benefit (SD, PR, or CR per RECIST v1.1) following completion of 4 cycles of', 'first-line platinum-based therapy (cisplatin or carboplatin in combination with etoposide or', 'irinotecan).', '4. Subjects with a history of CNS metastases prior to the initiation of first-line platinum-based', 'chemotherapy must have received definitive local treatment and have documentation of stable or', 'improved CNS disease status based on brain imaging within 28 days prior to randomization, off or on', 'a stable dose of corticosteroids.', '5. Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the', 'fourth cycle of first-line platinum-based chemotherapy', '6. Availability of archived or representative tumor material for assessment of DLL3 expression.', '7.', 'Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.', '8.', 'Recovery to VI Grade 1 of any clinically significant toxicity (excluding alopecia) prior to', 'randomization.', '154']"
154,page_155,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Inclusion (Continued):', '9. Subject must have adequate bone marrow, renal and hepatic function as follows:', 'a.', 'Absolute neutrophil count (ANC) > 1,000/L', 'b.', 'Platelet count > 75,000/L', 'c.', 'Hemoglobin > 8.0 g/dL', 'd. Serum total bilirubin < 1.5 X upper limit of normal (ULN) or < 3 X ULN for subjects with', ""Gilbert's disease"", 'e.', 'Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 X ULN', '(< 5x ULN if evidence of hepatic involvement by malignant disease)', 'f.', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault formula (Refer to', 'Appendix E).', 'g.', 'Albumin > 3g/dL', '10. If female, subject must be either postmenopausal as defined as:', 'Age > 55 years with no menses for 12 or more months without an alternative medical cause.', 'Age < 55 years with no menses for 12 or more months without an alternative medical cause', 'AND an FSH level > 40 IU/L.', 'OR', 'Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).', 'OR a Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method', 'of birth control, starting at randomization through at least 6 months after the last dose of blinded', 'investigational product.', 'If the male subject is sexually active, he must agree, from randomization through at least 6 months', 'after the last dose of blinded investigational product, to practice the protocol specified contraception.', '11. Females of childbearing potential must have a negative serum pregnancy test result at Screening, and', 'a negative urine pregnancy test at randomization.', 'Females of non-childbearing potential (either postmenopausal or permanently surgically sterile as', 'defined in the protocol) at Screening do not require pregnancy testing.', 'Main Exclusion:', '1. Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other', 'monoclonal antibodies, antibody-drug conjugates, adioimmunoconjugates, T-cell or other cell-based', 'or biologic therapies, or any other anti-cancer therapy than that described in Inclusion Criteria 3 - 5', 'for SCLC.', '2.', 'Any disease-directed radiotherapy (except, PCI, palliative radiotherapy to a radiographically', 'documented non-progressing lesion for symptom control, or pre-planned radiotherapy for CNS', 'metastases present prior to start of first-line therapy and non-progressing) after last dose of first-line', 'chemotherapy.', '3. Any significant medical condition including any suggested by screening laboratory findings that in', 'the opinion of the Investigator or Sponsor may place the subject at undue risk from the study.', '155']"
155,page_156,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Exclusion (Continued):', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac', 'symptoms consistent with New York Heart Association (NYHA) Class III - IV heart failure (refer to', 'Appendix F) within 6 months prior to randomization.', '5.', 'Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization or earlier history of', 'recurrent Grade 2 or higher effusions with ongoing requirement for pericardiocentesis or', 'thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or higher (per NCI', 'CTCAE version 4.0) viral, bacterial, or fungal infection.', '8.', 'Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study', 'or for approximately 6 months after the last dose of blinded investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the study or for', 'approximately 6 months after the last dose of blinded investigational product.', '10. Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent within 1 week prior to', 'randomization.', '11. Subject has a history of active malignancies other than SCLC within the past 2 years prior to study', 'entry, with the exception of in situ cancer which was curatively treated.', '12. Any prior exposure to a pyrrolobenzodiazepine (PBD-based)-or indolinobenzodiazepine-based drug,', 'prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other', 'contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.', '13. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.', 'Investigational Products:', 'Rovalpituzumab tesirine or Placebo', 'Dexamethasone or Placebo', 'Doses:', 'Rovalpituzumab tesirine/Placebo: 0.3 mg/kg, Day 1 of each 6-week', 'cycle, omitting every third cycle.', 'Dexamethasone/Placebo 8 mg orally (PO) twice daily on Day -1, Day 1', '(the day of dosing), and Day 2 of each 6 week cycle, omitting every', 'third cycle.', 'Mode of Administration:', 'Rovalpituzumab tesirine/Placebo: Intravenous', 'Dexamethasone/Placebo: Oral', 'Duration of Treatment: Subjects will receive rovalpituzumab tesirine/placebo in combination with', 'dexamethasone/placebo on Day 1 of a 6-week cycle, omitting every third cycle until disease progression.', 'Criteria for Evaluation:', 'Efficacy: Efficacy assessments will consist of evaluations for tumor progression using Response', 'Evaluation Criteria in Solid Tumors (RECIST) v1.1 and will be based on a Central Radiographic', 'Assessment Committee (CRAC) review of medical images, as outlined in the Schedule of Assessments.', 'Additionally, efficacy will be assessed by overall survival.', 'Pharmacokinetic: Serum concentrations of rovalpituzumab tesirine ADC and the presence of anti-', 'therapeutic antibodies (ATA) will be determined.', '156']"
156,page_157,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Criteria for Evaluation (Continued):', 'Biomarkers: Pharmacodynamic and predictive biomarker assessments will include analyses of tumor', 'material and circulating tumor cells for DLL3 expression, blood samples for inflammatory, tumor, and', 'soluble markers. Samples may also be used for other nucleic acid or protein based exploratory', 'biomarkers to understand the sensitivity or resistance to rovalpituzumab tesirine and biology of SCLC.', 'Safety: Safety assessments include physical exam, vital signs, body weight, ECOG score, clinical', 'adverse events, laboratory tests (hematology, serum chemistries, urinalysis, and coagulation), ECGs,', 'echocardiogram, fluid retention questionnaire, radiographic images review for fluid retention, and', 'monitoring of concomitant medications.', 'Patient Reported Outcome (PRO):', 'Changes in the patient reported outcomes (PROs) EORTC QLQ-C30, EORTC QLQ-LC13, and', 'EQ-5D-5L from baseline will be assessed.', 'Statistical Methods:', 'Efficacy:', 'Progression-free survival (PFS) per CRAC and overall survival (OS) in patients with DLL3 high ED SCLC', 'are the two primary efficacy endpoints. To meet global regulatory requirements, a multiple testing', 'strategy will be implemented to control the family-wise type I error (alpha) for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival (PFS) per', 'CRAC in DLL3 high patients, overall survival (OS) in DLL3high patients, PFS per CRAC in randomized', 'patients, OS in randomized patients, and physical functioning scale score (EORTC QLQ-C30) in the', 'randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in H01 are H01a and Holb.', 'H01a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in DLL3hig set.', 'Hoib: Rovalpituzumab tesirine arm is not superior to placebo arm in os in DLL3 high set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in os in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning scale score', '(EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {H01a, Holb, H02, H03, and H04} in order. To', 'maintain the family-wise type I error for the study, the null hypotheses in H01 (H01a and H01b) will be first', 'tested with an alpha-split approach. The one-sided alpha of 0.25% and 2.25% will be assigned for PFS', 'and OS hypothesis in H01, respectively. Out of one-sided alpha of 2.25% allocated to OS hypothesis', '(Ho1b), the one-sided alpha of 10-6 will be spent for the early look at the OS data for futility analysis. If', 'the hypothesis for PFS in H01 (H01a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in H01 (H01b). Hence, the hypothesis for OS in H01 (H01b) will be tested either at a one-sided', '2.4999% or one-sided 2.2499% level of significance depending on the PFS hypothesis in H01 a is rejected', 'or not.', 'If either PFS or os endpoint reaches statistical significance, the study is considered positive. No further', 'tests will be performed if the os endpoint in DLL3high population (H01b) does not reach statistical', 'significance.', '157']"
157,page_158,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'The hypothesis in H02 will be tested if the hypothesis in Hoib is rejected. If the hypothesis in H02 is', 'rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS endpoint in DLL3high subjects', '(H01a) is also rejected or (ii) only H04 will be tested if the PFS endpoint in DLL3hig subjects (Ho1a) is not', 'rejected.', 'Futility Analysis:', 'Unblinded interim data will be analyzed and reviewed by the IDMC. A futility analysis will be', 'conducted when approximately 160 deaths in subjects with DLL3¹ high ED SCLC (approximately 50% of', 'the planned deaths) are observed. The trial may be stopped for futility if the estimated Overall Survival', 'Cox HR of Rova-T to Placebo at this analysis exceeds 0.9. The one-sided alpha of 10-6 will be spent for', 'the early look at the efficacy data for futility analysis.', 'Sample Size:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS) based on the', 'CRAC and overall survival (OS) in subjects with DLL3 high ED SCLC. To maintain the overall 1-sided', 'type I error at a 2.5% for this study, the type I error will be split, assigning 0.25% to progression-free', 'survival and the remaining 2.25% to overall survival. However, the OS endpoint will be tested at a', 'one-sided 2.2499% significance level as a one-sided alpha of 10-6 will be spent for the early look at the', 'OS data for futility analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed, taking into', 'account the expected patient population for the study, that median overall survival in the placebo and', 'rovalpituzumab tesirine arm will be around 9 months and 13 months, respectively. The increase of', 'median OS in rovalpituzumab tesirine arm corresponds to a hazard ratio of 0.69, i.e., a reduction in the', 'hazard of death by 31%. With all these assumptions, a total of 319 deaths among subjects with DLL3 high', 'are needed to achieve a 90% power based on a log-rank test at a one-sided significance level of 0.022499.', 'Assuming a 19-month accrual period and the last enrolled subject followed for 12 months, at least', '480 subjects with DLL3hig are expected to be randomized (240 subjects in each arm). A total of', '740 subjects regardless of DLL3 expression level (including 480 subjects with DLL36 high will enroll in', 'the study, assuming an approximate prevalence of 65% for subjects with DLL3high For one-sided', 'significance level of 0.022499, it is projected that an observed hazard ratio of 0.799 or less,', 'corresponding to a 2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The primary endpoints of OS and PFS in DLL3high patients will be analyzed at the same time', 'after', 'observing at-least 319 OS event. It is expected at approximately 420 PFS events will be observed at the', 'time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that median progression-', 'free survival for the placebo and rovalpituzumab tesirine arm will be approximately 3 months and', '4.5 months, respectively. The increase of median progression-free survival in rovalpituzumab tesirine', 'arm corresponds to a hazard ratio of 0.667. With all these assumptions, a total of 420 PFS events', 'assessed by the CRAC for the subjects with DLL3high are needed to achieve a 91% power based on a log-', 'rank test at a one-sided significance level of 0.0025. It is projected that an observed hazard ratio of 0.760', 'or less, corresponding to approximately 1 month or greater improvement in median PFS, would result in', 'a statistically significant improvement in the PFS.', '158']"
158,page_159,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Statistical Methods (Continued):', 'Pharmacokinetic:', 'Individual concentrations of rovalpituzumab tesirine ADC will be tabulated and summarized for subjects', 'treated with the active regimen and summary statistics provided. The incidence of ATA will be', 'summarized.', 'Biomarkers:', 'Biomarkers will be measured at baseline and post-treatment and analyses performed to identify markers', 'associated with rovalpituzumab tesirine response, pharmacodynamics, PK, or safety.', 'Safety:', 'The safety of rovalpituzumab tesirine will be assessed by evaluating the study drug exposure, adverse', 'events, all deaths, as well as changes in laboratory determinations and vital sign parameters.', 'Section 1.3 List of Abbreviations and Definition of Terms', 'Subsection Abbreviations', 'Add:', 'LD SCLC', 'Limited-stage disease small cell lung cancer', 'Section 3.3 Rovalpituzumab Tesirine', 'Last paragraph Previuosly read:', 'In a Phase 1 study (SCRX16-001), rovalpituzumab tesirine dosed at 0.2 - 0.4 mg/kg', 'exhibited encouraging efficacy in recurrent SCLC, achieving a 31% (8/26) and 85%', '(22/26) central review-adjudicated confirmed objective response rate (ORR) and clinical', 'benefit rate (CBR), respectively, in subjects whose tumors expressed DLL3 in > 50% of', 'cells. Median overall survival was 7.7 months in DLL3 > 50% subjects at all dose levels,', 'with a 1-year survival rate of 30%.9 Therefore, rovalpituzumab tesirine appears to be an', 'active anti-cancer therapy.', 'Has been changed to read:', 'In the Phase 1 first in human study of rovalpituzumab tesirine (Study SCRX16-001), the', 'best overall response (confirmed) for all SCLC subjects (dose escalation, retreatment, and', 'maintenance cohorts) was retrospectively assessed by the Independent Review Committee', '(IRC) by RECIST v1.1 criteria. The ORR (confirmed) was 16% (95% CI: 7.35,27.42),', '159']"
159,page_160,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'with 12% achieving PR. The clinical benefit rate (CBR) was 59% (95% CI: 44.93,', '71.40). The median duration of response by the IRC was 1.7 months (95% CI: 0.03,', '3.06). The median progression-free survival by the IRC was 3.0 months (95% CI: 2.56,', '3.84), with a probability of progression-free survival at 12 weeks of 52% (95% CI: 39,', '63). The median overall survival was 4.3 months (95% CI: 3.22, 5.65). The probability', 'of overall survival at 12 weeks was 69% (95% CI: 52, 81). In DLL3-positive ( 1%', 'tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay) subjects,', 'the ORR was 23% (95% CI: 10.42, 40.14), and the CBR was 77% (95% CI: 59.86,', '89.58). A slightly higher ORR (27%) and CBR (87%) were observed in DLL3-high', '(> 50% tumor cells staining positive for DLL3 with murine anti-DLL3 antibody assay)', 'subjects.', 'In the Phase 2 Study SCRX001-002 (TRINITY) in patients with SCLC recurrent after at', 'least two systemic chemotherapy regimens, rovalpituzumab tesirine dosed at 0.3 mg/kg', 'every 6 weeks for two cycles (with an option for additional two cycles upon progression', 'occurring > 12 weeks after the second dose) resulted in the following:', 'In DLL3 high @ 75% tumor cells staining positive for DLL3 with VENTANA', 'Rabbit IHC (SP347) DLL3 assay) subjects, ORR of 14% per IRC assessment,', 'median OS of 5.7 months and median PFS of 3.8 months', 'In DLL3 high subjects, the clinical benefit rate was 74% with a median duration', 'of clinical benefit of 3.0 months per IRC assessment', 'Additionally, DLL3 positive (> 25% tumor cells staining positive for DLL3 with', 'VENTANA Rabbit IHC (SP347) DLL3 assay) and DLL3 high groups had comparable', 'response rates given highly overlapping populations where approximately 85% of DLL3', 'positive subjects were also DLL3 high', 'In December 2018, enrollment in Study M16-289 TAHOE (""A Randomized, Open-Label,', 'Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for', 'Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who', 'have First Disease Progression During or Following Front-Line Platinum-Based', '160']"
160,page_161,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Chemotherapy"") was discontinued at the recommendation of the Independent Data', 'Monitoring Committee (IDMC) after review of available efficacy data which', 'demonstrated shorter overall survival in the rovalpituzumab tesirine arm compared with', 'the topotecan control arm. At the time enrollment was halted, 444 DLL3 high ( 75%', 'tumor cells staining positive for DLL3 with VENTANA Rabbit IHC (SP347) DLL3', 'assay) subjects had enrolled on the trial. The IDMC recommended that investigators and', 'subjects make individual decisions as to whether or not to continue treatment based on', 'patient level response. The results of the TAHOE study did not adversely impact the', 'safety profile for rovalpituzumab tesirine.', '19', 'Section 3.5 Benefits and Risks', 'Add: new second paragraph', 'As of 30 June 2018, 1246 subjects have received study medication in the rovalpituzumab', 'tesirine clinical program; an estimated 1039 subjects (with SCLC or other DLL3- -', 'expressing solid tumors) have received at least 1 dose of rovalpituzumab tesirine at doses', 'ranging from 0.05 mg/kg to 0.8 mg/kg on a q3w schedule and 0.3 mg/kg to 0.4 mg/kg on', 'a q6w schedule.', 'Section 3.5 Benefits and Risks', 'Second paragraph, first and second sentence previously read:', 'The most frequent treatment-emergent adverse event (TEAE) terms considered related to', 'rovalpituzumab tesirine have included fatigue (35%), pleural effusion (31%) and', 'peripheral edema (27%), while the most frequent, related TEAE groups of Grade 3 or', 'higher have included thrombocytopenia (12%), serosal effusions (11%), and skin', 'reactions (8%). 9 In addition, preclinical toxicology studies conducted in the rat and the', 'cynomolgus monkey have identified bone marrow, lung, and kidney as potential sources', 'of clinical adverse events (AEs) (AbbVie Stemcentrx data on file).', '161']"
161,page_162,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w, 96.8%', 'of subjects reported at least 1 adverse event. The most frequently reported adverse events', 'among subjects with SCLC treated with rovalpituzumab tesirine 0.3 mg/kg q6w were', 'decreased appetite (28.0%), photosensitivity reaction (27.7%), oedema peripheral', '(27.2%), dyspnoea (26.6%), and nausea (25.6%). Important identified risks following', 'treatment with rovalpituzumab tesirine include: pleural effusions (33.9%), pericardial', 'effusions (16.7%), generalized edema (2.7%) and photosensitivity reactions (27.7%).', 'Important potential risks following treatment with rovalpituzumab tesirine include', 'pneumonitis (1%). The following adverse events of special interest have also been', 'identified: cutaneous reactions (48.7%), thrombocytopenia and hemorrhage events', '(28%), edema (33.8%), hypoalbuminemia (16.2%), hepatotoxicity (19.3%),', 'nephrotoxicity (5.9%), anemia (19.7%), neutropenia (9.2%) and infusion related reaction', '(0.2%). In addition, preclinical toxicology studies conducted in the rat and the', 'cynomolgus monkey have identified bone marrow, lung, and kidney as potential sources', 'of clinical adverse events (AEs) (AbbVie Investigator Brochure v7).', 'Section 4.0 Study Objectives', 'Previously read:', 'The primary objective of this study is to evaluate if rovalpituzumab tesirine improves', 'progression-free and overall survival in subjects with extensive-stage SCLC who have', 'ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles of', 'first-line, platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or', 'etoposide) compared to placebo.', 'The secondary objectives are to evaluate rovalpituzumab tesirine anti-tumor activity by', 'determining objective response rate (ORR), clinical benefit rate (CBR), and duration of', 'responses (DOR), and to assess change in patient reported outcomes (PRO) with', 'EORTC QLQ-C30/LC-13 questionnaires.', '162']"
162,page_163,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The exploratory objectives are to characterize the pharmacokinetics and incidence of', 'anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine, to evaluate', 'pharmacodynamic and predictive biomarkers in blood and tumor for association with', 'sensitivity, efficacy and safety, to explore the DLL3 expression in circulating tumor cells', '(CTCs) for association with efficacy, and to assess EQ-5D-5L during treatment with', 'rovalpituzumab tesirine.', 'Has been changed to read:', 'The primary objective of this study is to evaluate if rovalpituzumab tesirine improves', 'progression-free survival, assessed by CRAC, and overall survival in subjects with', 'extensive-stage SCLC tumors with a high level of DLL3 expression (DLL3high who have', 'ongoing clinical benefit (SD, PR, or CR) following the completion of 4 cycles of', 'first-line, platinum-based chemotherapy (cisplatin or carboplatin plus irinotecan or', 'etoposide) compared to placebo.', 'The secondary objectives are:', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'CRAC and overall survival in all randomized subjects compared to placebo.', 'To assess change in patient reported outcomes (PRO) with physical', 'functioning as measured by the EORTC QLQ-C30questionnaire in all', 'randomized subjects compared to placebo.', 'The exploratory objectives are:', 'To evaluate rovalpituzumab tesirine anti-tumor activity by determining', 'objective response rate (ORR), clinical benefit rate (CBR), and duration of', 'responses (DOR) by CRAC and investigator assessment in DLL3high and in', 'all', 'randomized subjects.', 'To evaluate if rovalpituzumab tesirine improves progression-free survival by', 'investigator assessment compared to placebo in DLL3high and in all', 'randomized subjects.', '163']"
163,page_164,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'To assess change from baseline in all patient reported outcomes (PRO)', 'domains (except physical functioning) measured by EORTC QLQ-C30/LC13', 'and EQ-5D-5L.', 'To characterize the pharmacokinetics and incidence of anti-therapeutic', 'antibodies (ATAs) against rovalpituzumab tesirine.', 'To evaluate pharmacodynamic and predictive biomarkers in blood and tumor', 'for association with sensitivity, efficacy and safety.', 'To explore the DLL3 expression in circulating tumor cells (CTCs) for', 'association with efficacy.', 'Section 5.1 Overall Study Design and Plan: Description', 'Second paragraph, last sentence previously read:', 'Approximately 275 clinical sites will participate.', 'Has been changed to read:', 'Approximately 300 clinical sites will participate.', 'Figure 1. Study Schema', 'Footnote ""3."" previously read:', 'At least 3 but no more than 9 weeks between the administration of the last cycle of', 'platinum-based chemotherapy and randomization.', 'Has been changed to read:', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day 1 of the', 'fourth cycle of first-line platinum-based chemotherapy.', '164']"
164,page_165,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.2 Selection of Study Population', 'Add: new second paragraph', 'For the purposes of study eligibility, limited stage disease SCLC (LD-SCLC) is defined as', 'a disease confined to the hemithorax of origin, with or without the involvement of', 'regional lymph nodes, including ipsilateral and contralateral hilar, ipsilateral and', 'contralateral mediastinal, and ipsilateral supraclavicular nodes. Extensive stage disease', 'SCLC (ED-SCLC) is defined as all other SCLC.', 'Section 5.2.1 Inclusion Criteria', 'Criterion 1, 3, and 5 previously read:', '1.', 'Subject must voluntarily sign and date an informed consent, approved by an', 'Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the', 'initiation of any screening or study-specific procedures and should be willing and', 'able to comply with parameters as outlined in the protocol.', '3.', 'Histologically or cytologically confirmed extensive-stage SCLC with ongoing', 'clinical benefit (SD, PR, or CR per RECIST v.1.1) following completion of 4 cycles', 'of first-line platinum-based therapy (cisplatin or carboplatin in combination with', 'etoposide or irinotecan).', '5.', 'At least 3 but no more than 9 weeks between the administration of the last cycle of', 'platinum-based chemotherapy and randomization.', 'Has been changed to read:', '1.', ""Subject or the subject's legally acceptable representative must voluntarily sign and"", 'date an informed consent, approved by an Independent Ethics Committee', '(IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or', 'study-specific procedures and should be willing and able to comply with parameters', 'as outlined in the protocol.', '165']"
165,page_166,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '3.', 'Histologically or cytologically confirmed ED SCLC (extensive stage disease at', 'initial diagnosis), with ongoing clinical benefit (SD, PR, or CR per RECIST v.1.1)', 'following completion of 4 cycles of first-line platinum-based therapy (cisplatin or', 'carboplatin in combination with etoposide or irinotecan).', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day', '1', 'of the fourth cycle of first-line platinum-based chemotherapy.', 'Section 5.2.1 Inclusion Criteria', 'Criterion 9f previously read:', 'Calculated creatinine clearance > 30 mL/min by the Cockroft-Gault formula (Refer to', 'Appendix E)', 'Has been changed to read:', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault formula', '(Refer to Appendix E)', 'Section 5.2.2 Exclusion Criteria', 'Criterion 1, 2, 4, and 12 previously read:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for the', 'disease under study.', '2.', 'Any disease-directed radiotherapy (except PCI or pre-planned radiotherapy for CNS', 'metastases present prior to start of first-line therapy and non-progressing) after last', 'dose of first-line chemotherapy.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '166']"
166,page_167,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '(NYHA) Class III - IV heart failure (refer to Appendix E) within 6 months prior to', 'randomization.', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD)- - or indolinobenzodiazepine-', 'based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known', 'hypersensitivity or other contraindications to rovalpituzumab tesirine or excipient', 'contained in the drug formulation.', 'Has been changed to read:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for SCLC.', '2.', 'Any disease-directed radiotherapy (except PCI, palliative radiotherapy to a', 'radiographically documented non-progressing lesion for symptom control, or pre-', 'planned radiotherapy for CNS metastases present prior to start of first-line therapy', 'and non-progressing) after last dose of first-line chemotherapy.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '(NYHA) Class III - IV heart failure (refer to Appendix F) within 6 months prior to', 'randomization.', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD-based) or', 'indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine', 'clinical trial, or known hypersensitivity or other contraindications to rovalpituzumab', 'tesirine or excipient contained in the drug formulation.', '167']"
167,page_168,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.2.3.1 Prior Therapy', 'First paragraph previously read:', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', 'irinotecan; administration of the last cycle of first-line chemotherapy must be at least', '3 weeks but no more than 9 weeks prior to randomization.', 'Has been changed to read:', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', 'irinotecan; administration of Day 1 of the last cycle of first-line chemotherapy must be at', 'least 3 weeks but no more than 9 weeks prior to randomization. Subjects previously', 'treated for LD-SCLC are not eligible.', 'Section 5.2.3.2 Concomitant Therapy', 'Last paragraph, last sentence previously read:', 'However, due to the potential for rovalpituzumab tesirine-related skin photosensitivity,', 'subjects should be advised during treatment and for 30 days after last treatment to avoid', 'unprotected sun exposure, use a broad spectrum sunscreen with a sun protection factor', '(SPF) of at least 30 and re-apply sunscreen as activity-appropriate, and wear protective', 'clothing, a broad-brimmed hat, and sunglasses when outdoors or when driving or riding in', 'a car for more than 1 hour.', 'Has been changed to read:', 'However, due to the potential for rovalpituzumab tesirine-related skin photosensitivity,', 'Patients should be advised to avoid direct and indirect sun exposure as much as possible', 'from Cycle 1 Day 1 until 30 days after the final dose. When sun exposure is unavoidable,', 'patients should wear protective clothing and sunglasses, and use a broad-spectrum', 'sunscreen and lip balm (SPF 30 or greater). Thirty-one to ninety days after last dose of', '168']"
168,page_169,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Rova-T/placebo, the patient may resume outdoor activities with appropriate sun protection', 'including broad brimmed hat, protective clothing and sunscreen SPF 30 or higher.', 'Section 5.2.3.2.1 Allowed Concomitant Therapy', 'First paragraph, third sentence previously read:', 'Bone modifying agents for bone metastases are also permitted per local institutional', 'standards.', 'Has been changed to read:', 'Bone modifying agents (e.g., bisphosphonates, denosumab) for bone metastases are also', 'permitted per local institutional standards.', 'Section 5.3.1.1 Study Procedures', 'Subsection Vital Signs', 'First paragraph, second sentence previously read:', 'Vital signs include weight, sitting blood pressure, heart rate and body temperature.', 'Has been changed to read:', 'Vital signs include actual weight, sitting blood pressure, heart rate and body temperature.', 'Section 5.3.1.1 Study Procedures', 'Subsection Vital Signs', 'Second paragraph previously read:', 'Weight will be collected in the clinic prior to dosing at each cycle and the recorded weight', 'will be utilized for dosing calculations. For weight assessments, the subject should not', 'wear shoes.', '169']"
169,page_170,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Actual weight will be collected in the clinic prior to dosing at each cycle and the recorded', 'weight will be utilized for dosing calculations. For weight assessments, the subject', 'should not wear shoes. In the event of a 5% or greater increase in weight within', '2 consecutive visits or compared to baseline which ever has the shorter interval, a prompt', 'workup for fluid retention (e.g., edema, effusions, etc.) should be conducted. If weight', 'gain is due to proven or suspected fluid retention related to study drug, and dosing is not', 'prohibited per Section 5.5.4, dose should be calculated based on actual weight before the', 'event of fluid retention.', 'Section 5.3.1.1 Study Procedures', 'Subsection Echocardiogram', 'Previously read:', 'Echocardiograms will be performed per Appendix C, Study Activities to assess any', 'pericardial effusion, if present, as well as cardiac function (left ventricular ejection', 'fraction, LVEF).', 'Has been changed to read:', 'Echocardiograms will be performed per Appendix C, Study Activities to rule out', 'pericardial effusion (or assess, if present), as well as assess cardiac function (left', 'ventricular ejection fraction, LVEF).', 'Section 5.3.1.1 Study Procedures', 'Subsection Disease/Response Assessment (Radiographic Imaging)', 'Last paragraph previously read:', 'Scheduled tumor assessments will not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'metastases warrants otherwise. Subjects who discontinue treatment for reasons other than', '170']"
170,page_171,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'radiographic disease progression will continue to be followed every 6 weeks from C1D1', 'to determine the extent of tumor burden, until disease progression occurs.', 'Has been changed to read:', 'Scheduled tumor assessments should not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'progression warrants otherwise. In some cases, mandatory dose delays due to toxicity', 'will lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Subjects who discontinue treatment for reasons other than radiographic disease', 'progression will continue to be followed every 6 weeks from randomization to determine', 'the extent of tumor burden, until disease progression occurs.', 'Section 5.3.1.1 Study Procedures', 'Subsection MRI/CT of the Brain', 'Last sentence previously read:', 'MRI/CT of the brain is only required at screening and when clinically indicated (e.g., if', 'CNS progression is suspected).', 'Has been changed to read:', 'MRI/CT of the brain is required at screening and when clinically indicated (e.g., if CNS', 'progression is suspected) thereafter.', 'Section 5.3.1.1 Study Procedures', 'Subsection Fluid Retention Questionnaire (Including Subject Daily Weight)', 'Last paragraph, last sentence previously read:', 'The site will advise subjects to contact the site in cases where sudden weight gain is', 'observed for possible assessment in the clinic.', '171']"
171,page_172,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'The site will advise subjects to contact the site in cases where sudden weight gain (5% or', 'greater) is observed for possible assessment in the clinic.', 'Section 5.3.1.1 Study Procedures', 'Subsection End of Treatment (EOT) Visit', 'Add: new second sentence', 'The EOT procedures should be done within 7 days of documented decision to discontinue', 'treatment and prior to subjects beginning any new anti-cancer therapy if possible.', 'Section 5.3.1.1 Study Procedures', 'Subsection End of Treatment (EOT) Visit', 'Delete: third sentence', 'The visit should occur within 7 days of documentation of the decision to discontinue', 'treatment and prior to subjects beginning any new anti-cancer therapy if possible.', 'Section 5.3.3.2 Primary Variables', 'Previously read:', 'The primary endpoints are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) and overall survival (OS).', 'Has been changed to read:', 'The primary endpoints are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in DLL3 high population.', '172']"
172,page_173,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.3.3.3 Secondary Variables', 'Previously read:', 'The secondary variables are progression-free survival (PFS) based on investigator', 'assessment, objective response rate (ORR) per the CRAC and investigator assessment,', 'respectively, and clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, and the duration of response (DOR) per the CRAC and investigator', 'assessment, respectively. Response assessment will be based on RECIST v1.1. Changes', 'in patient reported outcomes (PROs) as measured by European Organization for Research', 'and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and Lung', 'Cancer Module (QLQ-LC13) are also secondary endpoints in this study.', 'Has been changed to read:', 'The secondary variables are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in randomized set population. Change in patient reported outcome (PRO) with', 'physical functioning as measured by European Organization for Research and Treatment', 'of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in randomized set', 'population is also a secondary endpoint in this study.', 'Section 5.3.3.4 Exploratory Variables', 'Add: new section title and text', '5.3.3.4', 'Exploratory Variables', 'The exploratory variables are progression-free survival (PFS) based on investigator', 'assessment, objective response rate (ORR) per the CRAC and investigator assessment,', 'respectively, clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, and the duration of response (DOR) per the CRAC and investigator', 'assessment, respectively. Response assessment will be based on RECIST v1.1. Changes', 'in patient reported outcomes (PROs) as measured by EQ-5D-5L and all other PRO', 'domains (except for physical functioning) as measured by European Organization for', '173']"
173,page_174,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)', 'and Lung Cancer Module (QLQ-LC13) are also exploratory endpoints in this study.', 'Section 5.3.5 Pharmacokinetic Variables', 'Previously read:', 'Plasma concentrations of rovalpituzumab tesirine ADC as well as the timing and', 'incidence of ATAs will be tabulated and summarized.', 'Has been changed to read:', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the timing and incidence', 'of ATAs will be tabulated and summarized.', 'Section 5.5.1 Treatments Administered', 'First paragraph, last sentence previously read:', 'If the dose of dexamethasone is vomited within 15 minutes of taking the medication, the', 'subject should retake the medication.', 'Has been changed to read:', 'If the dose of dexamethasone/placebo is vomited within 15 minutes of taking the', 'medication, the subject should retake the medication.', 'Section 5.5.2.1 Packaging and Labeling', 'Subsection Rovalpituzumab Tesirine and Placebo', 'Add: new last sentence', 'Rova-T drug product is classified as a Dangerous Goods/Hazardous Material and is', 'packaged and shipped by AbbVie according to US Department of Transportation (DOT)', 'and International Air Transport Association (IATA) certified regulations.', '174']"
174,page_175,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.5.2.2 Storage and Disposition of Blinded Investigational Product(s)', 'Subsection Rovalpituzumab Tesirine/Placebo', 'Add: new last sentence', 'Specific storage conditions for reconstituted and diluted rovalpituzumab tesirine/placebo', 'will be provided in a separate document outside of this protocol.', 'Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'Fourth sentence previously read:', 'The rovalpituzumab tesirine drug product is dosed based on body weight.', 'Has been changed to read:', 'The rovalpituzumab tesirine drug product is dosed based on actual body weight.', 'Section 5.5.2.3 Preparation/Reconstitution of Dosage Form(s)', 'Add: new tenth sentence', 'Specific dose preparation and documentation details will be provided to the site pharmacy', 'in a separate document.', 'Section 5.5.4.1 Dosing', 'First paragraph', 'Add: new last sentence', 'In cases of weight gain due to fluid retention, dosing should be based on most recent pre-', 'fluid retention actual weight.', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Toxicity ""Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or', 'higher"" previously read:', 'Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or higher', '175']"
175,page_176,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Grade 4 LFTs or Grade 3 LFTs with concomitant Bilirubin Grade 2 or higherb', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Add: new toxicity ""Grade 2 pneumonitis"" and ""Grade > 3 pneumonitis""', 'Grade 2 pneumonitis', 'Reduce dose to 0.1 mg/kg', 'Discontinue Rova-T', 'Grade > 3 pneumonitis', 'Discontinue Rova-T', 'N/A', 'Table 5. Dose Reductions and Discontinuation for Unacceptable Toxicities', 'Add: new footnote ""b.""', 'b. If potential DILI is suspected please follow guidelines of Section 6.1.8.3.', 'Section 5.5.5.2 Blinding of Data for Independent Data Monitoring Committee', '(IDMC)', 'Last sentence previously read:', 'Final PFS data with interim OS data will be analyzed and reviewed by the IDMC for', 'recommendation.', 'Has been changed to read:', 'For the futility analysis, OS, other efficacy and safety data will be analyzed and reviewed', 'by the IDMC for recommendation.', 'Section 5.5.7 Drug Accountability', 'Fourth paragraph', 'Add: new last sentence', 'Rova-T is classified as a Dangerous Good/Hazardous Material according to US', 'Department of Transportation (DOT) and International Air Transport Association (IATA).', '176']"
176,page_177,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Dangerous Goods/Hazardous Materials must be packaged and shipped according to', 'applicable regulations.', 'Section 6.1.1.3 Adverse Events Expected Due to SCLC or Progression of SCLC', 'Last paragraph previously read:', '""Disease progression"" should not be captured when reporting AEs or SAEs, even if fatal,', 'as disease progression is an efficacy endpoint for the trial. Rather, symptoms of disease', 'progression should be reported as AEs or SAEs as appropriate.', 'Has been changed to read:', 'Although exempted from expedited reporting to Health Authorities and Institutional', 'Review Boards (IRBs) as individual cases, these SAEs must be reported to the Sponsor', 'within 24 hours of the site being made aware of the SAE.', 'AEs or SAEs should not be reported as ""Disease progression,"" even if fatal, as PD is an', 'efficacy endpoint for the study. Rather, report the specific disease (clinical) manifestation', ""of the progression (eg, 'malignant pleural effusion, 'spinal bone metastases,'"", '\'lymphadenopathy,\' \'brain metastases\') or if not possible, report ""malignant neoplasm', 'progression"" as the AE or SAE as appropriate.', 'Section 6.1.4 Deaths', 'Second paragraph previously read:', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'AE and will not be subject to expedited reporting. These events should be captured as', 'disease progression and recorded on the AE eCRF. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', '177']"
177,page_178,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Deaths that occur during the protocol specified AE reporting period (Section 6.1.6) that', 'are more likely related to disease progression will therefore be considered as an expected', 'SAE and will not be subject to expedited reporting. These events should be recorded on', 'the AE eCRF as described in Section 6.1.1.3. After the AE reporting period, deaths', 'attributed to progression of disease under study should not be recorded on the AE eCRF.', 'Section 6.1.5 Adverse Event Collection Period', 'First paragraph, first sentence previously read:', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following discontinuation of blinded investigational product', 'administration will be collected, whether solicited or spontaneously reported by the', 'subject.', 'Has been changed to read:', 'All adverse events reported from the time of blinded investigational product', 'administration until 70 days following the last dose of blinded investigational product will', 'be collected, whether solicited or spontaneously reported by the subject.', 'Section 6.1.6 Adverse Event Reporting', '""Primary Therapeutic Area Medical Director:"" previously read:', 'Therapeutic Area Medical Director', 'AbbVie', '200 Sidney Street', 'Cambridge, MA 02139', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', '178']"
178,page_179,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Senior Medical Director', 'AbbVie', '1 North Waukegan Road', 'North Chicago, IL 60064', 'USA', 'Telephone Contact Information:', 'Office:', 'Mobile:', 'Email:', 'Section 6.1.6 Adverse Event Reporting', 'Fifth paragraph previously read:', 'The sponsor will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'Directive 2001/20/EC. The reference document used for SUSAR reporting in the EU', ""countries will be the most current version of the Investigator's Brochure14 and the most"", 'current version of the Summary of Product Characteristics (SmPC).', 'Has been changed to read:', 'AbbVie will be responsible for Suspected Unexpected Serious Adverse Reactions', '(SUSAR) reporting for the Investigational Medicinal Product (IMP) in accordance with', 'global and local guidelines and Appendix A of the Investigator Brochure will serve as the', 'Reference Safety Information (RSI). The RSI in effect at the start of a DSUR reporting', 'period serves as the RSI during the reporting period. For follow-up reports, the RSI in', ""place at the time of occurrence of the 'suspected' Serious Adverse Reaction will be used to"", 'assess expectedness.', '179']"
179,page_180,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 6.1.8.1 Management of Serosal Effusions/Serositis', 'First paragraph, first sentence previously read:', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., pericardial', 'tamponade).', 'Has been changed to read:', 'Serosal effusions (pleural or pericardial, or ascites) have been observed with', 'rovalpituzumab tesirine and have the potential to be life-threatening (e.g., cardiac', 'tamponade).', 'Section 6.1.8.1 Management of Serosal Effusions/Serositis', 'First paragraph', 'Add: new fifth and sixth sentence', 'Effusion events were reported during treatment and may occur up to several months after', 'last Rova-T dose. As a result, subjects should be advised of signs and symptoms of fluid', 'retention and contact treating physician if they arise during this time.', 'Section 6.1.8.2 Management of Skin Reactions', 'Add: new second paragraph', 'Photosensitivity reactions may occur hours to days after sun exposure. Patients should be', 'advised to avoid direct and indirect sun exposure as much as possible from Cycle 1 Day 1', 'until 30 days after the final dose. When sun exposure is unavoidable, patients should', 'wear protective clothing and sunglasses, and use a broad-spectrum sunscreen and lip balm', '(SPF 30 or greater). Thirty-one to ninety days after last dose of Rova-T/placebo, the', 'patient may resume outdoor activities with appropriate sun protection including broad', 'brimmed hat, protective clothing and sunscreen SPF 30 or higher. Subjects with a grade 3', 'photosensitivity reaction should dose reduce Rova-T/placebo to 0.2 mg/kg after the first', 'occurrence and following a second grade 3 photosensitivity reaction, reduce Rova-', '180']"
180,page_181,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'T/placebo to 0.1 mg/kg. Subjects with a grade 4 photosensitivity reaction must', 'permanently discontinue Rova-T/placebo.', 'Section 6.1.8.2 Management of Skin Reactions', 'Second paragraph previously read:', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described below.', 'Has been changed to read:', 'If clinically consistent with photosensitivity, the AE should be reported as such (using', 'medically accurate and descriptive AE terminology), and managed as described in', 'Table 6.', 'Section 6.1.8.2 Management of Skin Reactions', 'Third paragraph, first sentence previously read:', 'Photo-documentation should be available upon request by the TA MD.', 'Has been changed to read:', 'Photo-documentation of skin toxicity should be available upon request by the TA MD.', 'Section 6.1.8.4 Monitoring and Management of Edema', 'Add: new section title and text', '6.1.8.4', 'Monitoring and Management of Edema', 'The majority of the edema events with rovalpituzumab tesirine have been reported as low', 'grade 1 or 2 (mild or moderate); however, a small number of fatal events of generalized', 'edema have been reported with rovalpituzumab tesirine. Physical exams and monitoring', 'of weight gain and signs or symptoms of fluid retention should be conducted during', 'treatment. Edema events were reported during treatment and may occur up to several', '181']"
181,page_182,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'months after last Rova-T dose. As a result subjects should be advised of signs and', 'symptoms of fluid retention as well as monitor their weight and contact treating physician', 'if they arise during this time.', 'Consistent with institutional guidelines or standard practice, the use of diuretics with or', 'without albumin may be considered in subjects with clinically significant edema and', 'hypoalbuminemia. The selection and use of diuretics in subjects should be based on', 'individual clinical characteristics and include monitoring of electrolyte status and signs or', 'symptoms of intravascular volume depletion such as hypotension and impaired renal', 'function.', 'Systemic corticosteroids, when initiated promptly, have been reported to be beneficial in', 'some prior cases.', '182']"
182,page_183,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Reported Term', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4', 'Generalized', 'Noted on exam;', 'Interfering with', 'Interferes with', 'Life-', 'edema', '1+ pitting edema', 'instrumental ADLs; oral', 'self care ADL;', 'threatening', '(Anasarca)', 'therapy initiated', 'intravenous', 'consequences', 'therapy indicated;', 'skin breakdown', 'Definition: A disorder characterized by fluid accumulation in the tissues of the body including the skin.', 'Edema trunk', 'Swelling or', 'Readily apparent', 'Gross deviation', 'obscuration of', 'obscuration of anatomic', 'from normal', 'anatomic', 'architecture; obliteration', 'anatomic contour;', 'architecture on', 'of skin folds; readily', 'limiting self care', 'close inspection', 'apparent deviation from', 'ADL', 'normal anatomic contour;', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.', 'Edema limbs', '5 - 10% inter-limb', '> 10 - 30% inter-limb', '> 30% inter-limb', 'discrepancy in', 'discrepancy in volume or', 'discrepancy in', 'volume or', 'circumference at point of', 'volume; gross', 'circumference at', 'greatest visible difference;', 'deviation from', 'point of greatest', 'readily apparent', 'normal anatomic', 'visible difference;', 'obscuration of anatomic', 'contour; limiting', 'swelling or', 'architecture; obliteration', 'self care ADL', 'obscuration of', 'of skin folds; readily', 'anatomic', 'apparent deviation from', 'architecture on', 'normal anatomic contour;', 'close inspection', 'limiting instrumental ADL', 'Definition: A disorder characterized by swelling due to excessive fluid accumulation in the upper or', 'lower extremities', 'Section 6.1.8.5 Pneumonitis', 'Add: new section title and text', '6.1.8.5', 'Pneumonitis', 'Pneumonitis has been infrequently reported with rovalpituzumab tesirine but has resulted', 'in fatal outcomes. Although the causal role of rovalpituzumab tesirine could not be ruled', 'out, the reports of pneumonitis had one or more confounders including underlying', 'pulmonary disease/cancer, prior thoracic radiation, prior cytotoxic chemotherapy or', 'clinical evidence suggestive of an alternative diagnosis including pneumonia.', '183']"
183,page_184,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Heavily pretreated SCLC patients and patients with a history of pneumonitis may be at', 'increased risk, and careful monitoring for signs and symptoms of pneumonitis is', 'important. The risk of pneumonitis is increased with prior radiation to lung.', 'In general, signs and symptoms coinciding with or preceding pneumonitis may include', 'new or worsening cough, chest pain and/or shortness of breath, fever, and radiographic', 'changes (reticular markings, ground glass opacities). Protocol defined disease', 'assessments provide the opportunity for on study pulmonary monitoring with ""gold', 'standard"" diagnostic method for detection of pneumonitis. The protocol allows for', 'additional imaging per physician discretion for signs and symptoms of pulmonary', 'toxicity.', 'The diagnosis of drug induced pneumonitis is one of exclusion. Other etiologies', 'including infection, which is a common cause of pulmonary infiltrates with clinical and', 'radiographic appearance similar to drug-induced pneumonitis, need to be carefully', 'considered and excluded before the diagnosis of drug induced pneumonitis can be', 'established.', 'If pneumonitis is suspected, close monitoring including additional laboratory and imaging', 'investigation per institutional guidelines may be necessary. Systemic corticosteroids may', 'be beneficial for rapidly progressive or more severe pneumonitis. For events of Grade 1', 'pneumonitis close monitoring is recommended; while dose modifications for Grade 2 and', 'discontinuation of Rova-T for Grades 3 and 4 are required. Please see Table 5.', '184']"
184,page_185,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 7.0 Protocol Deviations', 'Contact Information previously read:', 'Primary Contact:', 'Alternate Contact:', 'Study Management Associate III', 'Study Project Manager I', 'AbbVie', 'AbbVie', '1 North Waukegan Road', '1 North Waukegan Road', 'North Chicago, IL 60064', 'North Chicago, IL 60064', 'Office:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Has been changed to read:', 'Primary Contact:', 'Alternate Contact:', 'Study Project Manager II', 'Study Project Manager I', 'AbbVie Corporation', 'AbbVie s.r.o.', '8401 Trans-Canada Highway', 'METRONOM BUSINESS CENTER', 'Saint-Laurent, Québec', 'Bucharova 2817/13, Stodulky,', 'H4S 1Z1', '158 00 Praha 5', 'Canada', 'Czech Republic', 'Phone:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Section 8.1 Statistical and Analytical Plans', 'Second paragraph previously read:', 'Two analyses are planned for this study. The first will be performed when at least', '407 progression-free survival (PFS) events, assessed by a Central Radiographic', '185']"
185,page_186,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Assessment Committee (CRAC) according to RECIST v1.1, and at least 239 deaths have', 'occurred in subjects with DLL3high The second analysis will be performed when at least', '319 deaths have occurred in subjects with DLL3high', 'Has been changed to read:', 'The primary endpoints of OS and progress free survival (PFS) assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1 in DLL3 high', 'patients will be analyzed at the same time after observing at least 319 OS events. It is', 'expected at approximately 420 PFS events will be observed at the time of the primary', 'analysis.', 'Section 8.1 Statistical and Analytical Plans', 'First and second bullet previously read:', 'DLL3high Set: It includes all randomized subjects with DLL3 high Subjects', 'will be classified according to the treatment arm to which they are randomized', 'regardless the actual treatment received, following intent-to-treat principle.', 'The DLL3 high set will be the primary analysis set for the analysis of efficacy', 'endpoints.', 'Randomized Set: It includes all randomized subjects, with subjects grouped', 'according to the treatment arm to which they are randomized regardless the', 'actual treatment received, following intent-to-treat principle. The randomized', 'set will be used for supportive analysis of efficacy endpoints.', '186']"
186,page_187,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'DLL3high Set: It includes all randomized subjects with DLL3high ED SCLC.', 'Subjects will be classified according to the treatment arm to which they are', 'randomized regardless the actual treatment received, following intent-to-treat', 'principle. The DLL3high set will be the analysis set for the analysis of the', 'primary efficacy endpoints of os and PFS. All the exploratory efficacy', 'endpoints will be analyzed based on the DLL3 high set unless the OS and PFS', 'based on the randomized set are statistically significant.', 'Randomized Set: It includes all randomized subjects, with subjects grouped', 'according to the treatment arm to which they are randomized regardless the', 'actual treatment received, following intent-to-treat principle. The randomized', 'set will be the analysis set for key secondary efficacy endpoints of OS and', 'PFS, and key secondary endpoint of EORTC QLQ-C30 physical functioning', 'domain. All the exploratory efficacy endpoints will be analyzed based on the', 'randomization set if the OS and PFS based on the randomization set are', 'statistically significant.', 'Section 8.1.3 Efficacy Endpoints and Analyses', 'Delete: first sentence', 'Unless specified otherwise, efficacy analyses will be performed in the DLL3 high set.', 'Section 8.1.4 Primary Efficacy Enppoints', 'First paragraph previously read:', 'Progression-free survival (PFS) and overall survival (OS) are the two primary efficacy', 'endpoints. No order of testing of these two endpoints is specified.', 'Has been changed to read:', 'Progression-free survival (PFS) and overall survival (OS) in subjects with DLL3 high ED', 'SCLC are the two primary efficacy endpoints.', '187']"
187,page_188,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 8.1.4 Primary Efficacy Enppoints', 'Third paragraph, second sentence previously read:', ""The hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards model stratified by randomization stratification factors.', 'Has been changed to read:', ""The hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors.', 'Section 8.1.4 Primary Efficacy Enppoints', 'Third paragraph, last sentence previously read:', 'Estimates of the treatment effect will be expressed as hazard ratio including 95%', 'confidence intervals estimated through a Cox proportional-hazards analysis stratified by', 'randomization stratification factors.', 'Has been changed to read:', 'Estimates of the treatment effect will be expressed as hazard ratio including 95%', 'confidence intervals estimated through a Cox proportional-hazards regression model', 'adjusting for the main-effects of the stratification factors.', 'Section 8.1.4 Primary Efficacy Enppoints', 'Last paragraph, third sentence previously read:', ""The hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards model stratified by randomization stratification factors.', '188']"
188,page_189,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', ""The hazard ratios of the treatment arm over the placebo arm will be calculated by a Cox's"", 'proportional hazards regression model adjusting for the main-effects of the stratification', 'factors.', 'Section 8.1.4 Primary Efficacy Enppoints', 'Last paragraph, last sentence previously read:', 'Estimates of the treatment effect on will be expressed as hazard ratio including 95%', 'confidence intervals estimated through a Cox proportional-hazards analysis stratified by', 'randomization stratification factors.', 'Has been changed to read:', 'Estimates of the treatment effect on will be expressed as hazard ratio including 95%', 'confidence intervals estimated through Cox proportional-hazards regression models', 'adjusting for the main-effects of the stratification factors.', 'Section 8.1.5 Secondary Efficacy Enppoints', 'Previously read:', '8.1.5', 'Secondary Efficacy Endpoints', 'The secondary efficacy endpoints in the DLL3 high set are:', 'Objective response rate (ORR) per the CRAC based on RECIST v1.1', 'Change in patient reported outcomes (PROs) - physical functioning domain', 'PFS per investigator assessment based on RECIST v1.1', 'ORR per investigator assessment based on RECIST v1.1', 'Clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, based on RECIST v1.1', 'Duration of response (DOR) per CRAC and investigator assessment,', 'respectively', '189']"
189,page_190,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'The following endpoints in the randomized set are also included in the secondary efficacy', 'endpoints:', 'OS', 'PFS per the CRAC based on RECIST v1.1', 'ORR per the CRAC based on RECIST v1.1', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for complete response (CR) or partial response', '(PR) by CRAC (whichever is recorded first) to the date of progressive disease or death,', 'whichever comes first. If a subject is still responding (i.e., has not progressed nor died', ""after CR or PR), then the subject's data will be censored at date of the last radiographic"", ""assessment by CRAC. For subjects who never experienced CR or PR, these subjects' data"", 'will not be included in the duration of response analysis. Distribution of the duration of', 'response will be estimated for each treatment arm using Kaplan-Meier methodology.', 'Median duration of overall response with corresponding 95% CI for each treatment arm', 'will be provided.', 'ORR and CBR in the treatment arm will be compared using Cochran-Mantel-Haensze', 'test stratified by randomization stratification factors. Rates and 95% confidence intervals', 'will be reported for each treatment arm.', 'Has been changed to read:', '8.1.5', 'Secondary Efficacy Endpoints', 'The secondary efficacy endpoints in the randomized set are:', 'os', '190']"
190,page_191,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'PFS per the CRAC based on RECIST v1.1', 'EORTC QLQ-C30 physical functioning domain', 'Secondary time-to-event endpoints (PFS and OS) will be analyzed using the similar', 'statistical methods described for the primary endpoints.', '8.1.6', 'Exploratory Efficacy Enppoints', 'The exploratory efficacy endpoints in both DLL3 high and randomization set are:', 'Objective response rate (ORR) per the CRAC based on RECIST v1.1', 'PFS per investigator assessment based on RECIST v1.1', 'ORR per investigator assessment based on RECIST v1.1', 'Clinical benefit rate (CBR) per the CRAC and investigator assessment,', 'respectively, based on RECIST v1.1', 'Duration of response (DOR) per CRAC and investigator assessment,', 'respectively', 'Change from baseline in all PRO domains (except physical functioning)', 'measured by EORTC QLQ-C30/LC13 and EQ-5D-5L', 'ORR is defined as the proportion of patients with a best overall response (BOR) of', 'confirmed complete response (CR) or partial response (PR) by CRAC review according to', 'RECIST v1.1.', 'CBR is defined as the proportion of patients with a BOR of CR or PR, or SD by CRAC', 'review according to RECIST v1.1.', 'ORR and CBR in treatment arms will be compared using Cochran-Mantel-Haensze test', 'stratified by randomization stratification factors. Rates and 95% confidence intervals will', 'be reported for each treatment arm.', 'The duration of overall response for a given subject will be defined as the number of', 'months from the day the criteria are met for confirmed complete response (CR) or partial', '191']"
191,page_192,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'response (PR) by CRAC (whichever is recorded first) to the date of progressive disease or', 'death, whichever comes first. If a subject is still responding (i.e., has not progressed nor', ""died after CR or PR), then the subject's data will be censored at date of the last"", 'radiographic assessment by CRAC. For subjects who never experienced CR or PR, these', ""subjects' data will not be included in the duration of response analysis. Distribution of the"", 'duration of response will be estimated for each treatment arm using Kaplan-Meier', 'methodology. Median duration of overall response with corresponding 95% CI for each', 'treatment arm will be provided.', 'Section 8.1.6 Patient Reported Outcomes (PRO)', 'First sentence previously read:', 'Physical functioning scale score in EORTC QLQ-C30 is the primary PRO endpoint.', 'Has been changed to read:', 'Physical functioning scale score in EORTC QLQ-C30 is the key secondary endpoint.', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: first paragraph', 'Efficacy analyses for PFS per investigator assessment and ORR per investigator', 'assessment will be performed in the randomized set.', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: third paragraph', 'The physical functioning scale score (EORTC QLQ-C30) will be evaluated using an', 'ANOVA model in the randomized set.', '192']"
192,page_193,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 8.1.7 Planned Sensitivity and Subgroup Analyses', 'Delete: last paragraph', 'In', 'the DLL3high and randomized sets, CRAC assessed ORR will be compared between the', '2 arms, using a chi-square test for each subgroup. Odds ratios will be presented.', 'Section 8.1.8 Pharmacokinetic and Exposure-Response Analyses', 'First paragraph previously read:', 'Plasma concentrations of rovalpituzumab tesirine ADC as well as the incidence and', 'timing of ATA formation will be tabulated and summary statistics will be computed.', 'Plasma concentration and ATA data from this study may be combined with data from', 'other studies and analyzed using population pharmacokinetic methodologies.', 'Has been changed to read:', 'Serum concentrations of rovalpituzumab tesirine ADC as well as the incidence and timing', 'of ATA formation will be tabulated and summary statistics will be computed. Serum', 'concentration and ATA data from this study may be combined with data from other', 'studies and analyzed using population pharmacokinetic methodologies.', 'Section 8.3 Type I Error Adjustment Procedure for Multiple Testing', 'Previously read:', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) for comparisons of rovalpituzumab tesirine', 'arm versus placebo arm with respect to progression-free survival (PFS) per CRAC,', 'overall survival (OS), ORR per CRAC, and physical functioning scale score (EORTC', 'QLQ-C30).', 'The following null hypotheses are considered for subjects with DLL3 high.', 'H1: Rovalpituzumab tesirine arm is not superior to placebo arm in both PFS and OS.', '193']"
193,page_194,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'H2: Rovalpituzumab tesirine arm is not superior to placebo arm in ORR per CRAC.', 'H3: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30).', 'The null hypotheses will be tested in a fixed sequence of {H1, H2, H3) in order. To', 'maintain the family-wise type I error for the study, the null hypothesis H1 will be first', 'tested with an alpha-split approach. The hypothesis for PFS will be tested at a one-sided', '0.25% level of significance and the hypothesis for OS at a one-sided 2.25% level of', 'significance. If either PFS or os endpoint reaches statistical significance, the study is', 'considered positive. No further tests will be performed if H1 is not rejected. Each', 'hypothesis of H2 and H3 will be tested in order specified above if H1 is rejected and the', 'preceding hypothesis shows statistically significant results at the 1-sided 2.5% level of', 'significance. Otherwise testing in the hierarchical sequence will stop.', 'The secondary efficacy endpoints, e.g., PFS per investigator assessment, ORR per', 'investigator assessment, CBR per CRAC, CBR per investigator assessment, DOR per', 'CRAC, DOR per investigator assessment, and PRO evaluations in the DLL3 high set will be', 'tested at a one-sided 2.5% level of significance. Similarly, OS, PFS per CRAC, and ORR', 'per CRAC in the randomized set will be tested at a one-sided 2.5% level.', 'Has been changed to read:', 'To meet global regulatory requirements, a multiple testing strategy will be implemented to', 'control the family-wise type I error (alpha) to one-sided 0.025 level for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival', '(PFS) per CRAC in DLL3 high set, overall survival (OS) in DLL3 high set, PFS per CRAC in', 'randomized set, OS in randomized set, and physical functioning scale score (EORTO', 'QLQ-C30) in randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in H01 are Ho1a and Holb.', '194']"
194,page_195,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Ho1a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'DLL3 high set.', 'Holb: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in DLL3 high', 'set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in OS in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in', 'randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning', 'scale score (EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {Hola, Hoib, H02, H03, and H04} in', 'order. To maintain the family-wise type I error for the study, the null hypotheses in Hoi', '(Ho1a and H01b) will be first tested with an alpha-split approach. The one-sided alpha of', '0.25% and 2.25% will be assigned for PFS and OS hypothesis in H01, respectively. Out of', 'one-sided alpha of 2.25% allocated to os hypothesis (Ho1b), the one-sided alpha of 10-6', 'will be spent for the early look at the os data for futility analysis. If the hypothesis for', 'PFS in H01 (Ho1a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in H01 (Hoib). Hence, the hypothesis for OS in H01 (Hoib) will be tested either', 'at a one-sided 2.4999% or one-sided 2.2499% level of significance depending on the PFS', 'hypothesis in H01a is rejected or not.', 'If either PFS or OS endpoint reaches statistical significance, the study is considered', 'positive. No further tests will be performed if the OS endpoint in DLL3 high population', '(H01b) does not reach statistical significance.', 'The hypothesis in H02 will be tested if the hypothesis in Holb is rejected. If the hypothesis', 'in H02 is rejected, then, either (i) H03 and H04 will be tested sequentially if the PFS', 'endpoint in DLL3 high subjects (Ho1a) is also rejected or (ii) only H04 will be tested if the', 'PFS endpoint in DLL3 high subjects (H01a) is not rejected.', '195']"
195,page_196,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagram of Hierarchical Testing of Primary and Secondary Endpoints is described in', 'Figure 3.', 'Figure 3.', 'Diagram of Hierarchical Testing of Primary and Secondary', 'Enppoints', 'Test Hola (PFS in DLL3 High set) at one-sided a = 0.25%', 'If Hola not rejected', 'If Holai is rejected', 'Test Holb (OS in DLL High', 'Test Holb (OS in DLL3High', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Holb isrejected', 'If Holb is rejected', 'Test Ho2 (OS in Randomized', 'Test Ho2 (OS in Randomized', 'set) at one-sided a = 2.2499%', 'set) at one-sided a = 2.4999%', 'If Ho2 is rejected', 'If H02 is rejected', 'Test Ho4 (PF scale in EORTC', 'Test H03 (PFS in Randomized', 'QLQ-C30 in Randomized set)', 'set) at one-sided a = 2.4999%', 'at one-sided a = 2.2499%', 'If Ho3 is rejected', 'Test Ho4 (PF scale in EORTC', 'QLQ-C30 in Randomized set)', 'at one-sided a = 2.2499%', '196']"
196,page_197,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 8.4 Determination of Sample Size', 'Previously read:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS). To maintain the overall 1-sided type I', 'error at a 2.5% for this study, the type I error will be split, assigning 0.25% to', 'progression-free survival and the remaining 2.25% to overall survival.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo arm will be around 9 months. 4,5 Based on a log-rank test, at', 'a', 'one-sided significance level of 0.0225 and a power of 90%, a total of 319 deaths among', 'subjects with DLL3', 'high are needed to detect an increase of median os to 13 months in', 'rovalpituzumab tesirine arm, corresponding to a hazard ratio of 0.69 (i.e., a reduction in', 'the hazard death of 31%). Assuming a 19-month accrual period and the last enrolled', 'subject followed for 12 months, at least 480 subjects with DLL3high are expected to be', 'randomized (240 subjects in each arm). A total of 740 subjects regardless of DLL3', 'expression level (including 480 subjects with DLL3high will enroll in the study, assuming', 'an approximate prevalence of 65% for subjects with DLL3high It is projected that an', 'observed hazard ratio of 0.795 or less, corresponding to a 2.3 months or greater', 'improvement in median OS, would result in a statistically significant improvement in the', 'final analysis of OS.', 'It is assumed, taking into account the expected patient population for the study, that', 'median progression-free survival for the placebo arm will be approximately 3 months. 4,5', 'Treatment with rovalpituzumab tesirine is hypothesized to increase median progression-', 'free survival to 4.5 months (i.e., a hazard ratio of 0.667). With approximately 407 PFS', 'events assessed by the CRAC for subjects with DLL3 high , the study provides a 90% power', 'to detect a hazard ratio of 0.667 in PFS at a one-sided significance level of 0.0025. It is', 'projected that an observed hazard ratio of 0.757 or less, corresponding to approximately', '197']"
197,page_198,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '1 month or greater improvement in median PFS, would result in a statistically significant', 'improvement in the PFS.', 'The primary analysis of PFS will take place when at least 407 CRAC assessed PFS events', 'and at least 239 deaths (an interim efficacy analysis of os with approximately 75% of', 'targeted 319 deaths) have occurred in subjects with DLL3high When both conditions', 'specified for the numbers of PFS and OS events are satisfied, the primary analysis of PFS', 'and the interim efficacy analysis of os will be performed at the same time. The final', 'analysis of OS is projected to be approximately 31 months from first subject enrolled', 'when approximately 319 deaths have occurred in subjects with DLL3 high', 'Has been changed to read:', 'There are two primary efficacy endpoints for this study: Progression-free survival (PFS)', 'based on the CRAC and overall survival (OS) in DLL3high ED SCLC patients. To', 'maintain the overall 1-sided type I error at a 2.5% for this study, the type I error will be', 'split, assigning 0.25% to progression-free survival and the remaining 2.25% to overall', 'survival. However, the OS endpoint will be tested at a one-sided 2.2499% significance', 'level as a one-sided alpha of 10-6 will be spent for the early look at the OS data for futility', 'analysis.', 'The sample size of the study is primarily determined by the analysis of OS. It is assumed,', 'taking into account the expected patient population for the study, that median overall', 'survival in the placebo and rovalpituzumab tesirine arm will be around 9 months and 13', 'months, respectively. The increase of median OS in rovalpituzumab tesirine arm', 'corresponds to a hazard ratio of 0.69, i.e., a reduction in the hazard of death by 31%.', 'With all these assumptions, a total of 319 deaths among subjects with DLL3 high are needed', 'to achieve a 90% power based on a log-rank test at a one-sided significance level of', '0.022499. Assuming a 19-month accrual period and the last enrolled subject followed for', '12 months, at least 480 subjects with DLL3 high are expected to be randomized', '(240 subjects in each arm). A total of 740 subjects regardless of DLL3 expression level', '(including 480 subjects with DLL3high) will enroll in the study, assuming an approximate', '198']"
198,page_199,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'prevalence of 65% for subjects with DLL3high For one-sided significance level of', '0.022499, it is projected that an observed hazard ratio of 0.799 or less, corresponding to a', '2.3 months or greater improvement in median OS, would result in a statistically', 'significant improvement in the primary analysis of OS.', 'The primary endpoints of os and PFS in DLL3 high patients will be analyzed at the same', 'time after observing at-least 319 OS event. It is expected at approximately 420 PFS', 'events will be observed at the time of the primary analysis.', 'It is assumed, taking into account the expected patient population for the study, that', 'median progression-free survival for the placebo and rovalpituzumab tesirine arm will be', 'approximately 3 months and 4.5 months, respectively. The increase of median', 'progression-free survival in rovalpituzumab tesirine arm corresponds to a hazard ratio of', '0.667. With all these assumptions, a total of approximately 420 PFS events assessed by', 'the CRAC for the subjects with DLL3 high are needed to achieve a 91% power based on a', 'log-rank test at a one-sided significance level of 0.0025. It is projected that an observed', 'hazard ratio of 0.760 or less, corresponding to approximately 1 month or greater', 'improvement in median PFS, would result in a statistically significant improvement in the', 'PFS.', 'Section 8.5 Interim Analysis', 'Section title and text previously read:', '8.5', 'Interim Analysis', 'An interim efficacy analysis is planned for overall survival after at least 239 deaths in', 'subjects with DLL3 high (i.e., 75% of planned deaths are observed) using a one-sided log-', 'rank test.', ""The O'Brien-Fleming method will be implemented to protect the type I error rate of"", '0.0225 for OS. A one-sided alpha spending of 0.0084 for the interim will be allocated for', 'declaring statistical superiority in OS at the time of the interim analysis. The final', 'analysis of OS will be performed at a one-sided nominal alpha level of 0.01998, adjusting', '199']"
199,page_200,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', ""for the interim look at OS data. If the interim analysis of OS meets the O'Brien-Fleming"", 'boundary for statistical significance, the final OS analysis will be considered descriptive.', 'Unblinded interim data will be analyzed and reviewed by the IDMC. The trial may be', 'considered for early stopping for superiority and the Sponsor will be unblinded to the', 'aggregated data by randomized treatment arms if the IDMC makes such a', 'recommendation after consideration of the PFS and OS results, and all supportive', 'evidence including other efficacy endpoints and safety.', 'In the event that the IDMC recommends continuing the study due to lack of evidence for', 'superiority, the unblinded interim results will be kept confidential to the investigators,', 'subjects, sponsors, and personnel involved in the conduct of the study until the end of the', 'study, since the final analyses of os and all other endpoints will be performed in an', 'inferentially seamless manner. Subjects already enrolled in the study will continue', 'rovalpituzumab tesirine or placebo treatment in a blinded fashion to obtain more mature', 'OS data for a robust characterization of treatment effect.', 'Details for the interim efficacy analysis will be provided in the IDMC charter.', 'Has been changed to read:', '8.5', 'Futility Analysis', 'A futility analysis will be conducted when approximately 160 deaths in subjects with', 'DLL3high ED SCLC (approximately 50% of the planned deaths) are observed. The trial', 'may be stopped for futility if the estimated Overall Survival Cox HR of Rova-T to', 'Placebo in the DLL3high set at futility analysis exceeds 0.9. The one-sided alpha of 10-6', 'will be spent for the early look at the efficacy data for futility analysis.', 'Unblinded interim data will be analyzed and reviewed by the IDMC. The trial may be', 'considered for early stopping for futility and the Sponsor will be unblinded to the', 'aggregated data by randomized treatment arms if the IDMC makes such', 'a', '200']"
200,page_201,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'recommendation after consideration of the OS results and other supportive evidence', 'including other relevant efficacy and safety data.', 'Details for the futility analysis will be provided in the IDMC charter.', 'Section 8.6 Accrual/Study Duration Considerations', 'Last sentence previously read:', 'It is projected that 480 subjects with DLL3 high will have enrolled for the interim analysis', 'by the time at least 407 PFS events per CRAC and at least 239 OS events should be', 'observed in subjects with DLL3high and subjects have completed approximately 5 months', 'of follow-up.', 'Has been changed to read:', 'It is projected that 480 subjects with DLL3 high ED SCLC will have enrolled for the', 'primary analysis by the time approximately 420 PFS events per CRAC and at least 319', 'OS events should be observed in DLL3 high subjects after approximately 8 - 10 months of', 'follow-up.', 'Section 10.1 Source Documents', 'First paragraph, fourth and fifth sentence previously read:', 'The Investigator Awareness Date (SAE CRF) may serve as the source for this data point.', 'This adverse event data point required for eCRF completion can be entered directly in the', 'eCRF.', 'Has been changed to read:', 'The Investigator Awareness Date of SAE should be noted in the source.', '201']"
201,page_202,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 15.0 References', 'Add: new Reference 19', 'AbbVie. Rovalpituzumab Tesirine Dear Rova-T Investigator Letter. 05 December 2018.', 'Appendix B. List of Protocol Signatories', 'Previously read:', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', 'Has been changed to read:', 'Name', 'Title', 'Functional Area', 'Clinical', 'Clinical', 'Pharmacokinetics', 'Clinical Drug Supply Management', 'Statistics', 'Bioanalysis', '202']"
202,page_203,"['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C. Study Activities', 'Category previously read:', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29, ,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Safety', 'Echocardiogram²', 'X', 'X', 'Assessments', 'Has been changed to read:', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatmentb', 'PTFU', '(OS)', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(1wk)', '(+1wk)', 'Safety', 'Echocardiogram""', 'X', 'X', 'X', 'Assessments', '203']"
203,page_204,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix C. Study Activities', 'Table note ""b."" previously read:', 'End of Treatment Visit occurs within 7 days of documentation of the decision to', 'discontinue treatment and prior to subjects beginning any new anti-cancer therapy if', 'possible.', 'Has been changed to read:', 'End of Treatment Visit procedures should be done within 7 days of documentation of the', 'decision to discontinue treatment and prior to subjects beginning any new anti-cancer', 'therapy if possible.', 'Appendix C. Study Activities', 'Table note ""e.,"" first sentence previously read:', 'Cycle 1 Day 1 procedures do not need to be repeated if performed within 21 days of', 'randomization unless clinically indicated.', 'Has been changed to read:', 'Cycle 1 Day 1 procedures, with the exception of weight, do not need to be repeated if', 'performed within 21 days of randomization unless clinically indicated.', 'Appendix C. Study Activities', 'Table note ""n."" previously read:', 'Echocardiogram will be performed to assess any pericardial effusion, if present, as well as', 'cardiac function (left ventricular ejection fraction, LVEF).', 'Has been changed to read:', 'Echocardiograms are required at Screening, Day 1 of each cycle starting C2D1, and EOT.', 'Screening echocardiogram will be performed within 7 business days of randomization to', '204']"
204,page_205,"['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'assess for the presence of any pericardial effusion as well as cardiac function (left', 'ventricular ejection fraction, LVEF). Subsequent echocardiograms should be performed', 'within -3 business days of dosing visit to assess for the presence of any pericardial', 'effusion. Additional echocardiogram monitoring may occur as clinically indicated during', 'the study.', 'Appendix C. Study Activities', 'Table note ""q.,"" seventh sentence previously read:', 'Scheduled tumor assessments will not be affected by delays in therapy and/or drug', 'holidays.', 'Has been changed to read:', 'Whenever possible, scheduled tumor assessments should not be affected by delays in', 'therapy and/or drug holidays. In some cases, mandatory dose delays due to toxicity will', 'lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Appendix C. Study Activities', 'Table note ""t."" previously read:', 'MRI/CT of the brain is only required at screening and when clinically indicated (e.g., if', 'CNS progression is suspected).', 'Has been changed to read:', 'MRI/CT of the brain is required at screening and when clinically indicated (e.g., if CNS', 'progression is suspected) thereafter.', '205']"
